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BAL: bronchoalveolar lavage 
BR: bronchoscope rinse 
COPD: chronic obstructive pulmonary disease 
CR: catheter rinse 
CT: cryotube  
DADA2: divisive amplicon denoising algorithm 2 
ICS: inhaled corticosteroids 
LLL: left lower lobe 
LUL: left upper lobe 
MC: mock community 
NCS: negative control sample 
OTU: operational taxonomic unit 
OW: oral wash 
PBAL: protected bronchoalveolar lavage 
PBS: phosphate-buffered saline 
PE: paired-end sequencing 
PSB: protected specimen brush 
QIIME: Quantitative Insights into Microbial Ecology  
RLL: right lower lobe 
RML: right middle lobe 
SBS: sequencing by synthesis 
SDS: Salmonella dilution series 







Studies on the lung microbiome face unique methodological challenges tied to the 
low bacterial load of acquired samples and the increased susceptibility to bacterial 
DNA contamination. Contamination may be introduced from i) the upper airways 
during sampling and ii) reagents, kits and the general laboratory environment during 
laboratory processing steps. Few publications exist on validity and reliability of 
applied methods of sampling, laboratory processing and bioinformatics analysis.  
Objectives 
The objective of the thesis was to address some of the methodological issues that 
remain unresolved in the field of lung microbiome research. In the first paper, we 
sought to determine whether protected (via a sterile catheter) bronchoscopic sampling 
techniques would reduce the influence of bronchoscopic carryover from the upper 
airways. In paper II, we examine the impact of laboratory contamination on airway 
samples and explore the expected inverse relationship between sample bacterial load 
and influence of contamination. We also compare different bioinformatic strategies to 
dealing with contamination. In paper III, we sought to determine whether processing 
samples through longer laboratory workflows would increase susceptibility to 
contamination, and to explore impact of choice of 16S rRNA gene variable region 
(V3 V4 or V4) on the presentation of the airways microbiome.  
Methods 
Study samples were collected from participants enrolled in the Bergen COPD 
Microbiome study (short name «MicroCOPD»). Samples included oral washes (OW), 
bronchoscopically acquired protected specimen brushes (PSB), protected 
bronchoalveolar lavages (PBAL), small-volume lavages (SVL) and negative control 




Bacterial DNA was extracted using a combination of enzymatic and mechanical lysis 
methods and processing through the FastDNA Spin Kit (MP Biomedicals). Bacterial 
community composition was determined by high-throughput sequencing of the 
bacterial 16S rRNA gene using the Illumina MiSeq sequencing platform. Three 
library preparation setups were included in the thesis, varying in number of PCR 
steps (1- or 2-steps) and target marker gene region (16S rRNA gene V3 V4 or V4): 
Setup 1 (2-step PCR; V3 V4 region); Setup 2 (2-step PCR; V4 region); Setup 3 (1-
step PCR; V4 region). Papers I and II were based on setup 1. Paper III included all 
three setups. Bacterial load was determined by quantitative PCR targeting the 16S 
rRNA gene region V1 V2 (paper II). 
Bioinformatics processing steps were performed using the Quantitative Insights Into 
Microbial Ecology (QIIME) bioinformatic package, versions 1 (papers I and II) and 2 
(paper III). Strategies for decontamination varied across papers and included i) 
keeping samples intact (i.e. do nothing), ii) removing all sequences observed in NCS 
and iii) the removal of sequences identified as contaminants using the Decontam R 
package tools. In paper I, sequences observed in NCS were removed. In paper II, all 
three strategies were applied and compared. In paper III, Decontam was used.  
Results 
Analyses for paper I were based on the underlying assumption that the more similar 
the bronchoscopically acquired specimens (PSB, PBAL and SVL) were the OW 
sample, the greater the influence of upper airway contamination. Between sample 
comparisons were made based on three parameters: i. taxonomy, ii. alpha diversity 
and iii. beta diversity. Across all three parameters, similarity to the OW sample 
decreased in order SVL>PBAL>PSB.  
In paper II, an estimated 10-50% of the bacterial community profiles for the lower 
airway samples (PSB, PBAL) were derived from laboratory contamination. This was 
determined based on comparison to a dilution series of known bacterial composition 
and load. The DNA extraction kit was identified as the main contamination source. 




R package provided a balance between keeping and removing sequences found in 
both NCS and study samples.   
In paper III, we found that the number of sequences and ASVs decreased in order 
setup1>setup2>setup3. This appeared to be associated with increased taxonomic 
resolution when targeting the V3 V4 region (setup 1) and an increased number of 
small ASVs in setups 1 and 2. For setups 1 and 2, we interpreted this as a result of 
contamination in the 2-step PCR protocol and sequencing across multiple runs (setup 
1). Analyses of taxonomic composition revealed that genera Streptococcus, 
Prevotella, Veillonella and Rothia dominated all setups, but that relative abundances 
differed. Analyses of beta diversity revealed that while OW samples clustered 
together regardless of number of PCR steps, samples from the lower airways (PSB, 
PBAL) separated. Removal of contaminants identified in Decontam did not resolve 
differences across setups.  
Conclusions 
We show that protected bronchoscopic sampling techniques (PSB, PBAL) may 
provide protection from oropharyngeal carryover and should be the preferred 
sampling technique in future studies (paper I).  
We demonstrate that bacterial load will vary across airway sample types and that 
bacterial contamination from the laboratory will have an increased impact on samples 
of lower bacterial load (paper II). We recommend that estimates of contamination are 
reported in all studies. We also recommend the use of contaminant identification 
tools based on statistical models that limit subjectivity (e.g. Decontam).  
Finally, we demonstrate that differences in number of PCR steps (1- or 2-steps) will 
have an impact on final bacterial community descriptions, and more so for samples of 
low bacterial load (e.g. lower airway samples) (paper III). Our findings could not be 
explained by differences in contamination levels alone, and more research is needed 





5. List of publications 
 
Paper I 
Grønseth R, Drengenes C, Wiker HG, Tangedal S, Xue Y, Husebø GR, et al. 
Protected sampling is preferable in bronchoscopic studies of the airway microbiome. 
ERJ Open Res. 2017;3 
 
Paper II 
Drengenes C, Wiker HG, Kalananthan T, Nordeide E, Eagan TML, Nielsen R. 




Drengenes C, Eagan TML, Haaland I, Wiker HG, Nielsen R. Exploring protocol bias 
in airway microbiome studies: one versus two PCR steps and 16S rRNA gene regions 








Chronic obstructive pulmonary disease (COPD) is a progressive disease of the lower 
airways, characterized by chronic inflammation and airflow obstruction [1]. Much 
research has been directed towards understanding the factors triggering the onset and 
progression of COPD. We have learned that there may be a genetic component (most 
important being alpha-1 antitrypsin deficiency) [2], and that smoking, air pollution, 
and occupational exposures [3] are important risk factors. However, enough 
understanding to enable the development of effective therapies, or the prevention of 
disease development has not been reached using current research methods.  
Advancements in DNA sequencing technologies have however provided us with a 
new angle by which we can study the airways and airway diseases. Through massive 
parallel sequencing of the bacterial 16S ribosomal RNA gene (16S rRNA gene), we 
can establish the type of bacteria present in a sample and their relative abundances. 
The application of sequence-based techniques has already revolutionized our 
understanding of the role of bacteria in the lower airways – the biggest revelation so 
far being that the lungs are not sterile, even in healthy individuals [4]. Research 
efforts have since this newfound understanding been directed towards finding a 
potential link between the bacterial communities of the airways and the development 
and progression of disease, COPD being most studied. Progress in this relatively new 
field of lung “microbiome” research has in large been characterized by an urge to 
rapidly publish data comparing healthy and diseased states. Few publications 
however exist on validity and reliability of applied methods of sampling, laboratory 
processing and bioinformatics analyses.  
The aim of the current PhD work is to address some of the methodological issues that 
remain unresolved in the field of lung microbiome research. In the following 
introductory sections (6.1 - 6.3), the general workflow for generating data on the 
bacterial component of the airway microbiome is described from steps of sampling, 
to library preparation for high-throughput sequencing, and finally bioinformatics 




of which pertain to all fields of microbiome research regardless of site being studied. 
In the final introductory section (6.4), specific challenges related to the low bacterial 
load of the lower airways, and the resulting increased susceptibility to contaminating 
bacterial DNA is discussed.  
In the literature, there is some inconsistency in the definition and usage of the terms 
“microbiome” and “microbiota”, and the terms are often used interchangeably [5]. 
Herein, the term “microbiota” is used to describe the microorganisms that make up a 
sampled community. “Microbiome” is used to describe the collection of genomes 
from these microorganisms. As the basis of the analyses for the current PhD work is 
the bacterial 16S rRNA gene, the usage of the terms “microbiome” and “microbiota” 
is limited to bacteria.  
6.1 Sampling the lower airway microbiome 
Obtaining valid (uncontaminated) lower airway microbiome samples is challenging. 
First of all, the lower airways are relatively inaccessible. Although percutaneous 
procedures exist, most sampling procedures must involve the passage of a sample 
(e.g. sputum) or sampling device (e.g. bronchoscope) through the upper airways. 
Regardless of route of sampling, which may be performed via the oral or nasal 
passage, contamination from the upper airways is more or less inevitable. Adding to 
the severity of the contamination issue is the difference in bacterial load between the 
upper and lower airways, which has been measured to be several logs greater in the 
upper airways [6]. Therefore, even minute amounts of carryover from the upper to 
lower airways during sampling may be enough to confound the analyses of a lower 
airway sample – this effect has however not been thoroughly studied in the literature. 
Furthermore, natural processes connecting the upper and lower airways (e.g. 
microaspiration, mucosal dispersion, inhalation), lead to an expected overlap (or 
similarity) between the sampled microbiota of the two sites [6, 7]. Recognizing when 




Despite the aforementioned issues, the field of lung microbiome research has pushed 
forward and studies have been published using a wide range of sampling techniques - 
often with little concern about the potential for upper airway contamination beyond 
its mention as a potential weakness in the discussion section of their reports [8]. The 
degree to which different sample types are of sufficient quality for microbiome 
analyses, particularly in terms of minimizing the influence of upper airway 
contamination, has not been thoroughly evaluated in the existing literature. A 
discussion on the most commonly used sampling techniques for studying the lung 
microbiome (sputum and bronchoscopy) is given below.   
6.1.1 Sputum sampling 
A priori, sputum samples are the most vulnerable to upper airway contamination. 
During the sampling procedure, sputum (i.e. mucus) is coughed up from the lower 
airways and expelled from mouth and into a container [9]. By passage through the 
mouth, the sample is in direct contact with the bacterial communities of the upper 
airways, rendering contamination more or less inevitable. Despite this, many 
researchers have still opted for sputum sampling. It is inexpensive, non-invasive, 
repeatable and used routinely in the clinical setting. In addition, samples can be 
readily acquired from most subjects, irrespective of age or health status. The debate 
on the validity of microbiome studies based on sputum sampling, however persists 
[10].   
Besides upper airway contamination, several other factors must be considered when 
sampling sputum. First of all, sputum can be collected either spontaneously or when 
sputum production is low, or the procedure is difficult for the subject (e.g. children), 
it may be induced [9]. Sputum induction involves the inhalation of nebulized 
hypertonic saline solution that triggers mucus secretion and irritation, leading to 
coughing. Induced sputum may be collected at different times. Based on the analysis 
of cell (e.g. neutrophils, alveolar macrophages) and protein (e.g. mucin, SP-A) 
composition in studies on inflammatory markers, it has been proposed that earlier 
samples are representative of the proximal airways, whereas later samples are 




is most likely representative of the proximal airways. Provided one accepts that 
different bacterial populations are found within the different regions of the lungs (e.g. 
as proposed by the adapted island model of lung biogeography [12]), one may expect 
that different microbiota populations will also be represented when sampling by one 
or the other technique (spontaneous or induced) or when samples are collected at 
different time points (induced). It is currently unclear whether spontaneous and 
induced samples can be used interchangeably in studies of the airway microbiome, 
and studies addressing the issue have been conflicting [10, 13]. 
6.1.2 Bronchoscopy sampling 
Sampling by bronchoscopy is currently considered the gold standard in the lung 
microbiome field. Bronchoscopy, or flexible video bronchoscopy is an endoscopic 
technique for examination and sampling of the airways and lungs. The endoscope 
(i.e. bronchoscope) is inserted through the mouth or the nose, and under local or 
general anaesthesia passed through the vocal cords and into the lower airways. The 
flexible bronchoscope has a diameter of 2-7 mm and contains a working channel that 
is used for instillation of fluids (medication, sampling fluids), as well as insertion of 
various instruments for sampling or delivering treatment in the airways and lungs. A 
number of different sample types can be collected through the bronchoscope 
including endo- or transbronchial biopsies, bronchoalveolar lavages (BAL) and 
specimen brushings (SB). BAL and SB are most commonly used for sampling the 
microbial communities of the alveolar space and conducting airways, respectively.  
Sampling BAL involves instilling a set volume of liquid into the lower airway region 
to be sampled, and then suctioning the liquid back through the bronchoscope working 
channel. When sampling BAL, an estimated 1/40 of the total lung surface area (i.e. 
17500 cm2) is covered [14]. The amount of liquid instilled may vary according to 
both the subject being examined and what the examiner is looking for. The amount of 
volume returned is lower than that instilled and may differ between study subjects as 
a natural consequence of anatomical variations and diseases of the lung and airways. 
The manner by which BAL sampling is performed has not been standardized in 




2x50 mL liquid in turn from the same segment. The resulting «BAL return 1» and 
«BAL return 2» may be pooled together or kept separate. SB sampling involves 
passing a specimen brush through the working channel to the sampling point and 
brushing the targeted region. SB sampling typically covers 1 cm2 of the airway 
mucosa - i.e. a significantly smaller area than that which is covered when sampling 
BAL.  
Sampling by bronchoscopy (whether by BAL or SB) comes with the added advantage 
of enabling a more targeted sampling than sputum. This however means that also the 
«biogeography» of the lower airways must be considered when deciding on an 
appropriate sampling scheme. Dickson et al. [12, 14] introduced “the adapted island 
model of lung biogeography” to explain differences in microbiota that one may 
expect to find across lung sites in health. The model assumes the upper airways are 
the main source community for the lower airways, and that upper-lower airway 
similarity will decrease as one moves further down the lower airways. Further the 
model assumes that bacterial communities in the lung do not replicate and that the 
bacterial composition at any one site is determined by processes of immigration (e.g. 
inhalation, microaspiration and mucosal dispersion) and elimination (e.g. the 
«mucociliary escalator», cough, local host immune cells) [14]. Particulary illustrative 
was their observation that brushings from the right upper lobe were more similar to 
the upper airways, than that from the left upper lobe [12]. The authors explained these 
findings as a likely result of differences in the angle by which the left and right main 
bronchi leave the trachea; the sharper upward angle of the left main bronchus appears 
to direct microaspirated bacteria down the right main bronchus. Importantly, the 
authors also conclude that the observed variation found across intrapulmonary sites 
within one subject, is less than that observed across different subjects – the take home 
message being that in health multiple sampling of different sites within the lungs may 
not be important.  
The diseased lung however is a different matter. Willner et al. [15] show in their 
study that variation exists between different sites in the CF lung. Erb-Downward et 




result of regional differences in the lung that may occur in the diseased state, and that 
hinder processes of elimination and result in favorable conditions for growth of 
certain bacteria. Thus, particularly in studies including subjects with disease, it may 
be important to sample multiple sites within the lungs.  
6.1.3 Bronchoscopy and upper airway contamination 
Athough a more «protected» approach than sampling sputum, bronchoscopy is not 
without risk of contamination from the upper airways. To reach the lower airway 
sampling point, the bronchoscope must pass through the upper airways, either via the 
oral or nasal route. Both routes are heavily populated with distinct upper airway 
microbiota [4, 6, 7, 16, 17], and both the outside of the scope and the inner working 
channel may carry with it contamination from the upper airways.  
To minimize the risk of bronchoscopic carryover from the upper to lower airways, 
several different preventative measures have been observed in the literature. In some 
studies participants have been instructed to rinse their mouths with antiseptic 
mouthwash (e.g. Listerine) prior to sampling [7, 18, 19]. In other studies, 
investigators have attempted to avoid the high bacterial load of the oral cavity by 
sampling via the nasal rather than the oral route [8, 20, 21]. However, as described in 
more detail later, the common passage through the supraglottic region, leaves the 
effect of choice of sampling route questionable. Most studies report that they avoid 
suctioning prior to passage through the vocal cords [6, 7, 12, 18, 20]. However, this 
likely provides little protection against the influence of contamination from the 
outside of the bronchoscope. Most studies also report that when sampling multiple 
lower airway sites, care is taken not to retract the bronchoscope back up through the 
upper airways (i.e. above the vocal cords) [7]. Furthermore, several studies have 
performed SB sampling through a sterile wax-plugged catheter passed through the 
bronchoscope working channel. The resulting sample is commonly referred to as a 
“protected” specimen brush (PSB), reflecting findings from a culture-based study 
indicating that sampling via a sterile inner catheter (preferentially with a plug at the 
scope tip) provides protection from contaminants found within the scope channel 




more sensitive culture-independent methods used in microbiome studies. The 
MicroCOPD study [23] (for which the work for the thesis is a part of), is the only 
study for which protected bronchoalveolar lavage (PBAL) sampling has been 
performed. 
Few studies on the lung microbiome have directly examined the relative contributions 
of contamination introduced from the outside and/or inside of the bronchoscope 
working channel – for the studies that have attempted to do so, conclusions have been 
contradicting. Charlson et al. [6] sought to examine the contamination picked up by 
the bronchoscope after passage through the upper airways via the oral route. They 
passed the bronchoscope to the supraglottic region (i.e. above the vocal cords) and 
back. Samples were collected from the outside bronchoscope tip and the inner 
bronchoscope working channel. They found that their samples were indistinguishable 
from oral (OW) and oropharyngeal (OP) samples and lower airway samples (BAL 
and PSB), but distinct from nasopharyngeal (NP) and negative control samples [6]. 
Their results therefore confirmed that both the outside and the inside of the 
bronchoscope working channel carried contaminants from the upper airways that 
could confound their analyses of the lower airways. Dickson et al. [14] examined the 
influence of bronchoscopic carryover when sampling PSB via the oral route. They 
passed the bronchoscope to just below the vocal cords, where they performed PSB 
sampling of the lumen space. In this study, the samples were indistinguishable from 
negative control samples and the authors concluded that bronchoscopic carryover had 
minimal influence on the analysis of their lower airway samples [14]. The two studies 
are however not directly comparable. While Charlson et al. actively sampled the 
outside and inside of the bronchoscope channel, Dickson et al. only sampled the 
airway lumen and an eventual coating of biofilm that the protected brush comes near 
when the wax-plug of the PSB is ejected. When actual sampling of the mucosal wall 
is performed, there is likely a greater risk of direct contact between the bronchoscope 
tip and the sampled microbiota. Thus, while protected sampling appears to provide an 
efficient barrier against contaminants found within the working channel, the degree of 





To validate their studies, investigators have used indirect methods to show that their 
lower airway samples are authentic (i.e. uncontaminated) representations. A common 
argument is based on the expectation of a “dilution” effect in serially sampled BAL 
[6, 7, 14, 20, 24]. The assumption is that if the bacterial communities detected in the 
lower airways are a result of upper airway contaminants having been brought down 
by the bronchoscope, the similarity of the samples to the upper airways will decrease 
with each successive sampling event. Charlson et al. [6] used measures of bacterial 
load to conclude on the degree of upper airway carryover by the bronchoscope. They 
observed a dilution effect between the first and second BAL return collected from the 
same wedged position at sampled site A of the right middle lobe (RML). When 
comparing BAL return 2 (site A) with a third BAL collected from an adjacent site B 
(also RML), they found similar levels of bacteria. They concluded that upper airway 
carryover mainly influenced the first BAL return.  
Not all studies have observered a dilution effect, and this has been used as evidence 
that upper airway contamination is negligible. Segal et al. [20, 25] and Bassis et al. 
[7], for instance did not observe a dilution effect in their respective studies when 
comparing BAL samples collected from the lingula and RML. In contrast to the 
previous study, where serial BAL was collected from the same wedged position, 
herein the samples compared were collected from different lungs (lingula and RML). 
An alternative explanation for the lack of an observed dilution effect may therefore 
be that the dilution effect was masked by the introduction of intrapulmonary 
contamination when repositioning the scope for sampling of the second site. If we 
accept the model of bacterial topography in the lungs as presented by Dickson et al. 
[14], the pulmonary site for which lung microbiota can be expected to be the most 
similar to the upper airways is the carina. When sampling across the left and right 
lungs, it can therefore become difficult to distinguish between carryover from the 
upper airways and intrapulmonary contamination – and consequentially so, difficult 
to conclude on the presence or lack of a dilution effect. In addition as described 
earlier, Dickson´s adapted island model of lung biogeography [12], predicts that 




bronchus. Thus we can expect a greater inherent similarity of microbiota, in terms of 
composition and load, between the upper and lower airways when sampling the RML 
than when sampling the lingula. Based on theoretical models, we are therefore 
reminded that observations of a dilution effect should perhaps be limited (at least) to 
samples from the same lung.  
A second argument commonly used to show that samples are uncontaminated by the 
upper airways is the observation that similar community descriptions are obtained 
when sampling via the oral or nasal route [20, 21]. Since these two sites hold distinct 
microbiotas, the argument is based on the expectation that if contaminated, the 
community descriptions should reflect one or the other of these two source 
communities. However, little is mentioned about the fact that both the nasal and oral 
cavities funnel to a common passage located above the vocal cords at the entry to the 
lower airways (i.e. the supraglottic region). In theory, one may expect that this region 
will hold bacterial communities more similar to the oral cavity than the nasal cavity 
due to an increased flow of saliva relative to nasal fluid (in health) [7]. Thus, an 
alternative interpretation of the observed similarity of lower airway community 
descriptions when sampling by either nasal or oral route is that the contamination 
signal reflects the supraglottic region, which in turn likely reflects a composite signal 
from both nasal and oral sites – and is likely dominated by the communities that 
resemble that found in the oral cavity. 
In summary, sampling the lower airways is difficult due to the potential cofounding 
issue of contamination from the upper airways. As described, different studies have 
come to different conclusions regarding the impact and degree of upper airway 
carryover being brought down by the bronchoscope during sampling. It can perhaps 
be agreed upon that protected sampling procedures (e.g. PSB) appear to provide an 
efficient barrier to upper airway carryover from within the scope channel. Despite 
this, no study has examined the benefits of sampling protected BAL (PBAL) in 




6.2 Amplicon-based marker gene analyses  
Amplicon-based marker gene sequencing workflows are most common in studies of 
the bacterial airway microbiome. Although much variation exists across protocols, 
most all laboratory workflows fit into the general framework outlined in Figure 1.  
There are two key pieces of information that are obtained using amplicon-based 
marker gene analyses targeting the 16S rRNA gene. First of all, we are able to 
establish the type of bacteria that are found in the sampled community (i.e. 
membership), as each amplicon sequence will reflect a bacterial taxa which can be 
identified when matched up against a database of known sequences. Second, we are 
able to determine the relative abundances of each of these members, based on the 
relative proportions of the different amplicons in the amplicon pool.  
The accuracy of amplicon-based marker gene analyses, will depend on the degree to 
which information regarding both membership and relative abundance is accurately 
transferred through each step of the laboratory workflow – including all steps of 
DNA extraction, library preparation for sequencing and sequencing itself. It is well 
established that both error and bias may be introduced at multiple steps within this 
framework. Herein, errors are defined as inaccurate representations of the marker 
gene sequence. Bias is used to describe inaccurate representations of the relative 
abundances of bacterial community members [26].  
In the following section, each step outlined in Figure 1, will be described in turn, with 
emphasis on methodological pitfalls along the way that may introduce error and/or 
bias to the sequencing data. In section 6.3 current bioinformatic approaches to dealing 


































































































































































































































































































































































































































































































































































6.2.1 DNA extraction 
The DNA extraction step (Figure 1, step A), has been recognized as one of the main 
sources of bias in the general microbiome field. While protocols for DNA extraction 
may vary in many regards, most important is perhaps the chosen method for bacterial 
cell lysis, for which there are many different examples in the literature (e.g. 
mechanical [6, 12], enzymatic, chemical or a combination [27]). Differences in cell 
wall structure across bacteria will render different types of bacteria more or less 
resistant to the various methods of cell lysis. If these differences are not accounted 
for, we can obtain a biased picture of the sampled community, already at this first 
step of the sequencing workflow.  
Peptidoglycan is an important structural component of the bacterial cell wall, and the 
main target in most cell lysis methods [28]. Peptidoglycan consists of chains of 
alternating N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) sugar 
derivatives [28]. These chains are in turn linked together via short peptides. In the 
broadest of terms, we can distinguish between two groups of bacteria classified 
according to cell wall structure - the gram-positive and the gram-negative bacteria. 
The gram-positive bacteria have a thicker peptidoglycan layer than the gram-negative 
bacteria and therefore the former are considered more resistant to most cell lysis 
procedures. However, depending on choice of lysis method, also more subtle 
differences in peptidoglycan structure may be important. When using enzymatic lysis 
methods for instance, small differences in peptidoglycan structure can render some 
bacteria more or less vulnerable to the lytic activity of a particular enzyme [29, 30]. 
An example of this involves the commonly used enzyme lysozyme, which exerts its 
lytic activity by cleaving the glycosidic bond between NAG and NAM. For bacteria 
with O-acetylated NAM (e.g. Neisseria gonorrhoeae, Staphylococcus aureus), 
lysozyme is unable to bind sufficiently to the peptidoglycan substrate [30]. Bacteria 
with this modification are therefore resistant to treatment with lysozyme and other 
enzymes are needed (e.g. mutanolysin and lysostaphin [29]).  
To ensure accurate representation in terms of both membership and abundance, 




found in the samples under study. This however requires a priori knowledge of the 
bacterial communities in these samples – this is knowledge we usually do not have, 
and particularly not for the lower airways. It might therefore be tempting to use the 
whole arsenal of cell lysis tools available in order to secure accurate community 
representation. However, due consideration must also be made towards maintaining 
the integrity and yield of the extracted DNA, for which will be processed through a 
number of additional protocol steps post DNA extraction (Figure 1, steps B and C).  
DNA integrity can be greatly impacted by choice of lysis method. When employing 
mechanical lysis methods there is an increased risk of DNA shearing and 
fragmentation. Because genomic DNA is released at an earlier stage of DNA 
extraction from the more easy-to-lyse gram-negative bacteria, these community 
members are likely more vulnerable to fragmentation than gram-positive bacteria. 
The main concern in amplicon-based microbiome studies, is that the fragmented 
DNA will increase the formation of recombinant amplification products (i.e. 
chimeras) in downstream steps of PCR (Figure 1, step B) [31]. As will be discussed 
further in a later section, chimeras represent a major source of error in microbiome 
analyses workflows because they may be interpreted as novel sequences (i.e. 
bacteria). Maintaining the integrity of the isolated DNA is therefore important for 
accurate representation of community composition, and choice of cell lysis method 
must carefully balance the goal of equal extraction efficiencies and DNA integrity 
against one another.  
In addition, concentration of DNA obtained after DNA extraction (i.e. DNA yield) is 
variable across DNA extraction methods [29, 32]. Although it may seem reasonable 
that obtaining higher DNA yield, will result in better representation of community 
membership by also increasing signal from rare taxa, studies have shown that 
increased DNA yield does not necessarily equate to better community representation 
[29]. However, when processing low biomass samples the issue of contamination 
becomes relevant and increased DNA yield may be particularly important [32]. The 




6.2.2 Library preparation for sequencing 
After DNA extraction, the next step in the amplicon-based marker gene sequencing 
workflow is library preparation for sequencing (Figure 1, step B). As described 
earlier, this entails PCR amplification of the target marker gene to be sequenced and 
the addition of index sequences necessary for sample multiplexing.  
Marker gene amplification  
The bacterial 16S ribosomal RNA (16S rRNA) gene, is the most commonly targeted 
marker gene in amplicon-based microbiome studies. The approximately 1500 base 
pair long gene encodes a structural RNA component of the bacterial ribosome, and is 
a critical component of the cellular process of protein synthesis (i.e. translation of 
DNA to protein). The vital function of its gene product means that the 16S rRNA 
gene is found in all bacteria – and thus it serves as the perfect marker gene for 
capturing the full collection of bacteria in the sampled community [33, 34]. Although 
highly conserved, along its full length, the 16S rRNA gene consists of alternating 
variable and conserved sequences [33, 35, 36]. Conserved sequences are similar 
across all bacteria. The variable regions (for which there are nine (V1-V9)), on the 
other hand vary enough to allow bacterial identification to genus and sometimes even 
species level [37].  
The popularity of the 16S rRNA gene as a target in microbiome studies comes in part 
from its gene structure enabling optimal use of current molecular tools. Current high-
throughput sequencing technologies have a limitation on the maximum length of the 
DNA that can be sequenced; the power of high-throughput sequencing technologies 
lies in the large number of sequences that can be sequenced simultaneously, not the 
length of each of these sequences. At the time of writing this is approximately a third 
of the full-length 16S rRNA gene (approximately 600 bp). The structure of the 16S 
gene is convenient as “universal” PCR primers targeting the conserved regions within 
the gene allow for isolation and amplification of one or more of the shorter variable 
region(s) within the gene from (in theory) all bacteria in the sampled community. The 




been shown to be as informative as the full length sequences [38]. It is however 
important to note here that the optimal choice of target gene region has not been 
agreed upon, and some variation in results can occur based on choice of target 
variable region.  
Indexing 
Indexing is a method by which each amplicon is given a label or “address” sequence 
that links it back to the sample from which it was PCR amplified. The index sequence 
is attached to the amplicons during PCR, by their inclusion in PCR primer sequences. 
Indexing is necessary because amplicon libraries from all samples to be sequenced on 
the same sequencing run are mixed together in the final stages of library preparation 
prior to sequencing. A more detailed description is given below. 
Figure 1 is a simplified representation of a typical library preparation workflow and 
shows steps as it occurs for one sample. In practice, this is usually performed for 96 
samples at a time, using 96-well PCR plates. The final step of library preparation 
involves combining aliquots from all 96 samples to generate one sample that is 
further processed through the sequencing protocol (i.e. multiplexing). Post 
sequencing, sequences are assigned back to their samples via the unique sample 
specific “index” sequence(s) that were added to each amplicon during PCR steps of 
library preparation (i.e. demultiplexing) [39, 40].  
As described in the Figure 1 text, index sequence(s) can be added during the same 
PCR step for which the target marker gene is amplified (i.e. 1-step PCR protocol) or 
during a separate PCR dedicated to the process of indexing (i.e. 2-step PCR protocol). 
Most common has been the use of a 1-step PCR protocol for which PCR primers 
include both the marker gene targeting sequence and the index sequence. Notably, the 
supplier of the most commonly used sequencing platform (Illumina), have chosen to 
base their commercial protocol for microbiome analyses on a 2-step PCR approach. 
Index sequences can be added to only one end of the amplicons (i.e. the single 




index approach is used, the design can be either combinatorial or non-redundant. The 
combinatorial approach takes advantage of the fact that relatively few primers are 
needed for multiplexing many samples. For example in the 96 sample setup, a total of 
8 forward and 12 reverse primers with unique indexes is sufficient for multiplexing 
96 samples.  
Bias and error during library preparation 
Post-sequencing analysis of bacterial community composition is built on the 
assumption that the pool of 16S amplicons generated during library preparation is an 
accurate representation of the original sample, in terms of both bacterial membership 
and abundance. In Figure 1 step B, the relative proportion of amplicons from each of 
the three bacteria perfectly reflects the relative proportions of these bacteria in the 
sampled community. However, in practice the PCR is not perfect in this regard and 
several factors may contribute to the introduction of bias and error.  
PCR primer bias is a problem that has attracted a lot of attention because of the 
inability to correct for this bioinformatically. Recall that “universal” PCR primers 
used in microbiome studies are designed to target conserved regions within the 16S 
rRNA gene – the designation “universal” implies that the primers are able to target all 
bacteria in the sampled community with equal efficiency. The issue of primer bias 
arises because the conserved regions are in fact not 100% similar (or conserved) 
across all bacteria [26, 36]. Preferential amplification, and hence a biased 
overrepresentation, of gene sequences for which the conserved region more closely 
matches the primer sequences is a general concern in microbiome studies. 
In the design of “universal” primers for amplification of all bacterial members in the 
sampled community, sequence variability is somewhat accounted for by the use of 
degenerate primers. Degenerate primers consist of a mixture of primers that vary only 
at the specific base positions that are less conserved. However, the use of degenerate 
PCR primers does not completely alleviate the issue of primer bias. First of all, it is 
not certain that variability across all bacterial genomes is accounted for. Second, is 




cytosine (C) (3 hydrogen bonds) is stronger than that between adenine (A) and 
thymine (T) (2 hydrogen bonds). Thus the higher affinity of PCR primers with G or C 
to its target template sequence, may result in the preferential amplification of genome 
targets with GC rich primer binding sites [41]. Thus, despite the use of degenerate 
universal primers, the issue of primer bias remains.  
In addition to PCR primer bias introduced as a result of the marker gene targeting 
sequence, there is the question of the influence of additional overhang sequences such 
as Illumina adaptor sequences and index sequences. It is not understood whether the 
use of longer primer sequences associated with the 1-step PCR protocol may interfere 
with amplification of the target marker gene when compared to the 2-step PCR 
protocol, that separates marker gene amplification and indexing [42].  
Besides PCR primer bias, inherent differences in 16S rRNA gene copy numbers 
across bacterial genomes may also lead to a biased representation of the sampled 
community. The ribosomal RNA operon (rrn), which holds the 16S rRNA gene, is 
often found in multiple and variable copy numbers across bacterial taxa – copy 
numbers typically range from 1 to 15 copies per genome [43]. Bacterial genomes 
with higher marker gene copy numbers may be overrepresented in the pool of 
amplicons generated after PCR amplification. In downstream analyses, this may 
result in a false impression that bacteria which are low in relative abundance in the 
sampled community, but contain high marker gene copy numbers, predominate. 
Further complicating matters is that sequence variation may be found between the 
16S rRNA gene copies found even within the same bacterial genome – in the 
actinomycete Thermobispora bispora for example, 6.4% sequence variation has been 
found between two 16S rRNA copies [44]. When sequenced, this variation may be 
interpreted as originating from different bacteria, inflating measures of diversity 
within the community. 
While, the issues of primer bias, GC content and copy number variation discussed 
above are examples of factors that may introduce bias (i.e. skew in relative 




misrepresentation of the sequence itself). Erroneous sequences are a concern because 
they are often difficult to identify and distinguish from true sequences. If not 
corrected for, erroneous sequences may even be interpreted as originating from other 
bacteria than those which are present in the sampled community – thus introducing 
false positives to the study. Two types of erroneous sequence are commonly 
described in the literature – that introduced by the polymerase during PCR and 
chimeras. The impact of polymerase incorporated errors vary according to DNA 
polymerase, but an estimated error rate of 1 substitution per 105-106  bases can be 
expected [26]. Bioinformatic approaches to dealing with such misincorporated bases 
are limited and pose a particular challenge when performing post-sequencing quality 
filtering steps, as will be discussed in section 6.3.2.  
Chimeras, represent another type of erroneous sequence. Chimeras are mixed PCR 
products derived from two or more parent sequences found within the sampled 
community - resulting in so-called “bimeras” or “multimeras”, respectively. They 
may form between sequences originating from different bacterial genomes but also 
from copy variants found within the same genome [45]. The rate of chimera 
formation has been reported to be as high as over 30% in some studies [46, 47]. Even 
within well curated public repositories, it is assumed that approximately 5% of the 
sequences are chimeras [35]. Chimeras form as a result of mistakes during PCR and 
several mechanisms have been proposed. Recall that PCR amplification is performed 
in cycles, consisting of the following three steps: i) template denaturation, ii) primer 
annealing and iii) extension. If the extension step is terminated prematurely, 
incomplete PCR products may form that contain both the universal primer sequence 
and sequences specific to the 16S variant for which the primer annealed. In the next 
PCR cycle, these may behave as primers for amplification of other 16S variants, 
resulting in the formation of mixed PCR products (i.e. chimeras). Wang and Wang 
[46] were able to show that by using longer extension times, the frequency of chimera 
formation decreased, providing support for this mechanism. Another perhaps less 
frequent mechanism of chimera formation, is that which results from damaged DNA 




are required for efficient lysis of some bacteria, and this may result in DNA breakage 
and fragmentation. During the extension step of PCR, an encountered break in the 
DNA template may result in the “jumping” of the incompletely extended primer to 
another template, again resulting in a mixed PCR product or chimera [31]. Several 
bioinformatic tools for identification and removal of chimeras have been developed, 
and will be discussed further in section 6.3.4.  
6.2.3 High-throughput sequencing 
The final step in the amplicon-based marker gene sequencing workflow is high-
throughput sequencing of the amplicon libraries (Figure 1, step C). While a number 
of different sequencing platforms exist (e.g. 454, PacBio, Illumina), each with own 
characteristic error patterns, herein the focus will be on the most commonly used 
platform – the Illumina MiSeq.  
A description of the MiSeq sequencing process is first in order. All sequencing steps 
are performed on an Illumina flow cell, which may be described simply as a glass 
surface covered with two types of short DNA sequences (i.e. oligonucleotides). The 
oligonucleotides are attached to the flow cell surface and are complementary in 
sequence to the Illumina adapters found at the ends of the amplicon libraries. These 
adapters were added during library preparation steps (Figure 1, step B). 
Before the actual sequencing can begin, a preparatory step referred to as “cluster 
generation” must be completed. During this process, the amplicon template DNA 
libraries (denatured to single strands in the final steps of library preparation), are first 
attached to the Illumina flow cell surface via complementary base pairing to the 
oligonucleotides that are attached to the flow cell. Each bound DNA fragment is then 
amplified via so-called bridge amplification PCR, to generate clusters consisting of 
approximately 1000 copies of the amplicon template DNA. After successful cluster 
generation, the flow cell consists of millions of distinct clusters, evenly spaced out 
across the flow cell surface, with each cluster representing an amplicon from the 




Sequencing is then performed using an approach termed sequencing-by-synthesis 
(SBS). In short, sequences are “read” by building the strands complementary to the 
fragments that make up each cluster – one base at a time. The process is also carried 
out simultaneously for all clusters spread out across the flow cell - hence the term 
massive parallel sequencing used for the technology. Sequencing begins with the 
addition of sequencing primer, which marks the start position for the sequencing 
reads. During each cycle of sequencing, four fluorescently labeled nucleotides (A, T, 
C, G) with reversible terminator labels, are allowed to flow across the flow cell 
surface. The appropriate nucleotide binds to the strand being synthesized through 
complementary base pairing with the template DNA fragments that make up each 
cluster. The cumulative fluorescent signal generated from each of the fragments 
within a cluster is then recorded, and used to determine the base call for that cluster. 
The fluorescent reversible terminator labels are then removed, and the process repeats 
itself until the pre-programmed number of cycles have been completed.  
The accuracy of the MiSeq sequencing process is determined in large by so-called 
phasing and pre-phasing events described hereafter [48]. Recall that for each cycle of 
sequencing, base calls are determined from the signal collected from all identical 
fragments that make up a particular cluster. The signal intensity is therefore 
dependent on the simultaneous incorporation and detection of the same nucleotide 
(i.e. base) across all fragments within a cluster. However, the chemistry is not perfect, 
and for each cycle it is expected that for a small fraction of the fragments, sequencing 
will either slow down (phasing) or progress ahead (pre-phasing) of the rest of the 
fragments. Phasing may for example result if the terminator label is not removed after 
a completed cycle. In turn, pre-phasing may result if a nucleotide lacks the terminator 
label, enabling the incorporation of more than one nucleotide in a cycle. For each 
sequencing cycle, the fraction of fragments in a cluster impacted by phasing and pre-
phasing events increases - and the sequencing signal for that cluster becomes more 
distorted. This results in increasingly high error rates towards the ends of sequencing 
reads, and is currently the main reason for the limitation on maximum read lengths 




substitution type errors (i.e. an A is called instead of G), in contrast to insertion or 
deletion type errors frequently seen for other platforms.  
Because of the issue of phasing and pre-phasing, the sequencing of the marker gene 
template and index(es) are typically performed in separate reads. The introduction of 
fresh primer for each new read will “restart” the sequencing process for all fragments 
within the cluster, mitigating the cumulated effects of phasing and pre-phasing [50]. 
And as described later, the paired-end (PE) sequencing approach, uses separation of 
reads to expand on the maximum read length that can be achieved using the currently 
available chemistry.  
6.3  Bioinformatic sequence processing 
In the previous section 6.2, the amplicon-based microbiome sequencing workflow has 
been outlined, with a focused discussion on potential sources of error and bias. In the 
following section, current bioinformatic approaches to dealing with some of these 
issues, as well as limitations that remain, will be discussed. Examples will be taken 
from one of the most popular bioinformatic pipelines – Quantitative Insight into 
Microbial Ecology (i.e. QIIME1/QIIME2). Note that QIIME is a wrapper for 
numerous other tools (e.g. DADA2) and for the current discussion, the default 
algorithms implemented in the pipeline will be referred to.  
6.3.1 Demultiplexing 
Recall that prior to sequencing, amplicon libraries from all samples to be sequenced 
on the same sequencing run are pooled together (i.e. multiplexed) [39, 40]. Once 
sequencing has been completed, the index sequence(s), which are the same for all 
amplicons from the same sample, are used to reassign sequences back to the sample 
from which they originated (i.e. demultiplexing). The sequencing output (Figure 1, 
step C), may be retrieved in the form of already demultiplexed fastq files. Other 
times, the fastq files have not been demultiplexed and bioinformatics processing 




Bias may be introduced during demultiplexing if sequences are not assigned back to 
the correct sample - a phenomenon referred to as index misassignment. There are 
several ways by which index misassignment may occur [51]. Primers may for 
instance be contaminated during their manufacture. Cross-contamination may also 
occur during library preparation by way of internal well-to-well contamination 
between samples placed next to one another on the PCR plate, or during sequencing 
due to the presence of indexed amplicons from previous sequencing runs. Beside the 
issue of cross-contamination, there is the issue of PCR or sequencing error. Errors 
during PCR or sequencing may result in the conversion of an index sequence to that 
of another index used in the same sequencing setup. Most indexes are however 
designed to ensure that multiple substitution errors would have to occur before any 
one index would begin to resemble another index [49]. Index misassignments may 
also be associated with mixed or overlapping clusters on the flow cell, resulting in the 
assignment of an entire index read from one cluster to a sequence read from an 
adjacent cluster, or the assignment of a sequence read from one cluster to the index 
read(s) from another cluster [50, 51]. The use of unique dual indexed libraries, 
instead of single indexed libraries have been shown to reduce the impact of index 
misassignments [50, 51]. Quality filtering of index sequences has been proposed as a 
mechanism for correcting for index misassignments [51], although this has not been 
implemented in most pipelines.  
6.3.2 Quality filtering 
The aim of the quality filtering step is to filter out erroneous sequences resulting from 
PCR point errors and sequencing error (chimeras are dealt with in a subsequent step). 
While the occurrence of PCR and sequencing errors may appear as rare events to be 
overlooked, when dealing with the millions of sequences generated in amplicon 
sequencing data - these errors if not corrected for may result in inflated measures of 
diversity [26, 49, 52, 53]. In the following sections, differences between PCR and 
sequencing error and challenges associated with the removal of each will be 
discussed.  




Most bioinformatic approaches to dealing with erroneous sequences have targeted 
errors generated during the sequencing process. These errors are relatively easy to 
identify compared to PCR incorporated errors, due to the sequencer generated Phred 
quality scores (Q score) that accompany sequence data (i.e. fastq files). By definition, 
the Q score is a measure of the probability by which a base is called incorrectly 
during the SBS process. It is calculated using the formula Q = -10 log10 P, where Q is 
the Q score and P is the estimated error probability [54]. A Q30 score (Q score of 30) 
will for example translate to a base call accuracy of 99.9%. Quality scores can be 
used as an indicator to trim off low quality bases at read ends or for error correction 
when handling PE data – each strategy described subsequently. However, care must 
be taken when interpreting results, as there has been some disagreement on the 
reliability of the association between Q scores and error probabilities. While Kozich 
et al. [55] reported that sequencing errors were highly associated with low Q scores 
for example, Schirmer et al. [48] found the association to be unreliable.  
Quality trimming 
The aim of quality trimming is in essence to determine the point along the read for 
which the Q scores begin to fall below the desired threshold values (recall that 
reduction in quality scores is expected across the read length (section 6.2.3). The 
method described by Bokulich et al. [52], was implemented in the QIIME1 pipeline 
and performed in the same step as demultiplexing. The methods applied when using 
QIIME2 differ (implemented in denoising algorithms, e.g. DADA2), and will be 
discussed in a subsequent section. In simple words, when applying the “Bokulich 
method”, sequences are screened for low quality bases, starting at the beginning of 
the sequence and progressing until the end of the sequence is reached. Decisions 
regarding the number of consecutive bases (default=3) that must maintain a user 
defined threshold Q score (default=3), the length of the sequence after trimming 
(default = 75% of the untrimmed sequence), and finally the maximum number of 
ambiguous base calls (default = 0), determine whether a sequence is kept or 
discarded. Deciding on the appropriate threshold Q score is perhaps the most 




of the sequencing data, one also risks losing accurate reads that have been assigned 
lower but perhaps acceptable Q scores (e.g. Q20). 
PE error correction 
The PE sequencing approach adds another dimension to quality filtering [55, 56]. As 
described previously (section 6.2.3), sequencing error rates tend to increase towards 
the end of sequencing reads (and Q scores decrease). Using a PE sequencing 
approach (i.e. separation of reads), it is possible to extend the maximum read length 
that can be obtained using current sequencing chemistries. When performing PE 
sequencing, the targeted region is sequenced from both ends of the DNA sequence, in 
two separate reads. By design, the marker gene targeting primers should be chosen so 
that the amplicons are short enough to allow for an overlap between PE reads. This 
will enable the merging of the paired reads to form a contiguous read, and the 
opportunity to resolve discrepancies at the read ends. Different choices can be made 
with regards to resolving discrepancies between the overlapping reads. For the most 
stringent filtering procedures, one can demand that the overlapping reads match 
perfectly - if they do not, then the sequence may be removed. Alternatively, the 
overlap can be used to correct for an incorrect base, as more often than not, one of the 
reads will have a higher Q score than the other at the given base position. While PE 
sequencing has mainly been used to achieve longer sequencing reads, others have 
suggested that the approach should be used for generating completely overlapping 
reads for improved error filtering [49].  
As mentioned above, because the Q score is a measure of the accuracy of the SBS 
process, it does not capture PCR errors incorporated during library preparation or 
cluster generation; an incorporated PCR error may indeed generate a perfect Q score. 
Current methods for dealing with PCR error (and also potentially missed sequencing 
errors) have largely been based on grouping sequences together into clusters called 




6.3.3 Clustering and denoising  
While much variation exists across different bioinformatic pipelines, a central step 
performed in all pipelines is clustering to OTUs or denoising to ASVs.  
Clustering to operational taxonomic units (OTUs) 
The most common approach has been to cluster sequences into operational taxonomic 
units (OTUs) based on a shared sequence similarity threshold of 97% (or dissimilarity 
of 3%). The method was built on the work by Stackebrandt and Goebel et al. [37] 
who were able to demonstrate that at 97% 16S sequence similarity one could 
distinguish between bacteria at species level. A representative sequence from each 
OTU is assigned a taxonomic label, and the number of sequences in each OTU is 
used to conclude on the relative abundance of the particular taxa in the sampled 
community. The list of OTUs, and the number of sequencing reads binned to each 
OTU form the working OTU table for which all subsequent bioinformatic analyses 
are performed.  
Clustering of sequences into 97% OTUs serves two purposes. First of all, it reduces 
the number of sequences that are processed further down the bioinformatic pipeline. 
A typical MiSeq sequencing run will generate millions of sequencing reads. After 
clustering to OTUs this volume is often reduced to the thousands. Second, clustering 
serves the purpose of error correction. Erroneous sequences with less than 3% 
incorporated error, will be placed in the same OTU group as the correct sequences 
[57]. The method is however still vulnerable to spurious OTUs that may form from 
sequences with greater than 3% incorporated error. The issue of spurious OTUs was 
addressed by Bokulich et al. [52]. The authors recommended the removal of small 
OTUs, defined as those for which there were fewer sequences than 0.005% of the 
total sequence count.  
Denoising to amplicon sequence variants (ASVs) 
Recently, new methods of handling amplicon sequencing data have been developed 




These methods have collectively been referred to as “denoising”, and the product 
sequences after denoising are referred to as an exact sequence variants (ESV) or 
amplicon sequence variants (ASVs). The most commonly used denoising method is 
implemented in DADA2 (divisive amplicon denoising algorithm 2) [59]. In simple 
words, the DADA2 denoising algorithm builds on the assumption that true biological 
sequences will be present at a higher frequency than erroneous sequences. Because 
ASVs are assumed to be free of PCR and sequencing error, there is no need to cluster 
sequences at 97% as was performed for OTUs. ASVs are thus referred to as the 
equivalent of 100% OTUs, making it possible to distinguish between sequences that 
vary by just one nucleotide. In addition to denoising to ASVs, the DADA2 method 
incorporates all general steps typical for amplicon sequencing data including, 
filtering, dereplication, chimera removal and joining of PE reads.  
6.3.4 Chimera removal 
Several bioinformatic tools have been developed for identification of chimeras. Early 
tools (e.g. Bellepheron [60], Pintail [35]) were designed for analysis of full-length 
16S sequences, and were later shown to perform suboptimally on short amplicon data 
[47, 61]. This triggered the further development of new tools. Some examples include 
ChimeraSlayer [47], Perseus [61], and UCHIME [62] - to name a few. Chimera 
removal is also an integrated part of the DADA2 method as described above, 
developed specifically for targeting denoised ASVs.   
The existing chimera detection tools listed above, are more or less based on a similar 
strategy. In short, the sequence in question is compared to a pre-defined set of non-
chimeric reference sequences [61, 62]. If the query sequence matches to two or more 
sequences in the reference set, it is assumed that it formed from a recombination 
event between these matched sequences during PCR – the query sequence is then 
flagged as chimeric. Different detection tools may vary with regards to the origin of 
the non-chimeric reference set. Using de novo abundance based approaches (e.g. as 
seen in Perseus [61], UCHIME-de novo [62] and DADA2) sequences of high 
abundance in the data to be analysed are considered non-chimeric, and used to build 




through a greater number of PCR cycles than the chimeras that form between them 
(i.e. the parent sequence must already exist). Using an alternative approach, the 
reference set is provided by the user and based on a preexisting database of chimera-
free sequences (e.g. as seen in ChimeraSlayer [47] and UCHIME – reference mode 
[62]).  
The accuracy of the chimera filtering step will in large be dependent on quality of the 
non-chimeric reference set. Using the de novo approach, it is for example assumed 
that preferential amplification of a chimera sequence did not occur during PCR, as 
this would place the chimera in the reference set. The accuracy of chimera filtering 
methods will also depend on the presence of sequencing errors, as with the short read 
lengths characteristic of amplicon sequencing data, differences to be detected and 
used for inferring a chimera are small [62]. Using the database based approach, 
another consideration is whether the community under study is adequately 
represented in the reference set, important because chimeras formed from parent 
sequences not found in the reference set will not be detected. For most datasets, the 
communities under study (e.g. the airways) are poorly characterized and the chosen 
database likely to be incomplete; thus the de novo approach is often preferred.  
6.4  Low biomass samples from the lungs  
In the following section, the framework presented in Figure 1 is put in context to 
studies on the lower airway microbiome, which presents with additional challenges 
related to the low bacterial load of acquired samples.  
6.4.1 Sample bacterial load and contamination  
It was the reports by Biesbroek et al. [32] and Salter et al. [63] that initially stirred up 
discussion regarding the degree to which accurate microbiota analyses could be 
achieved for samples holding low bacterial loads (for which the lungs are the classic 
example in the literature). Both studies demonstrated the existence of an inverse 
relationship between sampled bacterial DNA levels and the influence of bacterial 




extraction kits, PCR reagents, the technician etc.). The significance of these studies 
warrants the review of key findings from each.  
Biesbroek et al. [32] were concerned about the variable levels of DNA obtained from 
low biomass nasopharyngeal swabs. To explore the impact of bacterial load on the 
analyses of microbiota composition, they set up an experiment based on a serially 
diluted sample of saliva. Bacterial community composition began to differ from the 
original undiluted sample at a concentration of 105 bacteria/mL. The observed shift in 
bacterial composition coincided with an increase in the levels of bacteria mapping to 
the phylum Proteobacteria. Although the authors could not with certainty show that 
these bacteria originated from laboratory contamination, this was their interpretation 
of the data. Further, they defined 106 bacterial cells/mL as the threshold bacterial load 
for which accurate microbiota analyses could be performed. When extrapolating their 
findings to data obtained from the low biomass nares and nasopharynx, they found 
that choice of DNA extraction method (four different methods compared) determined 
whether samples fell above or below their set threshold level of bacterial load.  
The paper by Salter et al. [63] was published two years later. The authors recognized 
the difficulty in distinguishing between contaminants and actual members of the 
sampled community, e.g. as seen for Proteobacteria in the Biesbroek study [32]. 
They designed a similar dilution experiment to that conducted in the former study, 
but with an important modification. Rather than using saliva (or other complex 
natural sample), they based their study on a monoculture consisting of one bacterial 
species not likely to be introduced from the laboratory environment or from reagents 
and kits used for sample processing (Salmonella bongori). On analysis of the 
sequencing output, sequences classified to taxa other than S. bongori were interpreted 
as derived from contamination. In accordance with the Biesbroek study [32], they 
observed a clear inverse relationship between sample bacterial load and proportion of 
non-S. bongori sequences (i.e. contaminants).  
In summary, these groundbreaking studies have raised questions regarding the quality 




important questions regarding the proportion of sequences that can be expected to be 
representative of the sampled lung microbiota and not contamination introduced from 
the laboratory. However, as discussed in the following section, the lack of standards 
with regards to protocols for sampling and laboratory processing make it difficult to 
generalize on the state of the field.  
6.4.2 Sample bacterial load varies across protocols  
In the design of their studies, investigators are faced with several decisions along the 
laboratory pipeline, that can determine the strength of the signal from the sampled 
bacterial community. A description of some critical steps follows.  
Sampling. 
As discussed earlier (section 6.1.2), BAL and SB are the most common sample types 
in airway microbiome studies. The manner by which these samples are collected has 
however not been standardized, and different approaches may lead to differences in 
obtained sample bacterial load. This is mainly due to differences in dilution effects. 
When sampling BAL for instance, decisions regarding the amount of fluid to instill 
and whether to keep fractions separate or pooled, will determine the levels of bacteria 
in the collected sample. However, the decision on whether to fractionate BAL or not, 
is not straightforward due to the potential for bronchoscope carryover from the upper 
airways. As discussed earlier, the fractioning of BAL may be used as a method for 
which one can “dilute away” upper airway bronchoscope carryover [6, 24] – however 
this is at the cost of lowering the obtained sample bacterial load. When sampling SB, 
the volume of sampling fluid for which SB are placed in after sampling will be 
equally important – be it saline sampling fluid or buffer for DNA extraction. Also the 
number of SB taken per sampling site has not been standardized – and the greater the 
number of SB per site, the higher we may expect the levels of bacteria.  
Eukaryote cell removal  
Once samples have been collected, a decision must then be made on whether to keep 




cells [64, 65]. Eukaryotic cell removal is performed by centrifugation of the sample at 
a speed that pellets these larger cells out of solution, while leaving the smaller 
bacterial cells in suspension. Dickson et al. [64] compared results when processing 
whole (eukaryotic cells kept) and acellular (eukaryotic cells removed) BAL. They 
found that eukaryotic cell removal resulted in lower community richness - implying 
the concomitant removal of bacterial cells associated with eukaryote host cells (for 
instance via biofilms). Important to the current discussion - they also observed a 
lower bacterial load after the removal of eukaryotic cells. Both these findings warrant 
the use of whole samples over acellular samples. While most studies process whole 
samples, some key studies in the field have also used acellular samples [20, 25, 66, 
67]. In the study by Lozupone et al. [67] both whole and acellular samples were used 
in the same study.  
The publications by Biesbroek et al. and Salter et al. emphasize the importance of 
securing a high bacterial load already at the stage of sampling [32, 63]. This in order 
to overpower the contaminating bacterial signal introduced in subsequent steps - 
starting with bacterial DNA extraction.  
Bacterial DNA extraction  
A decision regarding the input sample volume used for DNA extraction is also one to 
be made. There is no standard in the field, and large differences are found across 
studies. For instance, the input volume BAL used in some studies is as low as only a 
few mL [6, 23], while in other studies volumes approximating 100 mL have been 
used [14, 64]. As described above however, several factors will determine the levels 
of bacteria in these samples (i.e. sample type, dilution effects and the use of whole or 
acellular BAL). Also, clinical factors such as disease state and the use of antibiotics 
may be important.  
In addition to input sample volume, a decision has to be made regarding choice of 
DNA extraction method. Importantly, differences across methods can result in 
variable DNA yields [29, 32]. This has not been a major concern in studies on 




major impact on studies on samples carrying low bacterial loads [32, 63]. Recall that 
Biesbroek et al. [32], show in their study how choice of DNA extraction kit 
determined whether samples fell above or below their defined threshold bacterial load 
for which accurate microbiota analyses could be achieved.  
Polymerase chain reaction (PCR)  
The PCR is a central tool in the amplicon-based marker gene sequencing workflow. 
In studies of low biomass samples, an increased number of PCR cycles is often used 
to obtain adequate levels of DNA for sequencing [32]. However, error and bias 
associated with the PCR, is expected to increase with increased number of PCR 
cycles. Furthermore, increasing the number of PCR cycles appears to result in weaker 
signals from the sampled microbiota and an increased signal from contamination. 
This was demonstrated in the study by Salter et al. [63] on comparison of sequencing 
output generated by processing the S. bongori dilution series through 20 and 40 PCR 
cycles.  
In conclusion to the introduction sections 6.1 - 6.4, there is a need for studies that i) 
add to the discussion on how to sample the microbiota of the lower airways with 
minimal influence of oropharyngeal carryover, ii) increases knowledge on the impact 
of laboratory contamination in a low-biomass setting, and strategies to handle this, 
and finally, iii) shed light on the impact of methodological choices related to marker 




7.  Objectives 
The main objective of the thesis was to evaluate the impact that various 
methodological choices could have on the presentation of the airway microbiome. 
Specifically we investigated: 
 
1. The bacterial composition observed when employing protected and 
unprotected bronchoscopic sampling methods of the lower airways (paper I). 
 
2. The impact of laboratory contamination, and bioinformatic strategies for 
dealing with contamination in samples with low bacterial loads (paper II). 
 
3. The impact of a one vs two step PCR protocol and choice of target amplicon 







8. Materials and methods 
8.1  Study design and participants  
The PhD project was conducted as part of a single-center observational study: The 
Bergen COPD Microbiome study (short name «MicroCOPD»). The data collection 
for the MicroCOPD study was carried out at the outpatient clinic at the Department of 
Thoracic Medicine, Haukeland University Hospital (Bergen, Norway). The design of 
the MicroCOPD study has been published [23].  
In brief, MicroCOPD is a bronchoscopy study designed to compare the airway 
microbiome of subjects with and without airway disease (i.e. COPD, asthma, healthy 
controls). The study was initiated in the spring of 2012, and two years of protocol 
development and a pilot phase followed. The first planned research bronchoscopy 
procedure for the main study was performed in April 2013. The last bronchoscopy 
was performed in June 2015.  
All together, 323 bronchoscopies were performed on a total of 249 study participants 
(130 with COPD, 16 with asthma and 103 healthy controls). All participants were 
volunteers recruited to MicroCOPD from two previous studies conducted at the same 
department; the GeneCOPD follow-up study [68] and the Bergen COPD cohort study 
[69–71]. A small number of participants were also recruited by interest generated by 
the local press. In addition, asthma patients were recruited from a respiratory 
medicine private practice. There were several inclusion criteria. In the original 
protocol, there was an age limit of 40 years for COPD patients, and all COPD 
patients were above 40 years of age. As the study eventually also included asthma 
patients, this age limit was abandoned. This also applied to the requirement of a 10 
pack year tobacco smoke exposure, enabling inclusion of also “never-smokers” with 
COPD for a total of three categories based on smoking habit (“current smokers”, “ex-
smokers” and “never-smokers”). Airway obstruction was identified by post-
bronchodilator spirometry, whereas all diagnoses were confirmed by experienced 




pulmonary function and radiologic imaging. Severity of airway obstruction was 
evaluated by the forced expiratory volume in 1 second (FEV1) in percent of predicted 
values based on Norwegian reference values [72]. The spirometry was performed on 
a Viasys Vmax ENCORE, and bronchodilation achieved by the administration of 0.4 
mg salbutamol by a large-volume spacer at least 30 minutes before the procedure. 
Exclusion criteria included all factors indicating that the subject would not be able 
tolerate research bronchoscopy. We postponed participation for subjects that had 
received antibiotics or corticosteroids the last 14 days.  
Only a subset of the participants from the MicroCOPD study was included in the 
three papers for the current PhD project. Paper I included 125 participants (58 control 
subjects, 64 subjects with COPD and 3 subjects with asthma). Papers II and III, 
included the same 23 participants (9 control subjects, 10 subjects with COPD and 4 
subjects with asthma).  
8.2  Study samples 
8.2.1 Procedural samples (Papers I, II and III) 
Sample types included oral washes (OW), bronchoscopically acquired protected 
specimen brushes (PSB), protected bronchoalveolar lavages (PBAL), small-volume 
lavages (SVL), and negative control samples (NCS). A description of the sampling 
procedure used in the MicroCOPD study follows. 
A sealed bottle (500 mL) of sterile phosphate-buffered saline (PBS) was opened prior 
to each procedure or used within 24 hours if multiple procedures were performed on 
the same day. The PBS had been sterilized by sterile filtration (0.22 µm) and 
autoclaving at 121 °C for 15 minutes by the manufacturer. 1 mL of the PBS was set 
aside for use as a negative control sample (NCS), never entering the study subject or 
being in contact with the bronchoscope.  
Study participants were given 0.4 mg of salbutamol (a bronchodilator); this was 




the risk of bronchoscopy-induced bronchospasm. Before the bronchoscopy 
procedure, the participant was asked to gargle 10 mL of PBS for the collection of an 
oral wash sample (OW). Flexible video-bronchoscopy was then performed in supine 
position via the oral route. Each participant received local anaesthesia with lidocain; 
pre-procedurally as a spray to the tongue and oropharynx, and per-operatively 
through a catheter to the vocal cords, trachea, and bronchi. To minimize upper airway 
contamination to the scope working channel, no suctioning was performed before 
passage of the scope through the vocal cords. Having entered the lower airways, three 
protected specimen brushes (rPSB) were first collected from the right lower lobe 
(RLL) using double sheathed wax-plug protected specimen brushes (Conmed, USA) 
and placed in 1 mL PBS. Next, two fractions of protected bronchoalveolar lavage 
(PBAL1/PBAL2) were collected from the right middle lobe (RML); this by instilling 
2 x 50 mL PBS through a wax-plugged catheter (Plastimed Combicath, France). The 
bronchoscope was then repositioned for sampling of the left lung. This was done 
without retracting the bronchoscope above the vocal cords. Three wax-plugged 
protected specimen brushes (lPSB) were collected from the left upper lobe (LUL) and 
placed in 1 mL PBS. Finally, a sample of small-volume lavage (SVL) was collected 
from the same segment as the lPSB by instilling 20 mL PBS directly through the 
working channel. For 100 participants, the left side was examined before the right 
side.  
8.2.2 Procedural control samples (Paper II) 
For the collection of procedural control samples, we returned to the bronchoscopy 
room and performed ten simulated (no patient) procedures over two days. For each 
procedure five samples were collected: a bronchoscope rinse (BR), a catheter rinse 
(CR), a protected specimen brush (PSB), a sample of phosphate buffered saline (PBS) 
transferred to a cryotube (CT) and a negative control PBS sample (NCS).                           
On each day, a sealed 500 mL bottle of PBS was opened for use in all five 
procedures. 1 mL PBS was transferred to both an eppendorf tube for collection of the   
NCS and to a cryotube for collection of the CT sample. Sampling PSB was 




the bronchoscope working channel. The brush was exposed to the air and then 
returned back through the bronchoscope. Using sterile scissors, the brush end was cut 
off and transferred to an eppendorf tube with 1 mL PBS. This was repeated until three 
brushes had been collected per sampling. Sampling CR was performed by passing a 
wax-plugged catheter (Plastimed Combicath, France) through the bronchoscope 
working channel and instilling 50 mL PBS. This was collected in a 50 mL Falcon 
tube on the other end and then suctioned back up. Sampling BR was performed by 
instilling 20 mL PBS and collected in a serial connected lavage trap. Samples were 
aliquoted and stored at - 80 °C. 
8.2.3 Salmonella dilution series (Paper II) 
Salmonella enterica serovar Typhimurium (ATCC 14028, USA) was plated out on 
blood agar plates and incubated overnight at 37 °C. The following day, colonies were 
transferred to a tube containing sterile physiological water using sterile cotton swabs 
until a McFarland density of approximately four was reached. The suspension was 
used to prepare a ten-fold dilution series across a total of seven samples. Aliquots 
were stored at -20 °C. 
8.2.4 Mock community (Paper III) 
A mock community (MC) sample consisting of genomic DNA from 20 different 
bacterial species (17 genera) was included on all sequencing runs. The MC consisted 
of uneven levels of genomic DNA from the different species of bacteria, with the 
number of rRNA operons per species varying from 1000 to 1000000 counts (Table 
1). The operon count (provided on the certificate of analysis) was used to calculate 
the relative abundance of the different bacteria in the sample.  
The reagent was obtained through BEI Resources, NIAID, NIH, as part of the Human 
Microbiome Project: Genomic DNA from Microbial Mock Community B (Staggered, 






Table 1. Mock community HM-783D  
Species Number of operons Relative abundance  
Acinetobacter baumannii 10000 0.22 % 
Actinomyces odontolyticus 1000 0.02 % 
Bacillus cereus 100000 2.19 % 
Bacteroides vulgatus 1000 0.02 % 
Clostridium beijerinckii 100000 2.19 % 
Deinococcus radiodurans 1000 0.02 % 
Enterococcus faecalis 1000 0.02 % 
Escherichia coli 1000000 21.91 % 
Helicobacter pylori 10000 0.22 % 
Lactobacillus gasseri 10000 0.22 % 
Listeria monocytogenes 10000 0.22 % 
Neisseria meningitidis 10000 0.22 % 
Propionibacterium acnes 10000 0.22 % 
Pseudomonas aeruginosa 100000 2.19 % 
Rhodobacter sphaeroides 1000000 21.91 % 
Staphylococcus aureus 100000 2.19 % 
Staphylococcus epidermidis 1000000 21.91 % 
Streptococcus agalactiae 100000 2.19 % 
Streptococcus mutans 1000000 21.91 % 





8.3  Bacterial DNA extraction (Papers I, II, III) 
The protocol for bacterial DNA extraction used in the MicroCOPD study was 
designed in-house by Tuyen Thi Van Hoang (UiB) and Professor Harald G. Wiker 
(UiB). The protocol includes both enzymatic and mechanical lysis methods, as 
recommended in the current literature [29]. A description follows.  
The volume of sample used as input to the DNA extraction protocol varied with 
sample type. For procedural samples: 1800 µl for OW and PBAL and 450 µl for PSB 
and NCS. For procedural control samples: 1800 µl for BR and CR, 550 µl for PSB 
and 450 µl for CT and PBS. For the SDS, an input volume of 500 µl was used.  
The samples were first treated with Sputasol (Oxoid Limited, England) (i.e. 
dithiothreitol) and incubated at 37 °C for 15 minutes on a thermomixer (1000 rpm); 
this to ensure a homogenous distribution of the bacterial cells in the sample. The 
volume of Sputasol added to each sample, was the same as the input sample volume 
for DNA extraction. Bacterial cells (and eukaryotic cells) were collected by 
performing a high speed centrifugation step, at 15700 g for 8 minutes. The resulting 
cell pellet was resuspended in 250 µl PBS. Next, enzymatic lysis was performed by 
treatment with an enzyme cocktail solution consisting of 25 µl lysozyme (10 mg/ml, 
Sigma-Aldrich, USA), 3 µl mutanolysin (25 KU/mL, Sigma-Aldrich), 1.5 µl 
lysostaphin (4000 U/mL, Sigma-Aldrich) and 20.5 µl TE5 buffer (10 mM Tris-HCl, 5 
mM EDTA, pH 8) and incubated at 37 °C for 1 hour on a thermomixer (350 rmp). 
Bacterial cells not sufficiently lysed by the enzymes, were collected by centrifugation 
at 15700 g for 15 minutes. The supernatant containing any extracted DNA was 
transferred to a new eppendorf tube and stored at 4 °C, while further processing of the 
hard to lyse pellet; this to prevent DNA shearing in the subsequent mechanical lysis 
step. Mechanical lysis was then performed on the pelleted cells by processing through 
the FastDNA Spin Kit (MP Biomedicals, USA). The pellet was first resuspended in 
800 µl CLS-TC lysis buffer and then transferred to a Lysing Matrix A tube (FastDNA 
Spin Kit). Mechanical lysis was performed using the FastPrep-24 instrument (MP 




combined with the supernatant from the enzyme lysis step. Further processing was 
performed as described by the manufacturers for the FastDNA Spin Kit. DNA was 
eluted in a total volume of 100 µl. 
8.4 Quantification of bacterial load (Paper II) 
Sample bacterial load was measured by probe-based quantitative PCR (qPCR) 
targeting the bacterial 16S rRNA gene region V1V2.  
Primers with sequences [5′-AGAGTTTGATCCTGGCTCAG-3′] (forward) and [5′-
CTGCTGCCTYCCGTA-3′] (reverse) were used together with probe [5´-6-FAM-
TAACACATGCAAGTCGA-BHQ-1-3´] (locked nucleic acid bases are underlined; 
6-FAM: 6-carboxyfluorescein; BHQ-1: Black Hole Quencher-1) [6, 7, 14, 21]. Each 
reaction consisted of 10 µl Takyon No ROX Probe MasterMix (2X) (Eurogentec, 
Belgium), 0.2 µl of each forward and reverse primer (10 µM), 0.15 µl of the 
hydrolysis probe (10 µM), 2 µl sample and RT-PCR grade water (Thermo Fisher 
Scientific, USA) for a total volume of 20 µl.  
Cycling was performed on a Light Cycler 480 instrument (Roche) using the following 
conditions: an initial cycle at 95 °C for 5 minutes followed by 45 cycles of 95 °C for 
5 seconds, 60 °C for 20 seconds and 72 °C for 10 seconds and a final extension cycle 
of 72 °C for 2 minutes. A standard curve was constructed from a 10-fold dilution 
series of genomic DNA from E.coli strain JM109 (Zymo Research, USA).  
8.5 Illumina MiSeq sequencing (Papers I, II, III) 
Analysis of bacterial community composition was performed by high-throughput 
amplicon-based sequencing of the bacterial 16S rRNA gene on the Illumina MiSeq 
sequencing platform. Three different setups for MiSeq sequencing were used in the 
project. The setups varied with regards to the number of PCR steps (one or two) and 
the target marker gene region sequenced (16S rRNA gene region V3 V4 or V4): 
Setup 1 (2-step PCR; region V3 V4); Setup 2 (2-step PCR; region V4); Setup 3 (1-




8.5.1  MiSeq sequencing setup 1 (Papers I, II, III) 
Sequencing setup 1 is based on the Illumina 16S Metagenomic Sequencing Library 
Preparation guide (Part # 15044223 Rev. B). The protocol consists of two PCR steps; 
the first for amplification of the target marker gene region to be sequenced, and the 
second for the addition of index sequences required for sample multiplexing.  
In the first PCR, the 16S rRNA gene region V3 V4 was targeted using primers [5′-TC 
GTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-
3′] (forward) and [5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAC 
TACHVGGGTATCTAATCC-3′] (reverse). Illumina overhang adapter sequences are 
underlined. Gene specific sequence (not underlined) were taken from Klindworth et 
al. [73], and included four degenerate bases named according to IUPAC nucleotide 
nomenclature (N = any base; W = A or T; H = A, C or T; V = A, C, or G).  
Each reaction consisted of 5 µl sample, 12.5 µl KAPA HiFi HotStart ReadyMix (2X) 
(Kapa Biosystems, South Africa), 0.5 µl of each primer (10 µM) and 6.5 µl RT-
PCR grade water (Thermo Fisher Scientific, USA) for a total volume of 25 µl. PCR 
cycling was performed using the following program: an initial cycle at 95 °C for 3 
minutes, followed by 45 cycles of 95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C 
for 30 seconds, and a final extension cycle at 72 °C for 5 minutes. PCR cleanup was 
performed using Agencourt AMPure XP beads (Beckman Coulter, USA).  
The second PCR was performed using primers from the Nextera XT Index kit 
(Illumina Inc., USA). The primers targeted the Illumina overhang adapter sequences 
added to each amplicon in the first PCR (underlined in the primer sequences given 
above). PCR cycling was performed using the following program: an initial cycle at 
95 °C for 3 minutes, followed by 8 cycles of 95 °C for 30 seconds, 55 °C for 30 
seconds, 72 °C for 30 seconds, and a final extension cycle at 72 °C for 5 minutes. 
PCR cleanup was performed using Agencourt AMPure XP beads (Beckman Coulter, 
USA). 
Amplicon libraries were quantified using the Qubit dsDNA HS Assay Kit (Life 




denatured with NaOH, and diluted to 10 pM using a buffer provided in the MiSeq 
reagent kit v3 (Illumina). Finally, the diluted, denatured library pool was spiked 
(15%) with PhiX from the PhiX Control Kit v3 (Illumina). MiSeq sequencing was 
performed using 2x300 cycles of paired-end sequencing using reagents from the 
MiSeq reagent kit v3 (Illumina). 
8.5.2 MiSeq sequencing setup 2 (Paper III) 
Sequencing setup 2 was based on the two-step PCR protocol described in the Illumina 
16S Metagenomic Sequencing Library Preparation guide (Part # 15044223 Rev. B).  
In the first PCR, the 16S rRNA gene region V4 was targeted using primers [5´-TCGTC 
GGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA-3´] 
(forward) and [5´-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACT 
ACHVGGGTWTCTAAT-3´] (reverse). Illumina overhang adapter sequences are 
underlined. Gene specific sequence (not underlined) were taken from Caporaso et al. 
[74] and included four degenerate bases named according to IUPAC nucleotide 
nomenclature (M = A or C; H = A, C or T; V = A, C, or G; W = A or T).  
Each reaction consisted of 5 µl sample, 12.5 µl KAPA HiFi HotStart ReadyMix (2X), 
1.25 µl of each primer (10 µM), and 5 µl RT-PCR grade water (Thermo Fisher 
Scientific, USA) for a total volume of 25 µl. PCR cycling was performed using the 
following program: an initial cycle at 95 °C for 3 minutes, followed by 45 cycles of 
95 °C for 30 seconds, 50 °C for 30 seconds, 72 °C for 30 seconds, and a final 
extension cycle at 72 °C for 5 minutes. PCR cleanup was performed using Agencourt 
AMPure XP beads (Beckman Coulter, USA).  
The second Index PCR step, library quantification, normalization and preparation for 
sequencing was performed as described for sequencing setup 1. MiSeq sequencing 
was performed using 2x275 cycles of paired-end sequencing using reagents from the 




8.5.3  MiSeq sequencing setup 3 (Paper III) 
Sequencing setup 3 was based on the one-step PCR protocol described in Kozich et 
al. [49]. Both steps of target gene amplification and indexing are incorporated into a 
single PCR step using primers that include the gene specific sequences, index 
sequences and the Illumina sequencing adapters.  
The 16S rRNA gene region V4 was targeted using primers [5´-AATGATACGGCGA 
CCACCGAGATCTACACNNNNNNNNTATGGTAATTGTGTGCCAGCMGCCG
CGGTAA-3´] (forward) and [5´-CAAGCAGAAGACGGCATACGAGATNNNNNN 
NNAGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-3´] (reverse). Illumina 
sequencing adapters, indexes, pad and linker regions (detailed in Kozich et al. [49]) 
are underlined. The gene specific sequences (not underlined) are the same as for the 
primers used in the sequencing setup 2 (section 8.5.2), from Caporaso et al. [74].  
Each reaction consisted of 5 µl sample, 18 µl Accuprime Pfx SuperMix (Thermo 
Fisher Scientific, USA), 1 µl of each primer (10 µM), for a total volume of 25 µl. 
PCR cycling was performed using the following program: an initial cycle at 95 °C for 
2 minutes, followed by 45 cycles of 95 °C for 20 seconds, 55 °C for 15 seconds, 72 
°C for 5 minutes, and a final extension cycle at 72 °C for 5 minutes. PCR cleanup 
was performed using Agencourt AMPure XP beads (Beckman Coulter, USA).  
Sequencing was performed using sequencing primers [5´- TATGGTAATTGTGTGC 
CAGCMGCCGCGGTAA-3´] (read 1 primer), [5´-AGTCAGTCAGCCGGACTACH 
VGGGTWTCTAAT-3´] (read 2 primer) and [5´-TTAGAWACCCBDGTAGTCCG 
GCTGACTGACT-3´] (index read primer).  
Library quantification, normalization and preparation for sequencing was performed 
as described for sequencing setup 1. MiSeq sequencing was performed using 2x250 
cycles of paired-end sequencing using reagents from the MiSeq reagent kit v3 
(Illumina).  
*Degenerate bases are named according to the IUPAC nucleotide nomenclature (N = 




8.6 Bioinformatics sequence processing 
Bioinformatics sequence processing was performed using the Quantitative Insights 
Into Microbial Ecology (QIIME) bioinformatic package (http://qiime.org) [75]. 
QIIME underwent an upgrade from QIIME1 to QIIME2 in January 1, 2018 and both 
versions were used in the project.  
8.6.1 QIIME1 (Papers I and II) 
For papers I and II, bioinformatic sequence processing steps were performed using 
the QIIME1 package, version 1.9.1. Sequences were first retrieved from the Illumina 
MiSeq in the form of two fastq files per sample – one for the forward read and one 
for the reverse read (i.e. demultiplexed, paired-end reads). Sequence processing 
began with the removal of PCR primer sequences. This was performed by instruction 
to trim off the first 17 and last 21 bases, which corresponds to the length of the 
forward and reverse primer sequences. The forward and reverse reads were then 
joined together to form contiguous sequences, using the default “fastq-join” method. 
We required a minimum of 100 bases of overlap between the forward and reverse 
reads. Quality filtering was performed by removal of sequences with a base quality 
(Phred) score of less than 20. In paper II, chimeras were removed after identification 
using the VSEARCH [76]. The working operational taxonomic unit (OTU) table was 
generated by clustering of sequences into 97% OTUs, using UCLUST [77] and the 
GreenGenes reference database (v.13.8) [78]. Small OTUs consisting of fewer than 
0.005% of the total sequence count in the dataset were discarded. Taxonomy 
assignment was performed using the naïve bayesian RDP Classifier [79] together 
with the GreenGenes reference database (v13.8). Sequences were aligned using 
PyNAST [80] and a phylogenetic tree was constructed using FastTree [81]. 
8.6.2 QIIME2 (Paper III) 
Demultiplexed paired-end sequencing reads (fastq files) were retrieved from the 
MiSeq sequencer and imported into the QIIME2 environment (release 2019.1). The 
DADA2 denoising method was applied using the dada2 denoise-paired plugin, 




the joining of paired end reads, ii) the removal of chimeras and iv) denoising to 
amplicon sequence variants (ASVs). An additional round of chimera filtration was 
performed using the vsearch uchime-denovo plugin. Abundance filtering was then 
performed by removal of ASVs with fewer sequences than 0.005% of the total 
number of sequences and removal of ASVs not found in at least two samples. 
Taxonomy was assigned using the feature-classifier classify-sklearn plugin together 
with a Naïve Bayes classifier (pre-trained on the full-length Greengenes 13_8 99% 
OTU reference database) available on qiime2.org. ASVs that classified above the 
phylum level were removed, in addition to ASVs that classified to mitochondria, 
chloroplasts or archaea.  
8.7 Decontamination strategies (Papers I, II, III) 
Two approaches to dealing with laboratory contamination were used in the thesis. In 
papers I and II, the “remove all” approach was used. In papers II and III, tools 
available within the the Decontam R package were used [82].  
8.7.1 The remove all approach 
When using the “remove all” approach, all OTUs found in NCS were discarded from 
the corresponding procedural samples collected under the same bronchoscopy 
procedure. In brief, the main working OTU table was first split by subject ID. OTUs 
found in NCS were removed along with samples with zero sequence counts. The 
resulting OTU tables (now free of NCS OTUs and NCS samples) were merged back 
together, generating the final decontaminated OTU table.  
8.7.2 Decontam 
Contaminant OTUs/ASVs were identified in procedural samples using the 
isContaminant function available in the Decontam [83] R package. The two 
algorithms that Decontam uses to identify potential contaminants are based on either 
the prevalence of ASVs/OTUs in NCS versus actual samples (prevalence based 
approach) or the co-variance of OTUs/ASVs with the total amount of DNA in 




the MiSeq. The possession of both negative controls and DNA quantitation data 
(qubit measurements) enabled us to take use of the approach “either”, within the 
isContaminant function. We set the user defined threshold value to 0.5 (default=0.1) 
for both algorithms. For the prevalence based approach, a setting of 0.5 implies that 
the OTU/ASV was as common in NCS samples as in procedural samples, whereas for 
the frequency-based approach, a threshold of 0.5 implies that the underlying 
statistical models for the sequence being a contaminant is as likely as the model for 
the sequence not being a contaminant. Our choice of the 0.5 setting was based on the 
intuitively available interpretation of this value, in addition to facilitate comparison 
with the “remove all” strategy. 
The output from the isContaminant analysis (method=”either”, threshold=0.5) was a 
list of all OTUs/ASVs identified as contaminants by either the “prevalence” or 
“frequency” based contaminant classification algorithms.  
8.8  Statistical analyses 
The samples in a microbiome study all have different yield in terms of number of 
sequences. To take this into account some analyses are performed on proportions 
(e.g. most of the taxonomic analyses show the relative abundance at various 
taxonomic levels). For other analyses a number of sequences is required as input. 
Many of these analyses require an equal number of sequences in each sample. The 
analyst can choose to normalize to an equal number of sequences, or rarefy. The latter 
implies drawing (randomly) a set number of sequences from each sample, while 
discarding those not randomized [84].  
We chose to rarefy our samples for alpha- and beta-diversity analyses, trying to 
balance between the exclusion of samples with few remaining sequences, and at the 
same time not discarding the signal from low-biomass samples of the airways. 
The study population was divided into subjects with- and without airway diseases. It 
is well known that the clinical characteristics of these differ, and it was not an 




was performed on the characteristics of the participants, but was presented in the first 
table of all three papers.  
Differences in taxonomic composition of samples were displayed in terms of plots of 
average composition of samples in all three papers. Since these were compositional 
data (i.e. relative abundances), we in paper I applied a beta distribution and used the 
betafit command in Stata to test for differences in the taxonomic composition 
between sample types.  
In paper II we compared the estimated bacterial burden in the different sample types. 
Statistical significance testing was performed on logarithmically transformed 
outcomes by nonparametric trend tests in Stata.  
For alpha-diversity (rarefied samples) we in paper I compared the Faith phylogenetic 
index by sample type using Wilcoxon matched pairs signed rank test as well as a 
nonparametric trend test (both performed in Stata). In the other two papers we did not 
perform formal tests of alpha diversity measures.  
For all three papers we chose unweighted UniFrac distance as our main outcome in 
beta-diversity analyses. In paper I, we compared beta diversity pairwise between 
different sample types, visualized by principle coordinates analyses. The significance 
of these differences was tested by applying a permanova test in QIIME1. Whereas we 
did not perform extensive beta diversity analyses in paper II, in paper III we used 
principle coordinates analyses to investigate the overlap between the NCS and 
procedural samples. In addition, we also visualized the overlap between procedural 
samples in experimental setups 2 and 3 (before and after Decontam).  
Beside using R, QIIME1 and QIIME2 we have used the statistical software Stata SE 
for Mac OS (versions 13 to 16, Stata Corp, College Station, TX, USA).  
8.9  Ethics 
MicroCOPD was conducted in accordance with the ethical principles outlined in the 




Ethics approved the study (REK Nord, project number 2011/1307). All study 





9. Summary of papers 
9.1 Paper I  
Protected sampling is preferable in bronchoscopic studies of the airway microbiome  
For the first paper, we set out to determine whether protected (via a sterile catheter) 
bronchoscopic sampling techniques would reduce the influence of bronchoscopic 
carryover from the upper airways. We compare three sampling techniques: i. 
protected specimen brushings (PSB), ii. protected bronchoalveolar lavage (PBAL) 
and iii. (unprotected) small volume lavage (SVL).  
Samples were collected from a total of 125 participants, consisting of 67 subjects 
with obstructive lung disease (3 asthma and 64 COPD patients) and 58 healthy 
controls. Our bronchoscopy sampling scheme was designed to mitigate the impact of 
confounding factors, including microaspiration and intrapulmonary contamination. 
This required sampling at multiple intrapulmonary sites within each participant, and 
in a strictly specified order: three PSB from the right lower lobe (rPSB), two fractions 
of PBAL from the right middle lobe (PBAL1/PBAL2), three PSB from the left upper 
lobe (lPSB) and SVL from the left upper lobe. For a subset of participants (n=49), the 
left lung was sampled before the right lung. An oral wash (OW) sample was collected 
prior to each bronchoscopy procedure, for use as an upper airway reference sample, 
along with a negative control sample (NCS) consisting of PBS used for collection of 
all samples.  
Analyses of bacterial community composition was performed by MiSeq sequencing 
of the bacterial 16S rRNA gene V3 V4 region. Bioinformatics processing was 
performed using QIIME1. Our approach to contamination was to remove all 
sequences observed in NCS.   
Our analyses were based on the underlying assumption that the more similar the 
bronchoscopically acquired specimens (PSB, PBAL, SVL) were the OW sample, the 




was based on three parameters: i. taxonomy, ii. alpha diversity and iii. beta diversity. 
Across all three parameters, similarity to the OW sample decreased in the order: 
OW>SVL>PBAL>PSB. Our analysis of taxonomic composition revealed an increase 
in the proportion of Proteobacteria and a simultaneous decrease in the proportion of 
Firmicutes. Measures of alpha diversity (Faith´s PD) decreased across sample types. 
By analysis of PCoA plots of unweighted UniFrac distances (beta diversity) we found 
that the overlap between OW and SVL samples was greater than that for OW and 
PBAL samples and OW and PSB samples.  
9.2 Paper II 
Laboratory contamination in airway microbiome studies 
For paper II, we sought to determine the impact of laboratory contamination on 
airway microbiome analyses, and to explore the expected inverse relationship 
between sample bacterial load and influence of contamination when processing 
samples through the MicroCOPD laboratory pipeline. Furthermore, we set out to 
determine the optimal bioinformatic approach to dealing with contamination post 
sequencing. Analyses included quantitative PCR and targeted amplicon sequencing of 
the bacterial 16S rRNA gene. 
Samples were collected from 23 participants from the MicroCOPD study, consisting 
of 14 subjects with obstructive lung disease (COPD, asthma) and 9 healthy controls. 
Sample types collected from each participant included oral washes (OW), two 
fractions of protected bronchoalveolar lavage (PBAL1/PBAL2), protected specimen 
brushes (PSB) and an aliquot of the phosphate buffered saline (PBS) used for 
collection of all samples (NCS). Additional procedural control samples were 
collected after ten simulated bronchoscopy procedures (no patient). Samples included 
a bronchoscope rinse (BR), a catheter rinse (CR), a protected specimen brush (PSB), 
a sample of PBS transferred to a cryotube (CT) and a sample of PBS used for 
collection of all samples. Molecular grade water samples were also processed through 




relationship between sample bacterial load and the influence of contamination, we 
included a ten-fold dilution series of a sample of Salmonella (SDS).  
Analysis of the SDS revealed an inverse relationship between sample bacterial load 
and the influence of contamination. When extrapolating these findings to quantitative 
data obtained for airway samples (PBAL, PSB), we found that an estimated 10-50% 
of the bacterial community profiles could be traced back to contaminating bacterial 
DNA introduced from the laboratory. The OW sample appeared unaffected by 
contamination. On examination of procedural control samples (BR, CR, PSB, CT, 
PBS), molecular grade water samples processed through DNA extraction and PCR 
water samples introduced post DNA extraction, the DNA extraction kit was identified 
as a main contamination source. 
We compared three different bioinformatic approaches for removal of contamination: 
i) keep all samples intact (i.e. do nothing), ii) remove all OTUs seen in NCS, and iii) 
correction based on statistical models (i.e. the Decontam R package). Contaminant 
removal based on Decontam appeared to provide a balance between keeping and 
removing OTUs found in both NCS and study samples.  
9.3 Paper III  
Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 
16S rRNA gene regions V3 V4 versus V4 
The lung microbiome has been studied using a wide range of protocols for high-
throughput sequencing of the bacterial 16S rRNA gene. We set out to determine the 
impact of number of polymerase chain reaction (PCR) steps (1- or 2-steps) and 
choice of target marker gene region (V3 V4 or V4) on the presentation of the upper 
and lower airway microbiome.  
The study included samples from 23 participants in the MicroCOPD study, consisting 
of subjects with (n=14) and without (n= 9) obstructive lung disease (COPD, asthma). 




from the right lower lobe and protected bronchoalveolar lavages (PBAL) from the 
right middle lobe. An aliquot of phosphate buffered saline used for the collection of 
all procedural samples was used as a negative control sample (NCS) for assessment 
of contamination. A PCR water sample, introduced post DNA extraction was also 
included for distinguishing between contamination introduced before and after DNA 
extraction. A mock community (MC) sample consisting of genomic DNA from 20 
different bacterial species was included as a positive control. 
Samples were processed through three different library preparation setups varying in 
number of PCR steps and targeted marker gene region: Setup 1 (2-step PCR; V3 V4 
region), Setup 2 (2-step PCR; V4 region), and Setup 3 (1-step PCR; V4 region). 
Sequencing was performed on the Illumina MiSeq.  
The number of sequences and amplicon sequence variants (ASVs) decreased in order 
setup 1>setup 2>setup 3. The observation appeared to be associated with an increased 
taxonomic resolution when sequencing the V3 V4 region (setup 1) and an increased 
number of small ASVs in setups 1 and 2. The latter was considered the result of 
increased susceptibility to contamination when following the 2-step PCR protocol 
(setup 1 and 2) and when sequencing across multiple sequencing runs (setup 1). 
Comparison of contamination profiles (based on NCS) revealed the dominance of 
ASVs assigned to family Enterobacteriaceae across all three setups. For setup 3, an 
additional ASV attributed to genus Escherichia coli (family Enterobacteriaceae) 
dominated. The same ASV also dominated the PCR water sample in setup 3, and we 
interpreted this as a contaminant introduced with PCR reagents for this setup. The 
elevated levels of Escherichia coli in the MC sample processed in setup 3 further 
supported this interpretation.  
Comparison of procedural samples revealed that the same taxa dominated across all 
setups, although at different relative abundances. Analyses of beta diversity revealed 
that OW samples clustered together regardless of number of PCR steps. PSB and 




differences between setups. This indicated that mechanisms related to sample 






10.1 Discussion on methods 
10.1.1 Study populations 
Paper I 
Bronchoscopic studies on the lower airway microbiome have in general been limited 
by small population sizes. The bronchoscopy procedure is invasive and costly, and 
the implementation of larger studies has therefore shown to be challenging. For some 
studies, the need for more power has been addressed by combining data from 
different centers [18, 19, 67]. However, an important weakness of large multicenter 
initiatives, is that differences in methods for sampling, processing and sequencing 
across centers may introduce experimental bias to the data that is difficult to adjust 
for.  
With 249 participants enrolled in the MicroCOPD study, we were for the first paper 
in a position to conduct a high power single-center investigation that would meet the 
increasing demand for such studies in the field. As sampling and sequencing for 
MicroCOPD was still ongoing as we started our analyses, we could not include all 
participants from the main study. Our analyses were therefore limited to a subset 
consisting of 125 participants, encompassing a relatively even proportion of subjects 
with obstructive lung disease (n=67) and control subjects (n=58). Furthermore, the 
participants with obstructive lung disease were represented by users and non users of 
inhaled corticosteroids (ICS). The study population also included current-, ex- and 
never-smokers.  
We found no widely accepted method to estimate sample size, but compared to 23 
(out of 25) previous bronchoscopy studies (published by 2016), we had a larger 
number of participants [4, 6–8, 12, 18–21, 25, 27, 64, 66, 67, 85–95]; the exception 
being two multicenter studies conducted as part of the LHMP [19, 67], where one 
might question the validity of this approach, with significant protocol differences 




airway contamination levels across bronchoscopic sampling techniques, we found 
that only five out of the 25 studies included protected sampling techniques [6, 12, 27, 
67, 88]. And only three studies included both protected and unprotected sampling 
techniques [6, 12, 27].  For these latter studies, the number of study participants did 
not exceed 15.  
In summary, this first paper gains power from a relatively large heterogenous study 
population. The full data-set collected in the MicroCOPD study, is however more 
than twice the size of the current paper. Although tempting, we decided not to look 
into details regarding disease state, use of ICS and smoking habits, as this would be 
the focus for later publications in the MicroCOPD study. In hindsight, we however 
acknowledge that smoking status may have confounded our analyses. Studies have 
indicated that smoking may alter the microbiota composition of both the upper and 
lower airways. Importantly, the upper airways appear to be more impacted than the 
lower airways [8, 18]. For participants in the “current-smokers” and “ex-smokers” 
categories, there is therefore the possibility that smoking may have expanded the 
distance between the lower airway samples and the upper airway samples. With only 
a few participants in the “never-smokers” category, stratification by smoking status 
was however not possible.   
Papers II and III 
For papers II and III, we included 23 participants from the MicroCOPD study - a low 
number compared to that which was available from the full data-set collected in the 
main study. However, the objectives of papers II and III were directed at resolving 
methodological issues associated with laboratory processing steps and the influence 
of variable sample bacterial load. Due to inherent bias expected to be found across 
sequencing runs, it was important that where possible, all study samples were 
included on the same sequencing run, for which there are 96 slots. We also wanted to 
take advantage of the multiple sample types collected per participant in the 




various technical control samples enabled us to analyze samples from 23 participants 
in these two studies. 
Whilst likely not of critical importance to the research question for papers II and III, 
we sought to obtain a balance in the number of participants in the healthy and 
diseased categories (9 control subjects, 14 subjects with obstructive lung disease). 
This because our hypotheses were driven by the expectation that methodological 
issues would be directly tied to sample bacterial load, and we recognized the potential 
for obtaining higher sample bacterial load in participants with respiratory disease. 
10.1.2 Procedural samples 
Since the aim of the first paper was to gain knowledge regarding airway sampling in 
microbiota studies, this section of the discussion mainly revolves around the first 
paper. Our findings, however, greatly influenced the design of the two subsequent 
papers.  
Paper I 
We sought to explore the potential of reducing the influence of oropharyngeal 
contamination through the use of protected bronchoscopic sampling techniques. As 
described in the introduction, protected sampling involves sampling via a sterile wax-
plugged catheter that is passed through the working channel of the bronchoscope. We 
hypothesized that the catheter would provide protection from contaminating bacteria 
present in the bronchoscope working channel. Second, we wanted to compare the 
performance of protected sampling techniques with the most common sample type 
utilized in studies of the lung microbiome – the unprotected bronchoalveolar lavage 
(BAL) sample.  
In addition to a large heterogenous study population (providing external validity), we 
included multiple sample types from each study participant – the number of which to 
our knowledge has not been seen in any previous study. Also, the sampling scheme 
used in the MicroCOPD study enabled us to account for the difficult and potentially 




internal validity). This was particularly important for the current paper as assessment 
of bronchoscopic carryover, was based on the similarity between the upper airway 
OW sample and lower airway samples collected across different sampled sites. 
To mitigate the impact of the aforementioned confounding factors, sampling in the 
MicroCOPD study was performed by collection of different samples across multiple 
sites and in a strictly specified order: three protected specimen brushes (rPSB) from 
the right lower lobe (RLL), two fractions of protected bronchoalveolar lavage 
(PBAL1/PBAL2) from the right middle lobe (RML), three protected specimen 
brushes (lPSB) from the left upper lobe (LUL), and (unprotected) small volume 
lavage (SVL) from the LUL. For a smaller subset of participants, the left lung was 
sampled before the right lung. An oral wash sample (OW) was collected before each 
bronchoscopy procedure for representation of the upper airway microbiota. For the 
current paper, we included all sample types collected in the MicroCOPD study. This 
enabled the evaluation of three sampling techniques: PSB, PBAL, and SVL.  
While PSB sampling has commonly been used in studies of the lung microbiome, we 
were not aware of any study that had previously performed BAL through a protective 
catheter (i.e. PBAL). This despite the potential benefits of protected sampling via a 
catheter, particularly against contaminants found inside the working channel as 
described in the introduction. We found that only three studies included both 
protected PSB and unprotected BAL [6, 12, 27]. The SVL sample collected in the 
MicroCOPD study, was obtained by sampling directly through the bronchoscope 
working channel. As such, comparisons could be drawn to the commonly used 
unprotected BAL.  
The comparison of all sampling techniques would ideally be based on sampling from 
the same pulmonary site. However, any one sampling event may alter the microbiota 
composition at the sampled site. Our comparison of the five different sample types, 
therefore included sampling at three different pulmonary sites – the right lower lobe 
(RLL), the right middle lobe (RML) and the left upper lobe (LUL). We searched the 




multiple sites might confound our analyses. The few studies we found, described two 
different situations when studying healthy [12] and diseased subjects [8, 15].  
For healthy subjects, we can look to the adapted island model of lung biogeography 
introduced by Dickson and colleagues [12], which was described in the introduction.  
Recall that the model predicts that in healthy individuals, we can expect the bacterial 
communities of the lungs to resemble that of the upper airways. The model further 
predicts that as we move down the lower airways, the similarity to the upper airways 
decreases. We found the model particularly relevant to our paper, as the anatomical 
distance to the upper airways varies considerably between our three sampled sites 
(RLL, RML, LUL). Recall again that our analyses were based on the underlying 
assumption that the more similar our samples were the representative upper airway 
sample (OW), the greater the influence of contamination by bronchoscopic carryover. 
The adapted island model of lung biogeography would assume that inherent 
differences in lung microbiota across sites would result in an expected decrease in 
similarity to the OW sample in the order of LUL> RML>RLL; that is even without 
the influence of bronchoscopic carryover or contamination that we were looking for. 
We recognized that the model introduced a potential confounding factor in our study 
design that we needed to account for in our analyses. In the diseased state, we also 
can expect greater difference in microbiota across sites that are independent of the 
influence of microaspiration [8, 15]. However, given the difference in bacterial load 
between the upper and lower airways, we might also expect that upper airway 
carryover using unprotected sampling techniques could blur out differences in 
microbiota across sites in health and even diseased states. This is however currently 
unclear, and thus the inclusion a large study population with representation from both 
healthy and diseased states was critical. 
As the question of differences in microbiota across sites within the same individual is 
unclear, it was important that the MicroCOPD sampling scheme also accounted for 
the potential of contamination across sampling sites. First of all, PSB samples were 
always collected before lavage (PBAL, SVL) sampling. This to minimize the 




our critique of one of the key papers in the field by Dickson et al. [12] comparing 
PSB and BAL sampling, was the sampling of BAL before PSB. Second, for a subset 
of the participants, we sampled the left lung before the right lung. The importance of 
this was twofold. First of all, one might predict that the first sampled site would be 
more influenced by oropharyngeal carryover, as for each subsequent sampling event 
this contamination would be more “diluted”. Second, repositioning the bronchoscope 
from one lung to the other involves passing the carina, a site for which microaspirated 
bacteria likely accumulate [14]. Thus, moving from one lung to the other, 
contaminating bacteria from the carina may give a false impression of oropharyngeal 
contamination in our analyses. By sampling also the left lung first, we could assess 
the influence of moving from left to right lung, right to left lung.  
Besides reducing the potential impact of intrapulmonary contamination during 
sampling, the sampling scheme enabled us to address the difficult issue of 
distinguishing between microaspirated bacteria and oropharyngeal carryover by the 
bronchoscope. First of all, by sampling PSB at the two sites with which the 
anatomical distance to the upper airways varies the most (RLL and LUL), we could 
determine whether differences in lung biogeography (and thereby microaspiration) 
was affecting our interpretation of the impact of oropharyngeal carryover. Second, 
the LUL was sampled using both the most protected sampling technique (PSB) and 
the sampling technique most vulnerable to oropharyngeal carryover (SVL). This to 
enable a direct comparison of these two sampling modalities, and therefore the ability 
to distinguish between the true microbiota likely found in PSB and increased 
oropharyngeal contamination in SVL. BAL from the RML (same wedged segment) 
was fractionated to PBAL1 and PBAL2, enabling assessment of the dilution effect 
described in the introduction. A dilution effect from PBAL1 to PBAL2 could indicate 
influence of oropharyngeal contamination.  
One weakness may be that, even our extensive sampling might not provide the detail 
needed to resolve the issue of how best to sample the airways. We did not collect 
samples from the last upper airway site for which the bronchoscope passes before 




introduction, this region likely consists of bacteria from the nasal and oral cavities, 
and particularly in diseased individuals, the bacterial communities derived from the 
nasal cavity may be relevant. Samples from this region may therefore be more 
representative of microbiota that are “microaspirated”. Samples from the lumen 
below the vocal cords might have told us more about what the bronchoscope brings 
down to the sampling sites, and samples from the carina and main bronchi might have 
shed light on the fraction of upper airways microbiota that reaches the lower regions. 
However, such comprehensive sampling would have greatly extended the procedure 
time with an associated increased need of sedation/anaesthesia and possibly also 
procedural complications.  
There are also alternatives to our protected sampling methods. For instance, some 
investigators use a two-scope technique where they change bronchoscope after 
anesthetizing the vocal cords; this to minimize contamination of the bronchoscope 
used for sampling. However, this implies more movement up and down the airways, 
and opens other routes of contamination. Protection might also be accomplished 
using a balloon catheter when performing BAL. This might minimize a “washing 
effect” of the bronchoscope tip when sampling lavage, and also increase yield by 
sealing the sampling site and preventing leakage to other parts of the airways.  
After sample collection, the next step in our microbiome analysis workflow was 
bacterial DNA extraction. As discussed in the introduction, controversy exists on 
whether eukaryote host cells should be removed from samples before proceeding 
with DNA extraction [64, 65]. While some studies have used acellular samples 
(eukaryote cells removed) [20, 25, 66], most studies have used whole samples 
(eukaryote cells kept). For the MicroCOPD study (and hence all papers of the thesis), 
we found the use of whole samples to be the most valid choice, as important members 
of the lower airway microbiota may be associated with eukaryote cells, for instance 
via biofilms [64]. However, there is currently no consensus in the field regarding the 
optimal sample type (acellular or whole). In fact some studies have even combined 
datasets obtained using both acellular and whole BAL, as in the multicenter LHMP 




consistency in methods is most important and for such studies reliability/validity is 
questionable. 
Papers II and III 
Four different sample types were analyzed from each of the 23 participants included 
in the papers II and III: oral washes (OW), protected specimen brushes from the right 
lower lobe (rPSB), protected bronchoalveolar lavage (PBAL) from the right middle 
lobe, and negative controls samples (NCS). 
Importantly, we included both high and low biomass airway samples. The lower 
airways were represented by two different sampling techniques (PSB and PBAL). 
The SVL sample was not included, as in our hands protected sampling procedures 
appeared to provide protection from upper airways (paper I). In addition, the included 
samples were taken from the same lung, thereby minimizing the impact of 
intrapulmonary contamination [12, 14]. By including the same participants and 
samples in papers II and III, we strengthened our analyses and were able to compare 
our different bioinformatic approaches. In paper II, the bacterial load was established 
for these samples, providing more validity to the conclusions made for paper III 
based on assumed differences in bacterial load.  
10.1.3 Bacterial DNA extraction  
Papers I, II and III 
As discussed in the introduction, the bacterial DNA extraction step may introduce 
bias to a study if the genomic DNA is not extracted with equal efficiency from all 
bacterial members of the sampled microbiota. The protocol for DNA extraction used 
in the MicroCOPD study, was designed in-house and based on what we perceived as 
the best of knowledge currently available for securing optimal bacterial community 
representation.  
Samples were first treated with a combination of the three lytic enzymes (lysozyme, 




combination of three enzymes we addressed the potential resistance of bacteria to the 
lytic activity of any one particular enzyme. Bacterial cells that were not sufficiently 
lysed on treatment with the enzyme cocktail, were subjected to mechanical lysis by 
bead beating. Importantly, genomic DNA that had been successfully isolated by 
treatment with enzymes, were removed before proceeding with the bead beating step. 
This to avoid the shearing of genomic DNA, for which had been successfully 
extracted on treatment with the enzymes and hence potentially minimizing the 
formation of chimeras in subsequent PCR steps, as described in the introduction.   
A weakness to our study is perhaps that we did not validate our DNA extraction 
protocol against a mock community sample (MC). While this would have provided us 
with an indication of the differences in extraction efficiencies across bacteria with 
different cell wall structures, it can however be argued that a MC sample will anyhow 
not accurately reflect the true complexity of a natural sample.  
We recognize the possibility that differences in extraction efficiency across bacterial 
taxa may have impacted our analyses. Recall for instance that for paper I, our 
assessment of upper airway carryover by the bronchoscope was based on the degree 
of similarity between the lower airway samples and OW samples. If a taxon found 
exclusively in OW samples is extracted with low efficiency, the OW samples may 
appear to be more similar to lower airway samples than is the actual case. Analyses 
for paper III were aimed at elucidating error and bias associated with laboratory 
processing steps occurring after DNA extraction. By using the same DNA extracts as 
input to each of the three library preparation setups compared, we minimized the 
potential for bias associated with DNA extraction.  
10.1.4  Determination of bacterial load  
For paper III, the levels of bacteria in our samples were determined by probe-based 
quantitative PCR (qPCR) targeting the bacterial 16S rRNA gene region V1 V2. We 
chose to use the same primer/probe set utilized by several others in the field [6, 7, 14, 
21]. The standard curve used for determining absolute bacterial numbers was 




The main weakness with our method, is that we did not account for the presence of 
human DNA in our samples. Human DNA may act as a competitive inhibitor in PCR, 
resulting in low reaction efficiencies. This is particularly a concern for samples where 
the levels of human DNA are high and the levels of bacterial DNA are low. Glassing 
and colleagues [96, 97] have shown that the presence of human DNA may have an 
impact not only on the 16S sequencing results for community profiling [97], but also 
on quantitative assessments of bacterial load [96] as discussed here (both are methods 
that build on the PCR). Glassing et al. [96] found that submucosal intestinal tissue 
samples (low biomass) containing high amounts of human DNA generated CT values 
(i.e. threshold cycle values) greater than that obtained for no template controls – i.e. 
their results indicated that there were higher levels of bacteria in the no template 
controls than in their tissue samples. We cannot dismiss the possibility that the 
presence of human DNA may have influenced our results. This particularly so 
because the samples used for construction of the standard curve – a pure culture of 
genomic E.coli DNA – was devoid of human DNA. One may therefore question 
whether possible differences in reaction efficiency between the standard samples and 
the samples being tested due to differences in human DNA content, could have led to 
an underestimation of bacterial load.  
10.1.5 Library preparation for sequencing  
Papers I and II 
For the first two papers of the thesis, library preparation for sequencing was 
performed using the commercial protocol by Illumina with title 16S Metagenomic 
Sequencing Library Preparation (Part # 15044223 Rev. B). Methodological issues 
associated with choice of protocol and target marker gene region are central themes 
in paper III and is discussed in section 10.2.3. The number of PCR cycles used for 
amplification of the target marker gene was increased from 25 cycles as specified in 
the commercial protocol, to 45 cycles. This was necessary in order to obtain adequate 
levels of DNA for sequencing. The issue of PCR cycle number was addressed in 





Three setups for library preparation and sequencing are compared in the third paper 
of the thesis: setup 1 (2-step PCR; V3 V4 region), setup 2 (2-step PCR; V4 region), 
setup 3 (1-step PCR; V4 region). The three setups were chosen to best answer two 
questions. First of all, will a 2-step PCR protocol render samples more vulnerable to 
laboratory contamination than a shorter 1-step PCR protocol? And second, will 
choice of target marker gene region (16S rRNA gene V3 V4 or V4) have an impact 
on final bacterial community descriptions?  
To address the first question, two protocols that differed with regards to the number 
of PCR steps was required. To ensure external validity, we sought to find protocols 
widely used in the field. For the 2-step PCR protocol (setups 1 and 2), the choice fell 
on the commercial protocol by Illumina. The protocol was used for preparing samples 
for sequencing in the MicroCOPD study, and hence the findings from paper III could 
be extended to interpreting results generated in previous and future papers in 
MicroCOPD. The 1-step PCR protocol was based on the protocol described in 
Kozich et al. [49].  
To address the second question, we first had to decide on which 16S rRNA gene 
variable regions to compare. Studies on the lung microbiome have been based on a 
wide range of 16S rRNA gene targets - including V1 V2 [6, 86], V1 V3 [8, 18, 19], 
V3 V5 [7, 19, 21, 64, 85, 98], V3 [87, 99], V4 [12, 14, 25, 67] and V3 V4 [23] – a 
decision regarding which target regions to compare was not a given. We however 
decided on the regions V3 V4 and V4. The V4 region stood out as the optimal choice 
as studies have collectively shown that the region generates the most accurate 
estimates of the three commonly used parameters - alpha diversity [100], beta 
diversity [38] and taxonomic assignment [79]. The short length of the V4 region also 
comes with the added advantage of enabling fully overlapping PE sequencing reads – 
which as discussed in the introduction, has shown to be a powerful means by which 
error correction may be performed (section 6.3.2). With the development of 




[59]) longer regions are now becoming more favourable. The V3 V4 region was 
chosen as the second target as this was the region targeted in the MicroCOPD study, 
again enabling the expansion of current findings to the previous and future work in 
the MicroCOPD study.  
Papers I, II and III 
A third consideration, relevant to all three library preparation setups is the potential of 
contamination between study samples processed together on the same sequencing run 
(i.e internal contamination). Such internal contamination has been perceived as less 
of a concern than external contamination derived from bronchoscopic carryover or 
the general laboratory environment. We can distinguish between two types of such 
internal “between sample” contamination - that introduced during steps of library 
preparation for sequencing and that introduced during the sequencing process itself 
[101]. 
Internal contamination can arise during library preparation as a result of “well-to-
well” contamination between samples that are placed next to each other on the PCR 
plate [101]. Library preparation for sequencing was performed for 96 samples at a 
time on 96-well PCR plates and involved multi-protocol workflows. Each individual 
protocol involved an extensive amount of manual pipetting, for which we used 
multichannel pipettes.  
The issue of internal contamination across samples on the same PCR plate may be 
particularly relevant to the MicroCOPD study, due to the inclusion of multiple 
samples types and differences in bacterial load across sampled sites. Because samples 
were organized on the PCR plate according to bronchoscopy procedure and not 
sample type, samples of high bacterial load (i.e. OW) were placed directly adjacent to 
samples of low bacterial load (i.e. lower airway samples, NCS). The potential for 
well-to-well contamination in the direction of OW to lower airway sample (PSB, 
PBAL, SVL) is concerning because of the expected overlap in bacterial communities 
between the sampled sites. In much the same manner as described for microaspiration 




comparing the similarity between OW samples and each of the different lower airway 
sample types (paper I). Well-to-well contamination in the direction of lower airway to 
NCS sample is also a concern, as this could lead to the false labelling of authentic 
airway community members as external contaminants (i.e. those derived from the 
laboratory environment or reagents). We did not conduct any experiments to 
determine the frequency of such contamination in the MicroCOPD study. We did 
however take the preventative measure of strictly using pipette tips with filters to 
avoid carryover by contaminated pipettes.  
Internal contamination may also occur during the sequencing process itself due to the 
issue of index misassignment (section 6.3.1). All three setups used in the current 
thesis were based on a so called combinatorial dual indexing approach based on 8 
forward primers with unique so called “i5” index sequences and 12 reverse primers 
with unique “i7” index sequences. Amplicons derived from different samples may 
therefore share the same “i5” or “i7” index sequence, but not both. As with the issue 
of well-to-well contamination, we did not experimentally determine the frequency of 
index misassignment in our library preparation setups. The use of unique indexes for 
all, could have reduced the potential for index misassignment. 
While the issue of internal contamination is not addressed in the current thesis, one 
may question whether the greater number of steps associated with a 2-step PCR 
protocol (setups 1 and 2) relative to a 1-step PCR protocol (setup 3) could leave 
samples more vulnerable not only to external contamination, but also internal 
contamination such as that described here. First of all, as samples are processed 
through a greater number of protocol steps in the 2-step PCR approach, there might 
be more opportunity for well-to-well contamination. Also, the timing of the index 
PCR step may be important. Recall that indexing is performed so that sequences are 
labeled according to the sample from which they originate. One may therefore expect 
that the earlier addition of index sequences in a 1-step PCR approach could lower the 
impact of well-to-well contamination compared to a 2-step PCR approach. This has 




Finally, also relevant to all three papers is the issue of repeatability of analyses. 
Ideally all laboratory processing, including sequencing, should have been replicated 
to avoid spurious findings dominating our conclusions. Even if we did not replicate 
analyses in paper II and III, hopefully the number of samples processed and 
consistency in our findings mitigate some of this weakness in our design.  
10.1.6 Bioinformatics processing 
Paper I 
Bioinformatic sequence processing and analyses were conducted using tools available 
within the QIIME1 package. As with laboratory protocols, we found that there was 
no consensus in the field with regards to bioinformatic sequence processing steps or 
analyses. Most decisions were therefore made based on the default settings and 
recommendations provided by the QIIME development team [102]. Nonetheless, we 
had to make decisions regarding stringency of quality filtering and the approach to 
dealing with NCS.   
Quality filtering.  
In two key steps of the pipeline we had to make a decision regarding the stringency of 
quality filtering. First, when joining paired-end reads, a decision had to be made 
regarding the degree of overlap between the forward and reverse reads, and whether 
or not we would allow any discrepancies between the two overlapping regions. We 
demanded a minimum overlap of 100 bases and allowed for zero discrepancy. This 
was quite strict and in hindsight it is clear that we may have lost reads that could have 
been “saved” by error-correction using the read with a higher base quality score 
(section 6.3.2). Further down the pipeline, quality filtering was performed using 
default settings in QIIME1 [52] (6.3.2 ) but for which we increased the default quality 
score set to 3 to 19, thereby filtering out reads with lower Q scores than 20. With 
such a high threshold, we may have filtered out many accurate sequences together 
with erroneous sequences.  




A main strength of the MicroCOPD study, is the collection of procedural NCS for 
each separate bronchoscopy procedure. The NCSs were never in contact with the 
study participant or the bronchoscope, but were processed through all subsequent 
laboratory steps (DNA extraction, library preparation for sequencing and sequencing) 
alongside the procedural samples. This provided us with a unique opportunity to 
address the issue of contamination from the laboratory. However, the literature 
provided us with few guidelines for dealing with NCS and approaches varied across 
studies. The simplest approach found in our literature search, was the removal of all 
OTUs or taxa observed in NCS (i.e. the “remove all” approach) [21, 86]. Although 
simple, the approach does not account for taxa naturally overlapping both NCS and 
airway samples. Pseudomonas is for example commonly found in the lungs [21], 
while also a typical laboratory contaminant captured in sequenced NCS [20, 63]. The 
“remove all” approach also does not account for the potential impact of internal 
contamination that may occur in the direction airway sample to NCS, as described 
earlier (section 10.1.5). Another approach involved the select removal of probable 
contaminants based on reports from previous publications (i.e. the “black-list” 
approach) [63, 103]. The obvious limitation with the “black-list” approach, is that 
contamination may vary greatly from study to study, and even within the same study, 
variation can be expected across different time points and when using different lots of 
reagents and kits for sample processing [63]. Furthermore, we found that others had 
removed sequences observed in NCS based on arbitrarily chosen abundance 
thresholds [99]. However, we found that it is unclear where to draw the line with 
regards to a set abundance threshold level. The perhaps most sophisticated approach 
found in our literature search, was the application of the neutral model of community 
ecology for detection of likely contaminating OTUs [19]. The method was however 
used in few publications and we found it challenging to perform with our limited 
bioinformatics experience. While the above mentioned methods were based on 
identification of contaminating sequences to remove from the dataset, alternative 
approaches were based on the removal of entire samples that overlapped with NCS in 




common limitation to all methods is the possibility that not all contaminants are 
represented in the NCS [103].  
With the backdrop described above, we found that there was no clear best approach 
to dealing with contamination and NCS. For paper I, we therefore chose the simplest 
approach – the removal of all OTUs found in NCS. As NCS were collected for each 
bronchoscopy procedure, OTUs were only removed from the corresponding 
procedural samples collected under the same procedure. Thus limitations associated 
with the “remove all” approach, with regards to potential impact of internal 
contamination (resulting in the removal of biologically relevant taxa) would only 
impact samples collected under the same bronchoscopy procedure. Despite the risk of 
removing OTUs naturally occurring in both airway and NCS samples due to an 
external contamination source potentially influencing all samples on the same 
sequencing run (e.g. DNA extraction kit or PCR reagents), we found the “remove all” 
approach satisfactory in light of our research question. This because the same OTUs 
were subtracted from the OW and lower airway samples. We therefore reasoned that 
our comparison of the upper airway OW to the lower airway samples would not be 
largely affected. In contrast, if samples were kept intact (i.e. no contaminant removal 
strategy), the influence of contamination would likely be greater on samples with low 
bacterial load (i.e. the lower airway samples) – possibly inflating the difference 
between upper and lower airway samples. The challenges associated with handling 
NCS in analyses for paper I prompted us to address the issue in the second paper for 
the thesis, as described in the subsequent section.  
Paper II 
The bioinformatic processing steps for paper II were conducted as for paper I, using 
tools available within the QIIME1 package. For the current paper we however made 
it an objective to explore bioinformatic strategies for handling NCS for removal of 
laboratory contamination. The focus of the current discussion will therefore be on our 




As described for paper I, the inclusion of NCS was quickly becoming a requirement 
for publication in most journals. We however found that guidelines for handling NCS 
once they were collected were still lacking, even now years after the first paper was 
published. The bioinformatic field had however picked up on the issue and several 
tools were under development. Of particular interest to us was the Decontam package 
available in R [82], which was developed directly for dealing with contamination in 
amplicon-based studies. For the current paper, we sought to compare three strategies 
for dealing with contamination: i) keep all samples intact (i.e. do nothing), ii) remove 
all OTUs found in NCS and finally iii) remove OTUs identified as contaminants by 
Decontam.  
While the first two approaches were rather straightforward, the Decontam R package 
presented us with several options. Contaminant identification is performed using the 
Decontam isContaminant function using one of several methods; including the 
“frequency” or “prevalence” based methods. A third method “either”, combines the 
former two methods. The choice of method (“prevalence”, “frequency” or “either”) in 
any study will first of all depend on the availability of auxiliary data. Negative 
control samples are required when performing the “prevalence” based method. DNA 
quantitation data are required when performing the “frequency” based method. The 
“either” method uses both the “prevalence” and “frequency” methods and as such 
requires both negative control samples and quantitation data. For the current thesis, 
both negative control samples and DNA quantitation data (qubit measurements) were 
available, enabling us to take use of the Decontam approach “either”.  
It was decided that the strictest Decontam method would be chosen, for best 
comparison to the «removal all» approach. Therefore, we chose the «either» method, 
securing maximum contaminant identification where one of either the «frequency» or 
«prevalence» based method would fail. The methods were validated on a ten-fold 
dilutions series of Salmonella (SDS), for which we were able to confirm that the 




The frequency based approach and its dependency on total DNA measurements might 
be criticized. The total DNA measurement before loading the MiSeq is based on 
rather crude methods and will also measure non-bacterial DNA. However, the PCR 
has selectively amplified microbial DNA, and both our sequencing results and the 
sub-study investigated with qPCR has revealed a bacterial load that is worth 
examining. Furthermore, the non-bacterial DNA would most likely serve to weaken 
associations in a non-discriminant manner, and not affect the validity of identified 
contaminants.   
Paper III 
For the third paper, bioinformatic sequence processing steps were conducted using 
tools available within the QIIME2 package. A central tool in the pipeline is DADA2 
[59], which has the primary function of denoising sequences to ASVs. The DADA2 
workflow also includes all steps of filtering, dereplication, chimera removal and the 
merging of PE reads – all steps of which are executed in a single command using the 
DADA2 plugin in QIIME2. We chose to perform additional steps of chimera removal 
and abundance filtering post DADA2 processing – procedures that have not (yet) 
been recommended or expected to be necessary when working with ASVs. A 
discussion on our decision to include additional these steps follows.  
Chimera removal.  
We chose to perform two rounds of chimera removal because different algorithms 
will vary with regards to both sensitivity and specificity. The first round of chimera 
removal was performed as an integrated part of the DADA2 workflow, for which the 
de novo based approach isBimeraDenovo() is used [59]. The method is applied after 
denoising to ASVs and is highly specific for the detection of exact chimeras formed 
between two parent sequences (bimeras). For the detection of chimeras formed 
between more than two parent sequences (multimeras), we applied a second round of 
de novo based chimera removal using the vsearch uchime-denovo method [76], which 
is also available a a plugin in QIIME2. The method originally developed with OTUs 




risk of false positive identification. To my knowledge the use of two filtering 
procedures on ASV data has not been benchmarked although this has been discussed 
vaguely on the QIIME2 user forum. While the use of two rounds of chimera detection 
may seem excessive and with an added risk of false positive detection, we found it 
appropriate due to experimental conditions that may have left our data particularly 
vulnerable to recombination events during PCR; i.e. a high number of PCR cycles 
[46] and bead beating during DNA extraction [31]. In addition, studies have 
suggested that when using a one step protocol (setup 3), where longer primers are 
used, chimera formation may be increased.  
The additional “Bokulich” filter step.  
An additional abundance filtering step was also performed. In short, recall that ASVs 
for which there were fewer sequences than 0.005% of the total number of sequences 
were removed. This threshold abundance level was rather arbitrarily chosen, and 
based on the recommendations provided by Bokulich et al. [52] when performing 
quality filtering measures on OTU based data. As described in the introduction, the 
method was originally intended to reduce the number of spurious OTUs generated as 
a result of PCR and sequencing error, for which should not in theory be an issue 
when working with ASVs. ASVs are however a relatively new unit in the 
microbiome field and there are few recommendations for handling ASV data – and 
particularly so with regards to low biomass samples. We suspected that low abundant 
ASVs may reflect contaminants, undetected chimeras or organisms with little 
biological relevance, and chose to filter based on the “Bokulich” method as 
performed also for papers I and II when working with OTUs. To us it seemed 
unlikely that the 23 samples from the airways would hold over 1000 different taxa. 
The bioinformatic pipeline used differed for different sample types depending on the 
question being asked and purpose for these samples in subsequent analyses steps. 
While the procedural samples were processed through all steps of the bioinformatics 
pipeline - including denoising by DADA2, chimera removal by VSEARCH, removal 




minimum the phylum level and finally the removal of ASVs identified as 
contaminants using Decontam - the mock community (MC) and negative controls 
were handled differently. For MC samples, the main question we sought to answer 
was whether the three setups were equally efficient at recovering the different MC 
members. We also wished to determine the impact of contamination (i.e. all ASVs 
assigned to taxa not expected in the MC). Bioinformatic processing steps were 
therefore limited to DADA2, the additional chimera removal step by VSEARCH and 
the removal of ASVs that did not classify at minimum to phylum level. Removal of 
small ASVs (i.e. the “Bokulich method” described above) and removal of 
contaminants identified using Decontam, was not performed as we also wanted our 
analyses to capture the impact of contamination. The negative control samples – 
including both procedural NCS and PCR water samples, were processed through all 
steps of the pipeline except for the removal of contaminants identified using 
Decontam. As such the MC sequencing output is more reflective of the “raw” 
sequencer generated data, as small ASVs were not removed.  
10.1.7 Analyses 
Analyses were based on the OTU (QIIME1) or ASV (QIIME2) tables generated after 
bioinformatics processing of samples as discussed above. Common parameters used 
for microbiome analyses include i. taxonomy, ii. alpha- and iii. beta-diversity.  
Taxonomy 
Analyses of taxonomic composition were performed in all three papers using average 
relative abundance of taxa in the sampled communities. While this is a common 
approach in the literature, it is important to note that taking averages may distort 
conclusions if major or minor taxa are driven by extreme samples lacking taxa or 
overrepresented by taxa, for example as a result of internal contamination. While for 
paper I, the study population was large and this may not be an issue, it must be 
acknowledged that for papers II and III this may have affected our interpretation of 





Within sample comparisons (alpha diversity) were made using Faiths PD (paper I). 
For papers II and III alpha diversity was not assessed beyond the mention of number 
of sequences and OTUs/ASV generated per sample. However, without rarefaction, 
accurate comparisons across samples could not be made. But, nevertheless, this still 
provided us with useful information regarding differences in sequence depth. 
Beta diversity 
Between sample comparisons (beta diversity) were made using PCoA of unweighted 
UniFrac distances. By choosing unweighted rather than weighted UniFrac, every 
detected OTU in the samples were given equal significance regardless of relative 
abundance. This is likely important in order to recover small differences between 
samples. The upper and lower airway communities, for instance, appear from the 
literature and own analyses to be dominated by many of the same taxa. We may 
therefore expect that the use of the weighted UniFrac metric could result in the 
masking of small differences between samples. On the other hand, the limitation with 
the use of unweighted UniFrac is that equal significance is also given to OTUs/ASVs 
derived from contamination. Our bioinformatic pipeline, however included the 
filtering of small OTUs/ASVs, which may have reduced the impact of low abundant 
contaminants on analyses of beta diversity.  
Statistical analyses 
Analyses of microbiota based on next generation sequencing data is a relatively new 
field. Both the nature and magnitude of data available for scientists has changed 
substantially over the last few years, and we now analyze millions of sequences from 
several hundred samples. The sequences are again organized in several hundreds (at 
least) units (ASVs, OTUs, taxonomic levels). Associated features of the resulting data 
sets make statistical analyses particularly challenging.  
First the number of variables is very high, resulting in a multiple comparison 
problem. This is a problem well known from genetic studies, and although statistical 




Second, there is a large number of zero values which makes choosing a statistical 
distribution to base tests on, difficult [105]. Third, many of the parameters have a 
compositional distribution, which excludes many conventional statistical methods. 
And finally, the data presented in the current thesis are mostly paired in some way or 
another, and compared parameters are not independent of each other.  
Currently, there are a plethora of suggested workarounds for most of these problems. 
However, there is no agreed-upon solution, and when choosing one approach you 
often face limitations that necessitates analyses by yet another method. The results 
might conflict, and the researcher might end up in a conflict between full disclosure 
and the need to present a clear message.  
Nevertheless, most of the objectives in the current thesis were to shed light on 
methodological issues. We therefore chose to focus on descriptive analyses, and 
visualizations of these, to provide investigators with as much information as possible 
without categorical conclusions based on uncertain statistical tests. 
10.2 Discussion of main results 
10.2.1 Paper I 
Our evaluation of the impact of upper airway contamination when using different 
bronchoscopic sampling techniques was based on the underlying assumption that the 
more similar the lower airway specimens (PSB, PBAL and SVL) were the OW 
sample, the greater the influence of upper airway contamination on these samples. 
Between sample comparisons were made based on three parameters: i. taxonomy, ii. 
alpha diversity and iii. beta diversity. 
Taxonomy 
For comparison of taxonomic composition, we looked at the average relative 
abundance of the most prominent phyla by sample type. A clear trend with decreasing 




was observed. Driving this effect was an increase in Proteobacteria and a 
concomitant decrease in Firmicutes across sample types.  
The order by which similarity to the oral wash sample decreased across sampling 
types was in accordance with our prediction of which sampling techniques would 
offer the most protection from upper airway contamination. SVL being the only 
sample type that was unprotected, showed greatest resemblance to the OW sample, as 
expected. The lPSB sample for which sampling was performed from the same site as 
SVL, showed the least resemblance to the OW sample of all sample types. This 
indicated that differences in susceptibility to upper airway contamination and not 
lung biogeography, was responsible for the observed differences between samples. 
Also as expected, PBAL samples showed less similarity to the OW sample in the 
PBAL return 2, compared to PBAL return 1. As described in the section 6.1.3, this 
may indicate a dilution effect as upper airway contamination may be “diluted off” 
after the first PBAL sampling. Despite the use of protected sampling when using 
PBAL, the dilution effect may still be prominent if the outside of the bronchoscope is 
a major source of bronchoscopic upper airway carryover. Contamination from the 
outside of the bronchoscope channel may also be captured better by washings (i.e. 
PBAL) than brushings (i.e. PSB).  
The increase in Proteobacteria and simultaneous decrease in Firmicutes across 
sample types was however more challenging to interpret. Proteobacteria have 
previously been associated with contamination from the laboratory that is more 
pronounced in samples of low bacterial load. This was for instance found in the study 
by Biesbroek et al. [32] across serially diluted samples of saliva (section 6.4.1). Thus, 
the increase in Proteobacteria as samples become less similar to OW, may reflect a 
decrease in total bacterial load that have left these samples more influenced by 
laboratory contamination. The higher levels of Proteobacteria in PSB related to 
PBAL may also be expected as the input volume to DNA extraction was lower for 
PSB compared to PBAL (450 µl for PSB and 1800 µl for PBAL), thereby possibly 
securing a lower bacterial load for these samples. The observed simultaneous 




sampled microbiota. Indeed, Proteobacteria includes important bacteria of the 
airways such as Haemophilus, Legionella, Pseudomonas and Burkholderia. Without 
having quantified differences in bacterial load across sample types, we could however 
not further conclude on these possibilities. In addition, our approach to laboratory 
contamination was to remove all taxa found in NCS. The accuracy by which this 
approach is able to address all laboratory contaminants is not known, but is a central 
topic in paper II. 
Alpha diversity  
Alpha diversity measurements shed light on the level of biodiversity found within a 
single sample. In its simplest form this can be a count of the number of different 
operational taxonomic units (OTUs), amplicon sequence variants (ASVs) or bacterial 
species. The Faith´s phylogenetic diversity (Faith´s PD) metric used in the current 
study, takes into account not only the number of OTUs, but also how 
phylogenetically similar these are to one another. It does this by adding together the 
total branch length between all OTU placements in the phylogenetic tree. Thus, a 
sample will be more diverse the greater the number of OTUs and the greater the 
phylogenetic distance between these OTUs.    
We found that diversity decreased across sample types as the level of protection from 
upper airway contamination increased: OW>SVL>PBAL1>PBAL2>rPSB>lPSB. 
Importantly, this trend was the same as that observed when comparisons of 
taxonomic composition were made. Sampling the left or right lung first did not have a 
great impact on measurements of alpha diversity.  
Beta diversity 
Beta diversity measures the degree of (dis)similarity between samples. As with alpha 
diversity, we decided to incorporate phylogenetic information into our analyses. 
Using the UniFrac metric [106], the distance between samples was measured based 
on the branch length in the phylogenetic tree that is shared between their bacterial 




matrix, and the (dis)similarity between samples visualized by principal coordinates 
analysis (PCoA) plot.  
Using PCoA of unweighted UniFrac distances, we compared the OW samples to each 
of the five different sample types. We found that the similarity to the OW sample 
decreased in the order of SVL>PBAL>PSB. It was difficult to visually assess 
whether the overlap between PBAL1 and OW or PBAL2 and OW was greater and 
likewise, whether the overlap between lPSB and OW or rPSB and OW was greater. 
However, the general trend with regards to the three sampling techniques (PSB, 
PBAL, PSB) was in agreement with our results for both taxonomy and alpha 
diversity.  
By performing a permutational multivariate analysis of variance (PERMANOVA) 
test on the calculated UniFrac distance matrix, we could ascertain whether the 
(dis)similarities visualized in PCoA space were significant. This was particularly 
important for evaluation of the sample types mentioned above, that visually appeared 
to overlap equally with the OW samples in PCoA space. We found that all 
comparisons of OW and sample type were significant. Importantly, we were also able 
to confirm that the differences between OW and sample type increased in the order 
SVL< PBAL1< PBAL2< rPSB< lPSB as indicated by an increasing pseudo F-
statistic.  
Our results led us to conclude that protected sampling methods (PBAL, PSB) 
diminish the influence of oropharyngeal carryover by the bronchoscope. Our 
conclusion was however not in complete agreement with the findings presented in the 
three papers found in our literature search, for which both protected and unprotected 
sampling was performed [6, 12, 27].  
 
Charlson et al. [6] compared PSB samples (from the LLL) and BAL fluid (from the 
RML) obtained from six healthy subjects. Using PCoA analyses on weighted UniFrac 
distances, they found that all samples from lungs (irrespective of sample type) 




oropharyngeal swabs (OP)). Thus, protected sampling did not appear to influence the 
degree of similarity to upper airway samples. The study however lacked power in 
terms of the number of study participants and only one PSB sample was collected per 
subject. The sequencing depth was also lower than in our study. The authors also did 
not report results from PCoA analyses on unweighted UniFrac distances, which may 
have resulted in a different interpretation of the data. The combination of weighted 
(as opposed to unweighted) UniFrac analyses, and low sequencing depth may explain 
why differences were not detected between lower and upper airway samples, as seen 
in our study.   
 
Dickson et al. [12] compared PSB samples (from RUL and LUL) and BAL fluid 
(from RML and lingula) obtained from 15 healthy subjects. Based on principal 
component analyses of beta-diversity, they found that samples from the lungs (on 
average) clustered separately from that of the upper airway sample (PSB from the 
supraglottic region). They found no clustering by sample type, but noted that PSB 
samples from the RUL, showed the greatest resemblance to the upper airway sample. 
Collectively their results indicated that protected sampling techniques did not 
influence the degree of similarity to the upper airway sample. However, the sampling 
of BAL before PSB might have resulted in residual BAL fluid influencing the 
sampled PSB site. In the design of the sampling scheme used in the MicroCOPD 
study, we were careful to always sample PSB before BAL.  
 
Hogan et al. [27] compared PSB samples of mucus plugs and BAL fluid obtained 
from nine patients with CF. PSB and BAL were sampled from multiple lobes on the 
right lung (RUL, RML, RLL). On comparison of samples taken from the same lobe, 
they found that measures of alpha diversity (based on the Simpson Diversity Index 
metric) were consistently higher in PSB than in BAL. This was in direct contrast to 
our results. However, the CF lung likely reflects a completely different scenario than 
the healthy and even diseased COPD/asthma lungs sampled in our study. First of all, 
the CF lung is not considered particularly low biomass and therefore the impact of 




plugs may form specific niches for microbial colonization that may impact the 
comparison of sampling techniques. Their study did not include healthy control 
subjects. Our study included a greater number of participants, for which the observed 
decrease in diversity (SVL>PSB), was observed for both healthy and diseased states.  
10.2.2 Paper II 
Our analyses for the second paper were aimed at i) estimating levels of contamination 
across different airway sample types, ii) determining the main contamination source 
when processing samples through the MicroCOPD laboratory workflow, and iii) 
exploring bioinformatic approaches to dealing with the issue of contamination. 
Bacterial load varies with sample type 
The bacterial load was determined for the following procedural samples: OW, rPSB, 
PBAL1, and PBAL2. We found that bacterial load varied with sample type and 
decreased in order OW>PBAL1>PSB>PBAL2 (p < 0.001, non parametric trend test). 
We did not find differences in bacterial load across diseased states, which may reflect 
the fact that our diseased subjects had a fairly high lung function. Due to a low 
number of study participants, we therefore did not stratify our analyses on disease 
category. A discussion on our interpretation of these results follows. 
The average bacterial load in the samples from the lungs was highest for PBAL1. The 
bacterial load in PBAL2 and PSB samples were approximately an order of magnitude 
lower. PBAL1 and PBAL2 were obtained from the same wedged position of the 
RML, and the same volume sampling fluid was instilled. Thus, these samples can be 
directly compared. The observed decrease in bacterial load across these sample types 
(PBAL1>PBAL2) could be interpreted in several ways. First of all, it could mean that 
the first lavage fraction (PBAL1) collects a larger portion of the resident microbiota, 
by primarily sampling the more proximal airways, and also “cleaning up” the 
secretions that the bronchoscope might bring with it from its passage down the 
airways. However, the decrease in bacterial load could also be a result of a dilution 




[6] also compared the bacterial load obtained when sampling two fractions of BAL 
from the same site (site A). As us, they observed a decrease in bacterial load from the 
first to second BAL fraction. In addition, they sampled BAL from an adjacent site 
(site B), for which they found similar levels of bacteria as in the second return of the 
sampled site A. Their interpretation was that the first BAL fraction was contaminated 
with bacteria from the upper airways. Although we did not include sampling from an 
adjacent site “B”, the Charlson study provides us with another interpretation of our 
data – that PBAL1 may be more susceptible to contamination from the upper airways 
than PBAL2. This is also in agreement with results from paper I, where we found that 
PBAL1 was more similar to the upper airway OW sample than PBAL2 in terms of 
taxonomy, and measures of both alpha and beta diversity. PSB samples represent a 
different sampling modality than PBAL, and therefore we could not make 
comparisons across these sample types.  
The comparison of bacterial levels across studies is difficult because of the lack of 
standards in the field with regards to protocols for sampling and DNA extraction - 
and quantification of bacterial load is performed on samples after processing through 
these steps. To illustrate this, we can again look to the study conducted by Charlson 
et al. [6], for which we can find some similarity in protocols to those used in the 
current study. As us, they sampled BAL from the RML by instilling 50 mL saline and 
used 1.8 mL of the returned BAL as input to their DNA extraction protocol. Our 
protocols for DNA extraction however differed. Without conducting a head-to-head 
comparison of the two DNA extraction protocols, it is unclear whether observed 
differences in sample bacteria load are due to actual differences in sampled bacterial 
levels or a result of differences in extraction efficiency between protocols. Equally 
important is likely differences in contamination levels introduced when processing 
samples through different DNA extraction kits. Commonly used DNA extraction kits 
are not free of bacteria, and differences in contamination levels across kits can be 
expected [63]. Importantly, the measured bacterial load will reflect both the sampled 
microbiota and contamination introduced from sampling and DNA extraction [63]. 




Estimates of contaminant levels for samples with varying bacterial load were made 
using the “Salter approach” described in the introduction. In brief, our analyses 
included a ten-fold dilution series of Salmonella (SDS). For evaluating the impact of 
varying PCR cycle number, the SDS was processed through two PCR protocols 
differing only in the number of PCR cycles (30 and 45 cycles).  
On analysis of the sequencing output for the SDS samples, we observed the expected 
inverse relationship between sample bacterial load and the proportion of sequences 
mapping to taxa other than Salmonella (i.e. contamination) [32, 63]. At an input of 
between 10^3 and 10^4 Salmonella/mL, we observed that contaminants constituted 
more than 50% of the bacterial community profile for a sample. Despite differences 
in protocols, our results were in accordance with the findings by Salter et al. [63]. 
This may be explained by the use of similar DNA extraction kits (both from MP 
Biomedicals, FastDNA Spin Kit). Further supporting our interpretation is the study 
by Biesbroek et al. [32], who found that choice of DNA extraction kit determined 
whether low biomass samples fell above or below their set threshold bacterial load 
for which contamination begins to dominate. When processing the SDS through an 
increased number of PCR cycles, we observed only a small increase in the proportion 
of non-Salmonella taxa (i.e. contamination). Thus the impact was low, validating the 
protocol used in the MicroCOPD study (45 cycles used).  
The SDS experiment was used to estimate levels of contamination in the different 
airway sample types (OW, PSB, PBAL). The OW sample appeared to be unaffected. 
For the lower airway samples (PSB, PBAL) however, an estimated 10-50% of the 
sequencing output was expected to be derived from contamination. A limitation to the 
Salter approach is that it does not capture PCR incorporated error (e.g. chimeras) that 
may be associated with a more complex natural sample (i.e. airway samples). As 
described in section 6.2.2, such erroneous sequences may result in sequences 
mapping to taxa not found in the sampled community. Although different than 
external contamination derived from the laboratory environment and reagents, such 
PCR incorporated errors would have the same impact on the bacterial community 




sampled community. We may therefore expect that the procedural samples would be 
more impacted by PCR cycle number than what was estimated using the SDS. 
The objective of the SDS experiment was to demonstrate a method by which levels of 
contamination could be reported on in airway microbiome studies, and not to define a 
threshold bacterial load applicable to all studies. Important because contamination 
levels may vary greatly across studies due to differences in protocols. For a more 
detailed discussion on protocol effects on bacterial load, the reader is directed to 
section 6.4.2.  
The SDS sample was also used as a tool to determine optimal methods and settings 
when performing contaminant removal using the Decontam R package tools. We 
recognize also that because the SDS is a less complex sample than the procedural 
samples, findings may not be directly transferable. On comparison of 
decontamination strategies, we could have also included other approaches, such as 
contaminant identification using the neutral community model [19]. 
10.2.3 Paper III 
Paper III was aimed at (dis)proving our hypothesis that contaminating bacterial DNA 
introduced during laboratory processing steps would render samples processed 
through the longer 2-step PCR protocol (setups 1 and 2) more vulnerable to 
laboratory contamination than when processed through the 1-step PCR protocol 
(setup 3). We also wished to explore differences that may result from targeting the 
16S rRNA gene V3 V4 region versus the V4 region.  
By processing the same DNA extracts through each setup it was possible to mitigate 
potential bias from differences in contamination introduced by the DNA extraction 
kit. This was important as we have previously shown that the DNA extraction kit is a 
main source of contamination in our experiments (paper II).  
The differences in sequencing output generated by processing samples through each 
library preparation setup was based on four separate analyses: i) comparison of 




a mock community sample processed through each setup, iii) comparison of 
contamination profiles for each setup by examination of ASVs recovered in NCS, and 
finally iv) comparison of community descriptions obtained from procedural samples 
before and after the removal of contaminating ASVs using the Decontam strategy. 
Bioinformatics processing steps 
The comparison of the three different setups began with examination of the number 
of sequences and ASVs retained at each step of the bioinformatic pipeline. We 
expected that the removal of error and bias at each step would result in increasingly 
more similar datasets. Indeed, we did observe that the number of sequences and 
ASVs became more similar; however at the end of the pipeline differences remained 
with the number of sequences/ASVs still decreasing in the order: setup 1> setup 
2>setup 3. A closer examination of the number of sequence/ASVs retained at each 
step provided insight into the differences in the raw sequencing output generated 
when processing samples through each setup. A discussion on the most telling 
observations and our interpretation follows - namely that resulting from the additional 
filtering of small ASVs and that from the additional chimera removal step.  
The perhaps most interesting observation, was that the additional filtering step for 
removal of low abundant ASVs (i.e. the “Bokulich method”), led to the greatest 
reduction in the number of ASVs across all three setups. The impact was greatest for 
setups 1 and 2, both of which were based on the 2-step PCR protocol. These 
observations were in accordance with our prediction that small ASVs likely represent 
low abundant contaminating sequences, and that samples processed through the 
longer 2-step PCR protocol would be more susceptible to contamination than samples 
processed through the shorter 1-step PCR protocol. The greatest proportion of these 
“contaminating” small ASVs were observed in setup 1, and this was substantially 
greater than for setup 2, for which was based on the same number of PCR steps. We 
recognized that our observations could be a result of setup 1 samples being spread 
across four separate sequencing runs; this because contamination may vary across 




sequences representative of contaminants. Analyses of MC samples included on each 
of four sequencing runs for setup 1, confirmed that contamination profiles differed 
across the four sequencing runs for setup 1. When reanalyzing the data on the subset 
of samples that were sequenced on the same sequencing run, this was confirmed, 
since the differences across setups were now lower.  
Also interesting was that the additional round of chimera filtering, led to an additional 
loss of sequences and ASVs. The additional chimera removal step had greatest 
impact on sequence data derived from setup 1. Interpretation of this observation is not 
straightforward as there again are multiple possible explanations. The observation 
may indicate that the proportion of chimeras is truly greater when processing samples 
through setup 1. This would be in line with studies that have indicated that longer 
target amplicons will be more inclined to form chimeras, and multimeras. On the 
other hand, it may reflect the fact that algorithms for chimera detection have more 
difficulty in identifying chimeras, the shorter the sequence. Thus there is the 
possibility that chimera removal may not be as effective for setups 2 and 3 targeting 
the shorter V4 region.  
Protocol effects on mock community  
A mock community (MC) sample of known bacterial composition was included on 
each sequencing run for the current paper III. In general, MC samples are used to 
answer one central question – does my protocol generate data that accurately 
represents the sampled bacterial community? Although not a perfect representation of 
a natural sample (i.e. lower complexity), the MC is a valuable tool for which bias 
introduced during library preparation and sequencing can be estimated. The MC can 
take form as a mixture of bacterial cells or a mixture of their genomic DNAs. In the 
form of a bacterial cell mixture, the MC is processed through all steps of the 
amplicon-based marker gene sequencing workflow from DNA extraction to 
sequencing. In the form of a mixture of genomic DNA, the DNA extraction step can 
be omitted, allowing assessment of downstream steps (PCR and sequencing) without 




or “even” in composition, meaning that the different types of bacteria are represented 
at different or equal concentrations, respectively.  
For the current paper choice of MC fell on mock community HM-783D (Bei 
Resources) consisting of genomic DNA from 20 different bacterial species at varying 
concentrations in the range of 1000 to 1000000 rRNA operon counts per species. A 
MC of genomic DNA was chosen, rather than a MC of bacterial cells, because we 
wished to validate laboratory steps post-DNA extraction. In addition, the use of 
genomic DNA was favorable because the number of rRNA copies for each species 
was known. Analyses were therefore not influenced by variation in copy numbers. A 
staggered community was chosen in order to assess the degree to which both low and 
high abundant MC members were recovered. For setup 1, the MC was included on all 
four sequencing runs enabling also the assessment of reproducibility/reliability for 
this setup. For setups 2 and 3, for which only one sequencing run was performed for 
each, it was not possible to determine reproducibility/reliability. This may represent a 
weakness in our interpretation of results from MC sequencing across the three setups. 
We found that the three setups were equally efficient at recovering the high abundant 
members. For low abundant members, recovery varied across setups. Recall that the 
MC was processed on each of the four sequencing runs for setup 1. While the first 
run recovered all MC members, Bacteroides was missing on run II, and Actinomyces 
was missing on runs III and IV. For setup 2, all MC members were recovered. For 
setup 3, three genera were not recovered including Propionibacterium, Actinomyces, 
and Enterococcus. It thus appeared that the recovery of low abundant genera was an 
unreliable event across both 1- and 2-step PCR protocols (as demonstrated from 
output in both setups 1 and 3). However, setup 3 was most impacted as multiple 
genera were missing from data generated from the same sequencing run. One 
possible explanation for these observations was that the degenerate V4 primers in 
setup 3, were suboptimal matches to the sequences from these bacteria (i.e. primer 
bias). However, this was quickly dismissed as the setup 2 primers contained the same 
sequences for targeting the V4 region, and these same bacteria were recovered in data 




protocols, found in accordance with our findings, lower diversity for samples 
processed through a one step PCR protocol. They suggested another more likely 
explanation for observed differences – that the additional sequences required on 
primers used used in 1-step PCR protocols (marker gene targeting sequence, index 
and adapter sequences) may interfere with primer-template interactions during PCR.  
Based on these results, we concluded that the 1-step PCR protocol may be less apt for 
detection of rare taxa. This was in accordance with the analyses of bioinformatics 
processing steps, for which we observed a lower total ASV count when following 
setup 3 compared to setups 1 and 2. Our analyses of the MC however, forced us to 
rethink our previous conclusion. Recall that based on the analyses of bioinformatics 
processing steps, we interpreted the lower total number of ASVs in setup 3, and the 
more excessive removal of small ASVs for setups 1 and 2, following the “Bokulich 
model”, as an indication that samples were less prone to contamination when 
processing through a shorter 1-step PCR protocol. By analyses of the MC, we 
however learn that differences in contamination levels may not be directly linked to 
the length of the laboratory protocol. Rather, this may be a result of differences in 
PCR primer structure, for which primers required for the 1-step PCR protocol are less 
able to pick up on low abundant taxa – be it derived from contaminating bacteria or 
true members of the sampled community.  
Protocol effects on contamination profiles  
Our working hypothesis linked any observed differences in sequencing output to 
differences in susceptibility to laboratory contamination. We therefore proceeded 
with an examination of negative control samples – the procedural NCS and PCR 
water samples.  
The procedural NCS were across all three setups dominated by ASVs belonging to 
the family Enterobacteriaceae. At ASV level we found that setup 1 was dominated 
by 3 different ASVs that all mapped to the genus Gluconacetobacter (Family 
Enterobacteriaceae). For setup 2, a single ASV was mapped to Enterobacteriaceae at 




the same as the cumulative abundance of the three ASVs mapping to 
Gluconacetobacter in setup 1- suggesting a common bacterial origin. The same ASV 
was also observed in setup 3. Overall this told us that Enterobacteriaceae dominated 
all samples and was likely introduced during DNA extraction steps. This was also in 
accordance with findings from the previous paper II, for which analyses of top 20 
OTUs were conducted on the same samples using QIIME1 and the OTU based 
sequence clustering approach. Also noteworthy, is that the similarity of the results for 
the current paper (processed using QIIME2 and denoising to ASVs) to that generated 
for the previous paper II, provides internal validity with regards to bioinformatics 
processing steps and findings reported for both papers.  
Perhaps the most interesting finding in our analyses of the top 20 NCS across setups, 
was the observation of a second ASV mapping to Enterobacteriaceae in setup 3. The 
ASV was in turn nearly undetectable in setup 2, having been observed in just 2/23 
NCS samples (relative abundances of just 0.16% and 0.26%). Using NCBI blastn, 
this second Enterobacteriaceae ASV was identified as Escherichia coli. To further 
grasp the origin of this ASV, we looked to the PCR water samples. Indeed, we found 
that the ASV dominated the PCR water sample from setup 3 and was absent in the 
PCR water sample from setup 2. This told us that the ASV was a contaminant 
introduced during library preparation steps (i.e. post DNA extraction) in setup 3. To 
further back up our findings, we also searched for the ASV in the MC samples. We 
found the same ASV present in both MC samples regardless of sequencing setup 2 or 
3 – this was as expected as Escherichia coli is a high abundant member of the MC 
with an expected relative abundance of 21.91%. In accordance with our finding that 
the Escherichia ASV also behaves as a contaminant in setup 3, we observed 
increased levels of the ASV for setup 3 compared to the expected and that observed 
in setup 2– thus in other words for setup 3, the ASV represented both a true member 
of the sampled community, but also a contaminant. In addition, as will be discussed 
in the subsequent section, the same Escherichia ASV was also observed in the low 
biomass airway samples (PSB, PBAL) processed through setup 3 (and not setup 2). 
Thus, several lines of evidence show that the Escherichia ASV is a result of a 




this included the observation of the ASV in both procedural NCS and PCR water and 
also the observation of elevated levels of the ASV in the mock community. While 
internal contamination - such as well to well carryover in the direction MC to PCR 
water sample may be theoretically be possible, the sum of our observations suggest 
this to be an unlikely alternative explanation. For such an internal contamination 
event to occur, we would also expect to observe other MC members in the PCR water 
sample (for instance the Rhodobacter); this was not observed when not taking into 
account potential members that overlap between airway and MC samples (e.g. 
Streptococcus, Staphylococcus) as this may indicate contamination from airway 
samples.  
Protocol effects on procedural samples  
Having compared NCS across setups, we were next interested in finding out whether 
differences in contamination would influence our interpretation of the lower airway 
microbiome. We were particularly interested in tracing the Enterobacteriaceae ASVs 
that were found to dominate the contamination profiles (NCS) for all three setups as 
described above. 
In accordance with expected patterns of contamination (section 6.4.1), we found that 
the proportion of Enterobacteriaceae was highest in the lower airway samples 
(PSB>PBAL) and nearly undetectable in OW samples. Also, consistent across setups 
was the observation that higher levels of Enterobacteriaceae were observed in PSB 
samples compared to PBAL samples. This is likely explained by differences in the 
bacterial load between the two sample types, rendering PSB samples more vulnerable 
to contamination. Recall that in paper II, it was established that the mean sample 
bacterial load decreased in order OW > PBAL1 > PSB > PBAL2. However, less 
sample volume was used as input to DNA extraction for PSB samples than PBAL 
samples (450 µl PSB vs 1800 µl PBAL), likely explaining the apparent increased 
impact of contamination on PSB samples. As expected from analyses of NCS, we 
also found that Enterobacteriaceae was found in greatest relative abundance in 




While the aforementioned observations were in line with expected patterns of 
contamination, the levels of Enterobacteriaceae were lower than the expected levels 
of contamination as estimated in paper II for setup 2 (section 10.2.2). We recognized 
that a significant proportion of contaminants were likely also represented by other 
taxa. For a more accurate assessment of contamination, comparison of samples was 
made before and after the removal of contaminants identified using the Decontam 
package tools. On analysis of unweighted UniFrac distances in PCoA space for 
setups 2 and 3, we found that high biomass OW samples clustered together regardless 
of setup, both before and after Decontam had been applied. The lower airway 
samples (PSB, PBAL) however separated according to setup 2 or 3. After removal of 
Decontam contaminants the overlap appeared to increase, but the observed separation 
according to setup was still apparent. We concluded that factors related to bacterial 
load, other than contamination was contributing to the observed protocol bias.  
No other study on the airway microbiome has addressed the issue of protocol effects 
(1- vs 2-PCR steps) on the presentation of the airways. We shed light on an issue that 
needs to be investigated further in future studies. Particularly concerning is that our 
findings indicate that the similarity between upper and lower airway samples may be 
protocol dependent. Furthermore, we show that similar community descriptions 
obtained for upper airway samples should not be interpreted as evidence that datasets 







1. The bacterial composition of samples obtained by protected specimen brushes 
and protected bronchoalveolar lavage was less similar to oral wash samples 
than more unprotected sampling methods. Future investigators should take 
these findings into consideration, and take measures to prevent potential 
contamination from supraglottic regions.  
 
2. Laboratory contamination was considerable in airway microbiome studies, and 
in particular the DNA extraction kits appeared to represent a major 
contamination source. However, bioinformatic strategies were able to correct 
for this, given availability of proper negative control samples.  
 
3. A one-step PCR protocol yields results that differ taxonomically from a two-
step PCR protocol. These differences are likely related to mechanisms in the 
PCR itself and not to contamination. Differences between V4 and a combined 






12. Future perspectives 
The field of lung microbiome research has up until now been characterized by an 
urge to rapidly publish data comparing healthy and diseased states. Few studies have 
however addressed validity and reliability of applied methods of sampling, laboratory 
processing and bioinformatics analyses. The findings in the current thesis underline 
the importance of addressing these issues in future studies.  
While our findings have suggested that protected bronchoscopic sampling techniques 
may minimize the influence of oropharyngeal contamination, there is still a need for 
further investigation. Studies for which the upper airway representative sample is 
obtained from the supraglottic region (the last upper airway site that the 
bronchoscope passes on its entry to the lower airways) may for instance provide 
deeper insight into impact of bronchoscopic carryover. Furthermore, we need a 
deeper understanding of the impact of dilution effects when sampling and when 
deciding on the volume of sample that is further passed down the laboratory pipeline.  
We found that differences in setups for library preparation for sequencing, related to 
the number of PCR steps (1- or 2-steps) led to different community descriptions for 
airway samples. Because differences in contamination levels alone could not explain 
these findings, we concluded that more research is needed to understand underlying 
mechanisms driving the observed protocol bias - these are likely related to the PCR. 
Besides impact of number of PCR steps, there is a need to investigate the impact of 
variation in PCR cycling conditions across studies. One study has for instance used 
touch-down PCR as a means to optimize their protocol [21]. The degree to which 
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ABSTRACT The aim was to evaluate susceptibility of oropharyngeal contamination with various
bronchoscopic sampling techniques.
67 patients with obstructive lung disease and 58 control subjects underwent bronchoscopy with small-
volume lavage (SVL) through the working channel, protected bronchoalveolar lavage (PBAL) and bilateral
protected specimen brush (PSB) sampling. Subjects also provided an oral wash (OW) sample, and negative
control samples were gathered for each bronchoscopy procedure. DNA encoding bacterial 16S ribosomal
RNA was sequenced and bioinformatically processed to cluster into operational taxonomic units (OTU),
assign taxonomy and obtain measures of diversity.
The proportion of Proteobacteria increased, whereas Firmicutes diminished in the order OW, SVL,
PBAL, PSB (p<0.01). The alpha-diversity decreased in the same order (p<0.01). Also, beta-diversity varied
by sampling method (p<0.01), and visualisation of principal coordinates analyses indicated that differences
in diversity were smaller between OW and SVL and OW and PBAL samples than for OW and the PSB
samples. The order of sampling (left versus right first) did not influence alpha- or beta-diversity for PSB
samples.
Studies of the airway microbiota need to address the potential for oropharyngeal contamination, and
protected sampling might represent an acceptable measure to minimise this problem.
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High-throughput sequencing has opened up a new window in microbial ecology, enabling the
characterisation of microbial communities in biological compartments thought to be completely sterile
only a few years ago. The implications for health and disease are widely unexplored, but are likely to be
significant [1]. Recent studies have found compelling evidence for the lungs to have a distinct microbiome [2],
providing a bacterial presence with which our immune system interacts [3, 4]. As almost all pulmonary
diseases have a local inflammatory component, there is a possibility of a disrupted microbiome being
integral to disease pathogenesis.
Thus, there is a current push to characterise the pulmonary microbiome, and its relation to different
pulmonary diseases. However, sampling the pulmonary microbiome is difficult. Sputum is fraught with
significant contamination from the oral cavity, and percutaneous sampling is unpractical with a high risk of
complications like pneumothorax or bleeding. The emerging gold standard for sampling is bronchoscopy.
But bronchoscopy also has its technical challenges, besides issues of discomfort, cost and sedation. The
bronchoscope must pass through either the oral or nasal cavity in addition to the pharyngeal cavity, and
might carry contaminants from the upper airways to the lower biomass compartment of the lower airways.
Samples are collected through the same bronchoscope working channel through which fluid is suctioned up
and out. The different modes of sampling (bronchoalveolar lavage (BAL) brushings, biopsies) might be
carried through catheters, which may or may not have a wax-sealed tip to ensure sterility. Added to this is
the conundrum caused by the constant influx of microbiota by microaspiration and inhalation that
probably is responsible for maintenance and creation of a large fraction of the lung microbiome [5].
In 25 studies of the human lung microbiome sampling the airway microbiome by bronchoscopy of healthy
subjects [2–4, 6–9] and patients with chronic obstructive pulmonary disease (COPD) [10–14], asthma
[15, 16], interstitial lung disease [17, 18], cystic fibrosis (CF) [19], HIV [20–23] and lung-transplanted
subjects [24–27]; only five used protected sterile brushes (PSB) to avoid contamination from the working
channel [7, 8, 16, 19, 22]. Some authors reported that suction was not used prior to entering the trachea
[2–4, 6–10, 20, 22], and three studies used separate bronchoscopes for anaesthesia and sampling of some
or all participants [3, 4, 7]. No study performed bronchoalveolar lavage (BAL) through a protected
catheter (protected BAL), and no study with more than 20 sampled subjects has compared protected with
unprotected sampling methods.
In preparation for the analyses of a large, ongoing COPD microbiome study [28], we sought to reduce
contamination as well as assess the performance of different sampling techniques. In the current paper we
present analyses to examine the degree of oropharyngeal influence on the airway microbiome applying
protected bronchoscopic sampling techniques. In addition we present an analysis on the effect of sampling
the left or right lung first.
Material and methods
The design of the entire MicroCOPD study has been published previously [28]. The current analysis
includes 58 control subjects, 64 subjects with COPD and three subjects with asthma. All participants were
at least 35 years old and were recruited from previous longitudinal case–control studies in addition to a
few volunteers [29]. Subjects had neither acute respiratory symptoms nor any reported use of antibiotics or
oral corticorticosteroids within the last 14 days prior to bronchoscopy. Other inclusion/exclusion criteria
are listed in the supplementary material.
The Regional Committee for Medical and Health Research Ethics approved the study (REK Nord, project
number 2011/1307). All participants provided written informed consent.
All participants received at least 0.4 mg of salbutamol through a spacer before the bronchoscopy
procedure. Flexible video-bronchoscopy was performed via the oral route in supine position. No suction
was used prior to having entered the trachea. All subjects received local anaesthesia with lidocaine both
before and during the procedure. All but 18 subjects received mild sedation (alfentanil) parenterally.
Participants were monitored according to current guidelines, and were observed for at least 2 h after the
procedure [30]. Six procedural samples, of which five were obtained during bronchoscopy, were analysed
for each participant: oral wash (OW); three protected specimen brushes (PSBs) from the right lower lobe
(right PSB) and three from the left upper lobe (left PSB); two 50-mL fractions of protected
bronchoalveolar lavage of the right middle lobe (PBAL1 and PBAL2); and small-volume lavage (SVL) in
the left upper lobe. In addition, we included negative control samples (NCSs) from the same bottle of
phosphate-buffered saline that was used for the procedure of the corresponding individual. For 49
subjects, we examined the left lung before the right lung. BAL and SVL were always collected after
obtaining PSB samples. Protected specimen brushes and protected bronchoalveolar lavage are illustrated in
supplementary figures S1 and S2.
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Bacterial DNA was extracted using a combination of enzymatic lysis with lysozyme, mutanolysin and
lysostaphin, and mechanical lysis methods using the FastPrep-24 as described by the manufacturers of the
FastDNA Spin Kit (MP Biomedicals, LLC, Solon, OH, USA).
Library preparation and sequencing of the V3-V4 region of the 16S rRNA gene was carried out according
to the Illumina 16S Metagenomic Sequencing Library Preparation guide (Part no. 15044223 Rev. B). The
V3-V4 region was PCR amplified (45 cycles) and prepared for a subsequent index PCR step using primers
adapted from KLINDWORTH et al. [31] as follows. 16S amplicon PCR forward primer (overhang adaptor
sequences are underlined): 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGG
NGGCWGCAG. 16S amplicon PCR reverse primer (overhang adaptor sequences are underlined):
5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC. The samples
were pooled and prepared for 2×300 cycles of paired-end sequencing on the Illumina Miseq sequencing
platform using reagents from the Miseq reagent kit v3 (Illumina Inc., San Diego, CA, USA).
The chosen bioinformatic pipeline was Quantitative Insights Into Microbial Ecology (QIIME, http://qiime.
org) v1.9.1. After creating a library of joined reads, operational taxonomic units (OTUs) were picked at a
97% similarity threshold, small OTUs and OTUs seen in negative control samples were removed,
taxonomy was assigned to the OTUs and a phylogenetic tree was constructed after alignment. We used the
GreenGenes version 13.8 as reference database [32]. Further details on the bioinformatic procedures can
be found in the supplementary material.
Differences in relative abundance of taxa were evaluated by applying a beta distribution and
non-parametric trend tests. Alpha-diversity was evaluated using Faith’s phylogenetic diversity (PD), or
“PD wholetree”. Beta-diversity was estimated with unweighted UniFrac and visualised by principal
coordinates analyses (PCoA) [33]. Diversity analyses require a similar number of sequences in each
sample, which was ensured by rarefaction. Statistical significance for alpha-diversity and beta-diversity
between sampling methods was evaluated by Bonferroni-corrected Wilcoxon matched-pairs test in Stata
version 13.2 (Statacorp, Texas, USA) and permutational ANOVA (permanova) tests in QIIME,
respectively.
Results
Only three subjects had asthma: two men and one woman. The 64 COPD subjects were slightly older,
included more men and had a larger tobacco-smoking burden than the 58 control subjects (table 1).
For each of the 125 participants, seven samples were sequenced (negative control sample, OW, right PSB,
PBAL1, PBAL2, left PSB, SVL). A total of 12.5 million sequences were obtained from the six procedural
samples after bioinformatics clean-up, as described in the methods section. For alpha- and beta-diversity,
we rarefied our data at 1000 sequences.
Taxonomy
Figure 1 shows the taxonomic classification by sampling method at the phylum level. As the degree of
protection from influence of oral environment increased, the proportion of Proteobacteria increased,
whereas Firmicutes diminished (p<0.01). At the genus level all sample types where dominated by
streptococci, but the mean proportion of the largest Streptococcus OTU showed the same declining pattern
by sample type (OW 14.5%, SVL 13.6%, PBAL1 11.8%, PBAL2 11.3%, right PSB 8,6% and left PSB 5.4%;
non-parametric trend test p<0.001).
TABLE 1 Characteristics of 125 subjects of the MicroCOPD study
COPD Asthma Control
Subjects 64 3 58
Males 34 (53.1%) 2 (67.7%) 34 (58.6%)
Current smokers 15 (23.4%) 0 16 (27.6%)
Ex-smokers 48 (75.0%) 2 (67.7%) 35 (60.3%)
Never-smokers 1 (1.6%) 1 (33.3%) 7 (12.1%)
Smoking exposure pack-years 28.49±16.08 20.88±24.22 22.83±18.55
FEV1 % predicted 56.83±16.30 88.31±11.37 100.71±11.00
Age years 68.73±7.23 64.41±9.1 64.89±8.43
Use of inhaled corticosteroids 44 (68.8%) 1 (33.3%) 1 (1.7%)
Data are presented as mean±SD unless otherwise stated. COPD: chronic obstructive pulmonary disease;
FEV1: forced expiratory volume in 1 s.
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Alpha-diversity
Figure 2 shows a boxplot of the alpha-diversity metric, Faith’s phylogenetic diversity, by sampling method
and by disease category, excluding the three asthma subjects. The phylogenetic diversity within a sample is
an indication of richness as the diversity increases both when a higher number of different OTUs are
present, and when the phylogenetic distance is larger within the phylogenetic tree (less genetically similar).
Bonferroni-corrected Wilcoxon matched-pairs signed-ranks tests showed that the oral wash samples were
more alpha-diverse than all other sampling methods (p<0.001). The diversity was lower in COPD patients






























FIGURE 1 Mean taxonomic distribution at the phylum level, by sampling method, for all 125 individuals
(unrarefied). OW: oral wash; SVL: small-volume lavage in the left upper lobe; BAL1: first fraction of protected
bronchoalveolar lavage (BAL) from right middle lobe; BAL2: second fraction of protected BAL from right







































FIGURE 2 Box-plot of alpha-diversity measured by wholetree phylogenetic differences grouped according to sampling method and chronic
obstructive pulmonary disease (COPD) status. Rarefied at 1000 sequences. OW: oral wash sample; SVL: small-volume lavage from left upper lobe;
PBAL1: first fraction of protected bronchoalveolar lavage (BAL); PBAL2: second fraction of protected BAL; right PSB: protected specimen brush
from right lower lobe; left PSB: protected specimen brush from left upper lobe.
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were less exposed to potential oral and bronchoscope contamination (OW>SVL>PBAL1>
PBAL2>rightPSB>leftPSB, non-parametric trend test p<0.01).
Beta-diversity
To compare between sample compositions (beta-diversity), we constructed principal coordinates analysis
(PCoA) plots of unweighted UniFrac distances including all procedural samples. Figure 3 shows the PCoA
plots for the oral wash versus each of the other sampling methods. Each dot represents a diversity
measurement for one sample, and the OW sample is always shown in green. As can be seen, most
respiratory tract samples clustered differently from the OW samples, but the visual impression is that the
differences in diversity were smaller between OW and SVL and OW and PBAL samples than for OW and
the PSB samples. Another way of comparing the beta-diversity was employed using a permanova test;
estimating the beta-diversity between OW samples and each of the other sampling methods. This method
tests to which degree the variation in a matrix of UniFrac distances can be explained by an imposed
categorisation (i.e. sampling method). Overall permanova test confirmed that the beta-diversity differed by
sampling method (pseudo F 8.73, p=0.001, 999 permutations). When the distance matrix was split
according to the comparisons in figure 3, all were significant (p<0.01, permanova, corrected for multiple
comparison), with the permanova pseudo F-statistic gradually increasing for the comparison of OW with
SVL, PBAL1, PBAL2, right PSB and left PSB respectively, again indicating that PSB samples were more
clearly separated from OW samples than SVL and PBAL.
Finally we investigated whether the order of sampling (left versus right lung first) influenced alpha- and
beta-diversity in PSB samples. We found no significant difference in alpha- or beta-diversity for the right or
the left PSBs as judged by phylogenetic diversity and unweighted UniFrac (supplementary figures S3 and S4).
Discussion
We have shown that protected BAL and protected brush samples differed more from oral wash samples
than unprotected lavage through the bronchoscope working channel. Thus, unprotected sampling of the
airway microbiome might convey an image of a microbiome that is more similar to the oral microbiome,
than it would have been with protected sampling.
Oral wash
Small volume lavage, LUL
Protected BAL, fraction 1, RML
Protected BAL, fraction 2, RML
Protected brush, RLL
Protected brush, LUL
FIGURE 3 Principal coordinates analyses on unweighted UniFrac distance matrix comparing sampling methods in the MicroCOPD to oral wash
samples. Rarefied at 1000 sequences. LUL: left upper lobe; BAL: bronchoalveolar lavage; RML: right middle lobe; RLL: right lower lobe.
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To our best knowledge this is the first study that presents both protected brush and protected lavage
sampling as compared with both the oral microbiome and unprotected sampling. With more than 120
examined subjects it is by today the largest single site bronchoscopy study of the lung microbiome.
As other authors we find evidence of a lung microbiome separated from the oral microbiome by a larger
fraction of Proteobacteria and a proportionately lower fraction of Firmicutes [2, 8, 15, 20]. However, SEGAL
and associates [3, 4] mainly found that the airway microbiome was characterised by enrichment from
supraglottic areas of the respiratory tract, and in particular by Prevotella and Veillonella OTUs, which are
Bacteriodetes and Firmicutes, respectively. They examined 49 subjects, with supraglottic brushes and BAL
through the working channel, and observed that two clusters dominated airway samples: one dominated
by OTUs present in negative control samples, and one dominated by OTUs present in supraglottic
brushes. One interpretation might be that these two clusters represent two different modalities of
contamination, the first one from laboratory procedures and the second from bronchoscopic carryover.
SEGAL et al. argue that if it was bronchoscopic carry-over, they would have observed a dilutional effect
when they compared a first BAL of the lingula, with the second BAL of the right middle lobe. However,
this comparison was done for only 15 individuals, and anatomically one might expect lower biomass in
the lingula than the right middle lobe.
Other authors have also investigated the possibility of bronchoscopic carryover. BASSIS et al. examined oral
wash samples of 12 subjects and compared them with a first BAL of the lingula and a second BAL of the
right middle lobe [6]. They did not find any difference in quantitative PCR between the first and second
BAL, and no difference in beta-diversity when comparing the OW with the two BALs. Their interpretation
was that if there was significant carryover, there should have been observed some sort of dilutional effect.
Nevertheless, the two sampled sites are separated by the carina, and the bronchoscope must be
repositioned between sampling, and these two sites are indeed in different communication with the
outside world, possibly leading to an a priori larger biomass in the right lung. Also, DICKSON et al.
compared supraglottic brushes with PSB and BAL through the working channel [8]. In principal
component analyses of beta-diversity they found no clustering by sample type, except that the supraglottic
samples differed from the intrapulmonary sample communities. However, by performing unprotected BAL
before PSB, residual BAL fluid might have affected the brush areas making them more similar to the BAL
sample sites. Finally, 15 sampled subjects might not be sufficient to detect the differences we observed in
the current study with more than 100 participants.
It is quite plausible that microbes migrate from the oropharyngeal cavity to the airways, generating a
normal overlap between the oropharyngeal and airway microbiomes [5]. But as we have shown, co-existing
sample contamination likely also is an issue. The oropharyngeal microbiome has a known large biomass,
with a high diversity. By passing through this cavity, contamination to the outside of the bronchoscope
including its tip is inevitable. Use of suction will contaminate the working channel [7]. Since the oral
biomass is much greater than the airway biomass, even a small contamination will have a disproportionate
effect on the supposed airway microbiome if the unprotected measurements are performed through the
working channel. Using the working channel for unprotected lavage repeatedly at different lobes will lead
to contamination from one lobe to another. Using larger volume lavage may negate this effect to some
degree, but not eliminate the problem.
Results from the current study suggest that protected sheet sampling is the superior sampling
methodology. Comparing unprotected SVL and PSB both taken from the upper left lobe in our study, SVL
was most similar to the oral sample by visual assessment of the 10 most abundant taxa, and likewise both
by alpha- and beta-diversity. A direct comparison of protected and unprotected lavage from the same lobe
is impossible, as any washing will impact the contents of later washings. However, the diversity of PBAL
from the right middle lobe was intermediate between that found in OW and that found in the PSB.
Besides the above-mentioned study by DICKSON and colleagues [8], only two other studies have compared
PSBs to other sampling methods [7, 19]. CHARLSON et al. [7] sampled laboratory reagents, the
bronchoscope itself during various parts of the procedure, and the oropharyngeal microbiome in addition
to BAL through the working channel and PSBs. They concluded that the microbiome from the lower
respiratory tract was indiscriminate from the oropharyngeal microbiome irrespective of sampling method.
However, the study included only one PSB per sampling, had lower sequencing depth than the current
study, included only six healthy individuals and there were no adjustments made for OTUs seen in the
negative control samples [7]. HOGAN et al. compared PSB, and SVL samples of nine CF patients [19]. For
eight CF patients who had PSB and SVL taken from the same lobe, diversity was consistently higher in the
PSB samples [19], the opposite of our findings. HOGAN et al. employed the PSB only at visible mucus
plugs, and the airways of adult CF patients are perhaps no longer representing a low biomass
environment. In addition the number of study subjects was limited.
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The main strength of our study was comprehensive sampling of a large, heterogeneous sample of subjects
with and without COPD, while taking precautions to avoid excessive influence from laboratory and
bronchoscopic contamination. However, some potential weaknesses should be acknowledged. First, we
have not performed quantitative PCR, and thus cannot conclude regarding the amount of 16S rRNA gene
copies in the samples before amplification. Second, our analyses do not include a mock community, and
we are therefore not able to provide sequencing error rates for the current study. We could also have
spiked our samples with bacteria that would have indicated the efficiency of our DNA extraction. Third,
pre-bronchoscopy all participants received 0.4 mg salbutamol. This was done for obtaining
pre-bronchoscopy post-bronchodilator lung function values, but had the added benefit of protecting
against procedural bronchospasm. Salbutamol was given as an aerosol through large volume spacers that
are cleaned daily, and we are not aware of reports on contamination through metered dose inhalers.
Furthermore, since both patients and controls received salbutamol, our conclusions should not be affected.
Fourth, some results are difficult to compare with those of other authors because of differences in DNA
extraction, PCR amplification, sequencing and bioinformatic approach. This is the result of a field where
standards for 16S rRNA gene amplicon studies of microbial communities currently do not exist. To
facilitate reproducibility we have used well-documented analytic approaches and mostly default settings for
our bioinformatic pipeline (QIIME), in addition to using primers and PCR recommendations from a
major next-generation sequencing provider (Illumina). Regardless of this, we cannot rule out that some of
our findings only pertain to the current set of methodological choices such as the choice of sequencing
hypervariable region V3V4 [34]. To minimise the influence of small/spurious OTUs we have excluded
singletons by using default settings in our OTU picking, and removed OTUs that constituted less than
0.005% of the total number of sequences.
Insights concerning the airway microbiome in disease and health might provide vital understanding of
disease mechanisms and provide new targets for treating lung diseases such as COPD, asthma, cystic
fibrosis and interstitial lung diseases. However, to date only a minority of studies have performed
protected sampling, and might have been affected by exposure to exposure to microbiota encountered
before reaching the sampled sites. We have shown that unprotected sampling is likely to be affected by this
phenomenon, and we encourage the use of protected specimen brushes when sampling the airway
microbiota.
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Laboratory contamination in airway
microbiome studies
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Abstract
Background: The low bacterial load in samples acquired from the lungs, have made studies on the airway
microbiome vulnerable to contamination from bacterial DNA introduced during sampling and laboratory
processing. We have examined the impact of laboratory contamination on samples collected from the lower
airways by protected (through a sterile catheter) bronchoscopy and explored various in silico approaches to dealing
with the contamination post-sequencing. Our analyses included quantitative PCR and targeted amplicon
sequencing of the bacterial 16S rRNA gene.
Results: The mean bacterial load varied by sample type for the 23 study subjects (oral wash>1st fraction of
protected bronchoalveolar lavage>protected specimen brush>2nd fraction of protected bronchoalveolar lavage;
p < 0.001). By comparison to a dilution series of know bacterial composition and load, an estimated 10–50% of the
bacterial community profiles for lower airway samples could be traced back to contaminating bacterial DNA
introduced from the laboratory. We determined the main source of laboratory contaminants to be the DNA
extraction kit (FastDNA Spin Kit). The removal of contaminants identified using tools within the Decontam R
package appeared to provide a balance between keeping and removing taxa found in both negative controls and
study samples.
Conclusions: The influence of laboratory contamination will vary across airway microbiome studies. By reporting
estimates of contaminant levels and taking use of contaminant identification tools (e.g. the Decontam R package)
based on statistical models that limit the subjectivity of the researcher, the accuracy of inter-study comparisons can
be improved.
Keywords: Microbiome, Contamination, Low biomass, Respiratory, 16S rRNA gene
Background
The most common method used for studying the bacter-
ial communities of the lower respiratory tract is high
throughput amplicon sequencing of the bacterial 16S
ribosomal RNA (16S rRNA) marker gene [1]. Some
studies use sputum samples [2, 3], with inevitable ques-
tions regarding the degree to which the samples are repre-
sentative of the lower respiratory tract as opposed to
contamination from the upper respiratory tract. The
emerging gold standard for lower respiratory tract samples
is protected bronchoscopy (sampling via a sterile catheter)
[4]. However, even with protected bronchoscopy the sam-
ples are processed through extensive laboratory workflows
that include at minimum steps of bacterial DNA
extraction, PCR amplification of the marker gene, and
preparation for sequencing. Each step opens up the possi-
bility for the introduction of contaminating bacterial DNA
from the laboratory environment, with greatest impact on
samples with the lowest bacterial load [5].
Accurate analysis of the lower respiratory tract micro-
biome will require separate consideration of both of the
aforementioned contamination sources - that from the
upper respiratory tract introduced during sampling and
that introduced during laboratory processing steps. We
have previously shown that protected bronchoscopy of-
fers some protection from upper airway contamination
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[4]. In the current study, we address the issue of con-
tamination from the laboratory.
The impact of laboratory contamination is typically
evaluated through the inclusion of negative control sam-
ples (NCS) that are processed through all steps of DNA
extraction and library preparation for sequencing along-
side the study samples. The approach is not perfect as
one may expect to find taxa in the NCS that also belong
to the bacterial communities of the sampled site. Re-
searchers are thus faced with a difficult decision with
regards to what to do with the information acquired
from the NCS. Some groups have removed all taxa iden-
tified in NCS from their study samples [4, 6, 7]. Others
single out taxa they believe likely represent contaminants
[8]. Currently bioinformatic tools are being developed
that aim to wriggle out the authentic microbiota signal
using statistical models [9–11], but these have yet to be
tested on lower respiratory tract sequencing data (e.g.
Decontam [9]).
In the current paper we illustrate an effective workflow
for evaluating the quality of lower respiratory tract sam-
ples for accurate assessment of bacterial composition.
Objectives of the study were i) to determine the influ-
ence of contamination on lower respiratory tract sam-
ples as a function of bacterial load, ii) to determine the
main source of contamination in our laboratory setting
and iii) to explore common in silico approaches to deal-
ing with contamination.
Results
In order to establish the bacterial load in protected
airway samples collected using different sampling tech-
niques, we included oral washes (OW), two fractions of
protected bronchoalveolar lavage (PBAL1 and PBAL2)
and protected specimen brushes (PSB) from 23 partici-
pants of the MicroCOPD study [12]. The subject charac-
teristics are provided in Table 1.
Bacterial load varies with sample type
The bacterial load in the four sample types collected per
subject was measured by probe based quantitative PCR
(qPCR) targeting the bacterial 16S rRNA gene V1 V2
region. The bacterial load decreased in order OW >
PBAL1 > PSB > PBAL2 (p < 0.001, non-parametric trend
test) (Fig. 1). The mean number of bacteria (× 106/ mL
sample) was 34.2 (range 1.4 to 155.8) for OW (n = 23);
1.1 (range 1.7 × 10− 3 to 6.6) for PBAL1 (n = 23); 0.7
(range 4.3 × 10− 3 to 2.8) for PSB (n = 20) and 0.5 (range
19.9 × 10− 3 to 5.1) for PBAL2 (n = 23).
Bacterial load and impact of laboratory contamination
Salter and colleagues [5] have previously illustrated the
inverse relationship between the bacterial load in a sam-
ple and the influence of contamination on the bacterial
community readout. Once we had established that the
bacterial load varied with sampling technique (Fig. 1),
we questioned whether the differences in bacterial load
for each of the patient samples would also reflect differ-
ences in susceptibility to laboratory contamination.
Using the Salter approach [5], we estimated the degree
of contamination as a function of bacterial load (Fig. 2),
and translated this to an estimate of contamination in
the procedural samples (OW, PBAL, PSB). Using quanti-
tative PCR we determined that the initial Salmonella
sample had a concentration of 107 bacterial cells/mL. As
expected the oral wash samples having a high bacterial
load (mean of approximately 107 bacterial cells/mL), will
not be greatly impacted by contamination. Samples from
the lungs (PBAL, PSB) fell between dilution 2 and 3
(Fig. 2), with contamination representing 10–50% of
the bacterial community readout. The impact of vary-
ing number of PCR cycles was low (Fig. 2).
Monitoring procedural contamination
Having learned that contaminating bacterial DNA likely
represents a substantial proportion (10–50%) of the
sequencing output for the lower airway samples in our
study, we attempted to identify the main contamination
source. We performed ten simulated bronchoscopy
procedures (no patient) over two days to capture the
environmental contaminants that may have been intro-
duced during sampling.
All procedural control samples were sequenced to-
gether on the same sequencing run (Run A). Additional
control samples were sequenced on a second run (Run
B) and included samples of molecular grade water that
were processed through the DNA extraction protocol
without the introduction of PBS. Although sequenced
Table 1 Subject characteristics
Controls COPD Asthma
Subjects 9 10 4
Age 63.0 ± 6.7 68.2 ± 5.2 63.6 ± 3.1
Men 6 (66.7%) 8 (80.0%) 2 (50.0%)
Current-smokers 2 (22.2%) 1 (10.0%) 0
Former-smokers 5 (55.6%) 9 (90.0%) 3 (75.0%)
Non-smokers 2 (22.2%) 0 1 (25.0%)
Smoker pack years 11.8 ± 6.1 25.2 ± 8.1 12.1 ± 6.2
FEV1 (% predicted) 97.0 ± 13.7 72.6 ± 23.2 101.6 ± 9.3
Inhaled corticosteroids 0 2 (20.0%) 3 (75.0%)
LABA 0 3 (30.0%) 1 (25.0%)
LAMA 0 4 (40.0%) 0
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in
1 s, LABA long-acting beta-agonist, LAMA long-acting muscarinic antagonist. 1
smoker pack year = 20 cigarettes (one pack) smoked daily for 1 year. Age,
smoker pack years and FEV1 (% predicted) are presented as the
mean ± standard deviation
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on a separate sequencing run (Run B), the molecular
grade water samples would indicate whether the PBS
was the main source of contamination. A sample of mo-
lecular grade water that was not processed through the
DNA extraction protocol (PCR water) was also included
on both sequencing runs (Run A and B). This later
sample would reflect contamination introduced during
PCR and sequencing steps without interference from
contamination introduced during sampling and DNA
extraction steps.
The total number of sequences obtained from the pro-
cedural control samples (Run A) after quality filtering
Fig. 1 Measured bacterial load in procedural samples (OW, PBAL1, PSB and PBAL2). The mean bacterial load in OW samples was approximately
30 fold higher than PBAL1, 50 fold higher than PSB and, 70 fold higher than PBAL2. OW: oral wash (n = 23); PBAL1: first fraction of protected BAL
from right middle lobe (n = 23); PSB: protected specimen brush from right lower lobe (n = 20); PBAL2: second fraction of protected BAL from right
middle lobe (n = 23)
Fig. 2 Estimate of contaminant levels in ten-fold dilution series of Salmonella (SDS). The major operational taxonomic units (OTUs) observed in
the initial Salmonella sample (10^7 bacteria/mL) were assigned to f__Enterobacteriaceae;g__. Using the NCBI nucleotide BLAST tool we confirmed
that these OTUs (OTU821080, OTU813457 and OTU813217) matched to the genus Salmonella. With each successive dilution, the relative
abundance of f__Enterobacteriaceae;g__ decreased. By dilution 3 (45 PCR cycles), the percentage had reduced to 47.83%. For comparison, PCR
amplification of the 16S rRNA gene was performed at both 30 and 45 cycles for all SDS samples. The control is a sample of PCR water processed
through steps of PCR and sequencing alongside the SDS samples. Taxonomic rank is described using prefixes (f__: family, g__: genus)
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and chimera removal was 4.8 × 106. The mean number
of sequences and operational taxonomic units (OTUs)
obtained from the procedural controls were for phos-
phate buffered saline (n = 10): 64,745 sequences (123
OTUs); catheter rinse (n = 10): 98,379 sequences (131
OTUs); protected specimen brushes (n = 10): 106,853 se-
quences (132 OTUs); bronchoscope rinse (n = 10): 109,
765 sequences (134 OTUs); cryotube (n = 9): 115,633
sequences (138 OTUs). The number of sequences ob-
tained from the PCR water control sequenced on the
same run (Run A) was lower than for the procedural
control samples with only 43,433 sequences and 65
OTUs, suggesting that contamination was predomin-
antly introduced prior to PCR steps of library prepar-
ation. The procedural control samples (Run A) showed a
similar taxonomic distribution that was quite distinct
from that of the PCR water sample (Run A) (Fig. 3). This
indicated that contamination was either introduced with
the phosphate buffered saline used for collection of all
samples or during DNA extraction steps.
To differentiate between PBS and DNA extraction as
contamination sources, we compared the molecular
grade water samples (Run B) to the corresponding PCR
water sample sequenced on the same run. The molecular
grade water (n = 3) (Run B) contained a mean number of
124,941 sequences and 107 OTUs, whereas the PCR water
(Run B) contained 126,103 sequences and only 39 OTUs.
Importantly, the taxonomic profile of the molecular grade
water (Run B) resembled that of the procedural control
samples (Run A), whereas the PCR water did not, indicat-
ing that the main source of contamination was the DNA
extraction kit (Fig. 3).
Exploring in silico approaches to dealing with
contamination in LRT samples
We began our analyses by looking at how the top 20
OTUs present in NCS were distributed in the procedural
samples (OW, PBAL, PSB) in our 23 subjects (Fig. 4).
The NCS were dominated by an OTU that mapped to
the family Enterobacteriaceae. The Ralstonia OTU that
dominated the procedural controls (Fig. 3) was the
fourth most abundant OTU in the NCS with an average
relative abundance of just 5.45%. This likely reflects
differences in contamination introduced from different
Fig. 3 Distribution of operational taxonomic units (OTUs) in procedural controls and PCR water samples. An OTU belonging to the genera
Ralstonia dominated the procedural control samples with an average relative abundance of 51.81% in scope rinse (n = 10), 54.33% in catheter
rinse (n = 10), 55.36% in cryotube (n = 9), 52.82% in protected specimen brushes (n = 10) and 54.93% in phosphate buffered saline (n = 10). The
same Ralstonia OTU also dominated the molecular grade water samples (n = 3) at an average relative abundance of 29.42%. The PCR water
control sample was dominated by Rhizobium (38.11%), Anaerobacillus New Reference OTU 110 (20.69%) and Delftia (10.65%) in run A and
Anaerobacillus New Reference OTU 110 (32.93%), Anaerobacillus OTU 622288 (24.04%) and Delftia (10.68%) in run B. Taxonomic rank is described
using prefixes (o__: order, f__: family, g__: genus). Data unrarefied
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lots of the FastDNA Spin Kit [5]. An OTU assigned to
the Streptococcus genus was found in NCS at a relative
abundance of just 1.51%; the same OTU was a major
OTU in patient OW, PBAL and PSB samples. This is
most likely not a contaminant and may be an important
component of the bacterial lung microbiota. For a de-
tailed presentation of the Streptococcus OTUs found in
PSB and NCS samples, see Additional file 1: Figure S1
and Additional file 2: Figure S2.
Common in silico approaches to dealing with contam-
ination include i) leaving the samples intact (i.e. do
nothing), ii) removing all OTUs seen in NCS, and iii)
correction based on statistical models (i.e. the Decontam
R package). We next examined how the application of
each approach would impact the taxonomic profiles of
the procedural samples in our study (Fig. 5).
When leaving the procedural samples intact, the
Streptococcus genus dominated all sample types. With
the removal of OTUs seen in NCS, the relative abun-
dance of the Streptococcus genus was significantly re-
duced in all sample types (Fig. 5), as was predicted from
Fig. 4. With removal of OTUs identified as contaminants
using Decontam [9], the Streptococcus genus again
dominated the procedural samples. This approach thus
appeared to provide a good balance between removing
all OTUs found in the NCS and leaving intact OTUs
present in both NCS and procedural samples.
Comparison of the frequency-based distribution plots
for the top 4 OTUs observed in NCS and the Streptococ-
cus OTU (Fig. 6), visually illustrate how Decontam (here
frequency-based method) is able to differentiate between
a contaminant OTU and a non-contaminant OTU.
Decontam performance test on the Salmonella dilution
series (SDS)
In the Decontam introduction paper [9], the authors il-
lustrate how Decontam is able to diminish the contam-
inant signal from the serially diluted Salmonella datasets
published in the Salter paper [5]. As our study also in-
cluded a Salmonella dilution series (SDS), we were able
to test the Decontam package tools on sequencing data
generated in the context of our laboratory setting after
processing through our chosen bioinformatic pipeline.
The SDS in our study included seven samples of a
successively ten-fold diluted Salmonella monoculture
and a PBS negative control sample that went through
DNA extraction and sequencing steps alongside the SDS
(Fig. 7). As library preparation for sequencing of the
SDS was performed at both 30 and 45 PCR cycles and
the impact of varying number of PCR cycles was low
(Fig. 2), the sequencing output for both sample sets were
used as input in the Decontam analyses. We also in-
cluded a PCR water control sample that was sequenced
on the same sequencing run.
Fig. 4 Distribution of the 20 most abundant operational taxonomic units (OTUs) observed in negative control samples (NCS). The NCS were
dominated by OTU 759061 assigned to the family Enterobacteriaceae (20.93%), OTU 4389128 assigned to a genus within the class ML635J-21
(16.31%), OTU 437105 and New. Reference OTU 133 both assigned to the genus Ralstonia (8.30 and 5.45%, respectively). Taxonomic rank is
described using prefixes (c__: class, o__: order, f__: family, g__: genus). Data presented as the average relative abundance. Data unrarefied
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Using the isContaminant function in the Decontam R
package, we compared three methods for identification
of contaminant OTUs including i) the prevalence-based
method, ii) the frequency-based method and iii) the ei-
ther method. In the prevalence-based method, an OTU
is marked as a contaminant based on a comparison of
how often the OTU is observed in negative control sam-
ples compared to the samples under study. For testing
the approach on the SDS, the final two samples in the
SDS were assigned as negative control samples together
with PBS and PCR water samples (as conducted by
Decontam developers when testing the approach on the
Salter dataset [13]). Figure 8 shows the taxonomic pro-
file of the SDS samples after removal of contaminant
OTUs identified using the prevalence-based approach.
The impression was that many small OTUs were re-
moved. In the frequency-based approach, the labelling of
an OTU as a contaminant is based on the correlation
between the DNA concentration measurements made
for samples during steps of library preparation (in our
lab using the Qubit instrument) and the relative abun-
dance of the OTU across samples. Figure 9 shows the
taxonomic profile of the SDS samples after removal of
contaminant OTUs identified using the frequency-based
approach. The impression was that the frequency-based
approach removed fewer but more abundant OTUs
compared to the prevalence-based approach. In the final
approach tested in Decontam (“either”), all OTUs
marked as contaminants by either the prevalence or fre-
quency-based methods are removed (Fig. 10).
Of the three approaches tested in Decontam, the
“either” method was able to most effectively remove the
contaminant signal from the bacterial community pro-
files of the samples; even in the most diluted sample
over 50% of the sequences mapped to the Salmonella
genus. Of concern is however that the PBS sample also
consisted of over 50% Salmonella. Also present in the
PBS sample was oral/lung specific genera including Veil-
lonella, Streptococcus and Neisseria that are obvious
contaminants from the procedural samples sequenced
on the same run. The number of reads in the PBS sam-
ple after processing in Decontam was only 32. Therefore
we learn that although effective, removal of contaminant
OTUs identified in Decontam may also lead to the
magnification of another type of noise in the sequencing
data – particularly that from cross sample contamination
during library preparation or index misassignment dur-
ing MiSeq sequencing.
Discussion
In the current paper we illustrate an effective workflow
for evaluating the quality of lower airway samples for
amplicon-based analysis of bacterial composition. Our
results show that the low bacterial load in samples from
the lungs make them vulnerable to bacterial DNA con-
tamination, which in our study mainly originated from
Fig. 5 Taxonomic distribution in procedural samples when different approaches to dealing with contamination have been applied. When
negative control sample (NCS) operational taxonomic units (OTUs) are kept, the Streptococcus genus dominated the procedural samples with an
average relative abundance of 31.66% in oral wash (OW) (n = 23), 27.95% in protected bronchoalveolar lavage (PBAL) (n = 23) and 22.27% in
protected specimen brushes (PSB) (n = 23). With the removal of NCS OTUs, the Streptococcus genus no longer dominated the procedural samples
and was present at an average relative abundance of 4.80% in OW (n = 23), 6.12% in PBAL (n = 23) and 7.60% in PSB (n = 23). With the removal of
OTUs identified as contaminants in Decontam (method = “either”, threshold = 0.5), the Streptococcus genus again dominated the samples, with an
average relative abundance of 32.52% in OW (n = 23), 34.40% in PBAL (n = 23) and 35.08% in PSB (n = 23). Taxonomic rank is described using
prefixes (c__: class, o__: order, f__: family, g__: genus). Data unrarefied
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DNA extraction kits. Even with contaminants represent-
ing an estimated 10–50% of the sequencing output for
these samples, we demonstrate that most of the contam-
inating signal can be removed post sequencing using
recently developed bioinformatic approaches.
Through the processing and sequencing of a serially
diluted culture of Salmonella [5], we were able to define
the threshold bacterial load for which contamination
would begin to dominate the bacterial profile in our
samples. At an input of between 10^3 and 10^4 Salmon-
ella/mL, we observed that contaminants constituted
more than 50% of the bacterial profile of the sample.
The use of alternative protocols for sample processing
and sequencing can slide this defined threshold of
bacterial load up or down and should therefore be deter-
mined independently in separate studies. Biesbroek et al.
[14] for example show in their study how the choice of
DNA extraction kit will affect the DNA yield and in turn
the placement of samples above or below a defined
threshold of bacterial load for which contamination
becomes a problem. Despite differences in laboratory
protocols, our results are in agreement with Salter and
Fig. 6 Decontam frequency distribution plots distinguish contaminants from non-contaminants. A frequency distribution plot generated from
samples with varying DNA concentration indicates whether a particular sequence fits the Decontam contaminant (red line) or non-contaminant
(black stippled line) model. The first four plots represent the top four operational taxonomic units (OTUs) observed in negative control samples
(NCS): OTU 759061 is assigned to the family Enterobacteriaceae; OTU 4389128 is assigned to a genus within the class ML635J-21; OTU 437105 and
OTU New. Reference OTU 133 are both assigned to the genus Ralstonia. The final plot represents the Streptococcus OTU 1082539 that most likely
is not a contaminant, although present among the top 20 OTUs found in NCS. Its frequency distribution pattern more closely fits the Decontam
non-contaminant model in contrast to the others
Drengenes et al. BMC Microbiology          (2019) 19:187 Page 7 of 13
colleagues [5] who in their study also recommend an
input of more than 10^3–10^4 bacterial cells. The con-
cordance of our results may partially be explained by the
use of a DNA extraction kit from the same manufacturer
(FastDNA Spin Kit, MP Biomedicals).
Using the Salmonella dilution series as a reference we
were able to determine the degree of laboratory contam-
ination in the various sample types (OW, PBAL1,
PBAL2, PSB) collected from participants in the Micro-
COPD study. The average bacterial load in the samples
acquired from the lungs was highest for PBAL1 samples
(10^6 bacteria/mL) and approximately an order of mag-
nitude lower for PSB and PBAL2 samples. This could
mean that the first lavage fraction harvests a larger por-
tion of the resident microbiota, but also a dilution effect,
as lavage yield tends to increase in the second fraction.
We used a sterile inner catheter for lavage sampling, to
minimize contamination from BAL, something no other
study has done to our knowledge. It is however possible
that the first fraction of lavage (PBAL1) is more suscep-
tible to contamination from the upper airways during
sampling compared to PBAL2 and PSB samples [4].
Fig. 7 Taxonomic distribution in Salmonella dilution series (SDS). The taxonomic profile of the SDS samples (amplified using 45 PCR cycles) before
removal of OTUs identified as contaminants in Decontam. Taxonomic rank is described using prefixes (f__: family, g__: genus). Data unrarefied
Fig. 8 Taxonomic distribution in Salmonella dilution series (SDS) after removal of Decontam contaminants (prevalence-based). 109 out of 235
operational taxonomic units (OTUs) in the SDS dataset were identified as contaminants and removed (user defined threshold = 0.5). At the default
threshold, only 34 out of 235 OTUs in the dataset were identified as contaminants (figure not drawn). Taxonomic rank is described using prefixes
(f__: family, g__: genus). Data unrarefied
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Thus, the question remains as to whether PBAL1 with
its higher bacterial load is a more representative sample
compared to PBAL2 and PSB samples or if we are
simply swapping contamination sources (contaminating
bacterial DNA introduced from the upper airways
during sampling versus contaminating bacterial DNA
introduced during laboratory processing steps). The
optimal sample type may thus be a question of which
contamination source is easiest to identify and remove
post sequencing.
Through the sequencing of procedural control samples
and PCR negative control samples that were not proc-
essed through the DNA extraction protocol, we were
able to trace the main source of contamination back to
the DNA extraction kit. Our findings are in agreement
with several other studies [5, 15, 16]. The difference in
the microbiota readout for the procedural control
samples and the negative control samples are likely
explained by differences in lot number for the DNA
extraction kits. Salter and colleagues report differences
Fig. 9 Taxonomic distribution in Salmonella dilution series (SDS) after removal of Decontam contaminants (frequency-based). 58 out of 235
operational taxonomic units (OTUs) in the dataset were identified as contaminants and removed (user defined threshold = 0.5). At the default
threshold, only 9 out of 235 OTUs in the dataset were identified as contaminants (figure not drawn). Taxonomic rank is described using prefixes
(c__: class, o__: order, f__: family, g__: genus). Data unrarefied
Fig. 10 Taxonomic distribution in Salmonella dilution series (SDS) after removal of Decontam contaminants (approach either). 136 out of 235
OTUs in the dataset were identified as contaminants and removed (user defined threshold = 0.5). Taxonomic rank is described using prefixes (f__:
family, g__: genus). Data unrarefied
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in contaminant profiles for three replicates of SDS ex-
tracted using different lots of the FastDNA Spin Kit for soil;
similar to our results they also found that one SDS replicate
was dominated by unclassified Enterobacteriaceae.
Publications such as that by Salter and colleagues have
led to an increased awareness of the effects of con-
tamination on microbiome studies of low biomass
samples [5, 16]. Most studies now process negative control
samples that allow for monitoring of the contaminant sig-
nal introduced from the laboratory. However, the inclu-
sion of NCS only partly addresses the issue. In our study
for example, we recognized that a major Streptococcus
OTU found in procedural samples (OW, PBAL, PSB) was
also among the top 20 most abundant OTUs found in
NCS. A comparison of the relative abundance of the
Streptococcus OTU in procedural samples and NCS
indicated that the OTU was likely not a contaminant.
However, the question of where to draw the line with
regards to a set abundance threshold for which an OTU
should be identified as a contaminant or not is not always
as straightforward. The Decontam package in R has been
developed to identify contaminants using statistical
models [9]. The Decontam developers demonstrate the
accuracy of their approach on the Salmonella dilution
series datasets generated in the Salter publication. We
show in the context of our laboratory setting that Decon-
tam is efficient at removing the contaminant signal from
the SDS also in our study. Using Decontam we were also
able to confirm the identity of the Streptococcus OTU
found in both procedural samples and the NCS as a non-
contaminant.
We acknowledge that our study does not address all
issues related to bacterial load in microbiome sequen-
cing data. The serial diluted Salmonella monoculture
does not provide insight into the effects of bacterial load
on the relative abundance of bacteria in a more complex
microbiota sample. Biesbroek et al. [14] show in their
study examining the microbiota of a serially diluted
saliva sample, an increase in the relative abundance of
Proteobacteria and Firmicutes and a decrease in Bacter-
oidetes across the dilution series. Proteobacteria likely
reflect contaminants as has been suggested in several pa-
pers [14, 17], again illustrating the inverse relationship
between bacterial load and the influence of contamin-
ation as observed in our study. The observed increase in
relative abundance of Firmicutes and concurrent de-
crease in Bacteroidetes is however of concern, as these
phyla hold members often detected in studies of the lung
microbiome (e.g. Veillonella and Prevotella). The field
would benefit from studies addressing the potential ef-
fects of bacterial load on the measured relative abun-
dance of taxa in a more complex sample, particularly
those that are suspect core lung microbiota members.
Secondly, we did not quantify the amount of human
DNA in the procedural samples. The presence of human
DNA may affect the efficiency of the qPCR reaction
[16], and thereby also the accuracy of the direct compari-
son to the SDS. Studies evaluating the impact of contam-
ination might consider quantification of human DNA for
an even more accurate estimate of contamination.
Conclusions
Measured amounts of bacteria will vary in lower airway
samples collected with different bronchoscopic sampling
techniques (e.g. PBAL1, PBAL2, PSB in the current
study). These differences combined with the inverse re-
lationship between bacterial load and bacterial DNA
contamination will render some sampling modalities
dominated by contaminating taxa.
Differences in protocols for sampling, laboratory process-
ing and bioinformatics analysis across studies will require
investigators to evaluate the impact of contamination in the
context of their own laboratory setting. We encourage
investigators to report an estimate of the degree of contam-
ination in their datasets defined against a sample of known
bacterial load as exemplified in the current study. We
further suggest the use of contaminant identification tools
(e.g. Decontam) based on statistical models for the objective
removal of laboratory contaminants in lung microbiome
sequencing data. Such measures will enable more accurate
inter-study comparisons and may also resolve discrepancies
between studies that have likely impeded understanding the




Study subjects (n = 23) were chosen from the Bergen
COPD Microbiome Study (short name “MicroCOPD”)
[12], to give an equal representation of healthy (n = 9) and
diseased (asthma (n = 4), COPD (n = 10)) states. Details on
data collection and the bronchoscopy procedures have
been previously published [4, 12]. Briefly, adult subjects
recruited from Western Norway with and without ob-
structive lung disease, underwent voluntary bronchosco-
pies between 2013 and 2015. All subjects were examined
in the stable state, not having received antibiotics at least
2 weeks prior to the procedure. All bronchoscopies were
performed by experienced chest physicians at the out-
patient clinic at the Department of Thoracic Medicine,
Haukeland University Hospital. The regional ethical
committee (REK-Nord, case # 2011/1307) approved the
study, and all patients gave written informed consent.
Sample types acquired per patient included the first
and second fraction of 2 × 50mL bronchoalveolar lavage
(PBAL1 and PBAL2) sampled through a sterile inner
catheter (Plastimed Combicath, Le Plessis Bouchard,
France) of the bronchoscope while the scope itself was
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wedged in the right middle lobe, and three protected
specimen brushes subsequently sampled from the right
lower lobe (rPSB), an oral wash (OW), and a negative
control sample (NCS). Additional procedural control
samples were collected after ten simulated bronchoscopy
procedures (no patient) carried out over two days;
samples included a bronchoscope rinse (BR), a catheter
rinse (CR), a protected specimen brush (PSB), a sample
of phosphate buffered saline (PBS) transferred to a cryo-
tube (CT) and a sample of PBS used for collection of all
samples. The PBS used for sample collection was sterilized
by sterile filtration (0.22 μm) and autoclaving at 121 °C for
15min. To study the relationship between bacterial load
and the influence of contaminating bacterial DNA in our
laboratory setting [5], we included a ten-fold dilution
series of Salmonella enterica serovar Typhimurium
(ATCC 14028) (ATCC, Manassas, VA, USA) (SDS).
Bacterial DNA extraction using enzymatic and mechanical
lysis steps
Samples were treated with lytic enzymes mutanolysin,
lysozyme and lysostaphin (all from Sigma-Aldrich, St.
Louis, MO, USA) and subsequently processed through
the FastDNA Spin Kit (MP Biomedicals, LLC, Solon,
OH, USA) following the manufacturer’s instructions.
Procedural samples were processed using different lots
of the DNA extraction kit (#79113, #84562, #57212,
#62903). The procedural controls and the SDS were
processed using a kit of same lot number (#93678). The
sample volume used as input varied with sample type
(for procedural samples: 450 μl for PSB and NCS and
1800 μl for OW, PBAL1, PBAL2; for procedural control
samples: 450 μl for PBS and CT, 550 μl for PSB and
1800 μl for BR and CR; for samples in the SDS: 500 μl).
DNA was eluted in a total volume of 100 μl.
Quantification of bacterial load by quantitative PCR
(qPCR)
The bacterial load in the samples was determined by
probe-based qPCR targeting the bacterial 16S rRNA
gene (region V1 V2) using forward primer 5′-AGAGTT
TGATCCTGGCTCAG-3′, reverse primer 5′-CTGCTG
CCTYCCGTA-3′ and probe 5′-6-FAM-TAACACATG-
CAAGTCGA-BHQ-1-3′ (locked nucleic acid bases are
underlined; 6-FAM: 6-carboxyfluorescein; BHQ-1: Black
Hole Quencher-1) [7, 18–20]. PCR reactions were car-
ried out using the following cycling conditions: an initial
cycle at 95 °C for 5 min followed by 45 cycles of 95 °C for
5 s, 60 °C for 20 s and 72 °C for 10 s and a final extension
cycle of 72 °C for 2min. A standard curve was constructed
from genomic DNA from E. coli strain JM109 (Zymo
Research, Irvine, CA, USA).
MiSeq sequencing of the bacterial 16S rRNA gene
The bacterial composition in the samples was deter-
mined by paired-end sequencing of the 16S rRNA gene
(region V3 V4) following instructions provided in the
Illumina 16S Metagenomic Sequencing Library Prepar-
ation guide (Part no. 15044223 Rev. B). PCR cycling con-
ditions were modified from the commercial protocol and
consisted of an initial cycle at 95 °C for 3min followed by
45 cycles of 95 °C for 30 s, 55 °C for 30 s, 72 °C for 30 s and
a final extension cycle at 72 °C for 5min.
Bioinformatic sequence processing steps
Bioinformatic sequence processing steps were performed
using tools provided within the Quantitative Insights
into Microbial Ecology (QIIME) bioinformatic package,
version 1.9.1. In short, raw sequences were retrieved
from the MiSeq sequencer in the form of demultiplexed
forward and reverse fastq files (paired end reads). Primer
sequences were trimmed off and forward and reverse
reads joined. Chimera sequences identified using the
VSEARCH program [21] were subsequently removed.
Remaining sequences were grouped into open-reference
operational taxonomic units (OTUs) using UCLUST
[22] and the GreenGenes reference database (v.13.8)
[23]. Small OTUs, defined as those containing less than
0.005% of the total sequence count in the dataset were
then filtered out [24]. Taxonomy was assigned to OTUs
using the naïve bayesian RDP Classifier [25] together
with the GreenGenes reference database (v.13.8) [23].
The resulting OTU table displaying the sequence count
in each OTU for each sample was the starting point for
all subsequent analyses. The QIIME commands used for
generating the working OTU table are provided in the
Additional file 3: Supplementary Methods.
In silico contaminant identification and removal
Two approaches to contaminant identification and
subsequent removal were tested. In the first approach
contaminant OTUs were identified through their
presence in NCS. NCS OTUs were filtered out from the
procedural samples (OW, PSB, PBAL) collected under
the same procedure using QIIME commands (illustrated
in the supplementary methods). In the second approach,
contaminant OTUs were identified based on statistical
models using the Decontam package [9] in R. Contamin-
ant OTUs identified using the Decontam isContaminant
function (method = either, user defined threshold = 0.5)
were filtered out of the main OTU working table using
QIIME commands.
For greater details on study design, sample collection,
preparation of Salmonella samples, DNA extraction,
qPCR, 16S rRNA gene sequencing and bioinformatics,
please see the Additional file 3: Supplementary Methods.
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Additional file 1: Figure S1. Distribution of Streptococcus OTUs in
Protected Specimen Brush (PSB) samples (n=23). (PDF 8 kb)
Additional file 2: Figure S2. Distribution of Streptococcus OTUs in
Negative Control Samples (NCS) (n=23). (PDF 8 kb)
Additional file 3: Supplementary Methods. This file provides a detailed
description of protocols for sample collection, preparation of Salmonella
samples, DNA extraction, qPCR, 16S rRNA gene sequencing and
bioinformatics. (DOCX 240 kb)
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Background: Studies on the airway microbiome have been performed using a wide range of 26	
laboratory protocols for high-throughput sequencing of the bacterial 16S ribosomal RNA 27	
(16S rRNA) gene. We sought to determine the impact of number of polymerase chain 28	
reaction (PCR) steps (1- or 2- steps) and choice of target marker gene region (V3 V4 and V4) 29	
on the presentation of the upper and lower airway microbiome. Our analyses included 30	
lllumina MiSeq sequencing following three setups: Setup 1 (2-step PCR; V3 V4 region), Setup 31	
2 (2-step PCR; V4 region), Setup 3 (1-step PCR; V4 region). Samples included oral wash, 32	
protected specimen brushes and protected bronchoalveolar lavage (healthy and obstructive 33	
lung disease), and negative controls. 34	
Results: The number of sequences and amplicon sequence variants (ASV) decreased in order 35	
setup1>setup2>setup3. This trend appeared to be associated with an increased taxonomic 36	
resolution when sequencing the V3 V4 region (setup 1) and an increased number of small 37	
ASVs in setups 1 and 2. The latter was considered a result of contamination in the two-step 38	
PCR protocols as well as sequencing across multiple runs (setup 1). Although genera 39	
Streptococcus, Prevotella, Veillonella and Rothia dominated, differences in relative 40	
abundance were observed across all setups. Analyses of beta-diversity revealed that while 41	
oral wash samples (high biomass) clustered together regardless of number of PCR steps, 42	
samples from the lungs (low biomass) separated. The removal of contaminants identified 43	
using the Decontam package in R, did not resolve differences in results between sequencing 44	
setups.  45	
Conclusions: Differences in number of PCR steps will have an impact of final bacterial 46	
community descriptions, and more so for samples of low bacterial load. Our findings could 47	
not be explained by differences in contamination levels alone, and more research is needed 48	
	 3	
to understand how variations in PCR-setups and reagents may be contributing to the 49	





The bacterial airway microbiome has been studied using a wide range of protocols for high-54	
throughput sequencing of the bacterial 16S ribosomal RNA (16S rRNA) gene. Common to all 55	
amplicon based protocols is the application of the polymerase chain reaction (PCR) for i) 56	
amplification of the target marker gene to be sequenced and ii) the addition of index 57	
sequences necessary for sample multiplexing. These steps can be performed in a single PCR 58	
or in two separate PCRs. No study has addressed whether the increased number of 59	
laboratory processing steps associated with a 2-step PCR protocol, will leave samples more 60	
vulnerable to bacterial DNA contamination from the laboratory than when following a 1-step 61	
PCR protocol. The inverse relationship between sample bacterial load and the impact of 62	
contamination has been well documented in the literature by others [1, 2] and ourselves [3].	 63	
Thus, we predicted that while samples with a high bacterial load (i.e. upper airway samples) 64	
would be able to buffer against protocol effects resulting from differences in contamination 65	
levels, samples with a low bacterial load (i.e. lower airway samples) would not be resistant 66	
to these effects.   67	
 68	
In addition to number of PCR steps, sequencing protocols vary by choice of targeted marker 69	
gene region. Several different 16S rRNA gene variable regions have been targeted in studies 70	
of the lung microbiome, including V1 V2 [4, 5], V1 V3 [6–8], V3 V5 [7, 9–13], V3 [14, 15] and 71	
V4 [16–20]. Choice of target marker gene region has been limited by the short length of DNA 72	
that can be sequenced using current high-throughput sequencing technologies. The V4 73	
region has increased in popularity as studies on estimates of alpha- [21] and beta- diversity 74	
[22] (i.e. measures of diversity within and between samples, respectively) and taxonomic 75	
assignments [23] have collectivey indicated that this site generates the most accurate 76	
	 5	
descriptions. In addition, its relatively short length has allowed for the complete overlap of 77	
the forward and reverse sequencing read; advantageous because correction of sequencing 78	
errors is possible using the read with highest quality score [25]. The increased capacity of the 79	
MiSeq sequencer to sequence longer DNA sequences coupled with the development of 80	
novel denoising strategies (e.g. DADA2 [26]), has however led to an increased interest in the 81	
targeting of the longer V3 V4 region. It is however unclear how these results compare to 82	
earlier studies based on the shorter V4 region. 83	
 84	
In the current study, we sought to evaluate the impact of number of PCR steps (1- or 2-85	
steps) and choice of target marker gene region (V3 V4 vs V4) on the presentation of the 86	
upper and lower airway microbiome. To address these issues we processed samples of both 87	
high and low bacterial load through three library preparation setups varying in the number 88	
of PCR steps and target marker gene region: Setup 1 (2-step PCR; V3 V4 region), Setup 2 (2-89	
step PCR; V4 region), Setup 3 (1-step PCR; V4 region). The upper airways were represented 90	
by oral wash (OW) samples and the lower airways by protected specimen brushes (PSB) and 91	
protected bronchoalveolar lavages (PBAL) collected by bronchoscopy. Negative control 92	
samples (NCS) consisting of saline used in the collection of all samples was processed 93	









The study included 23 subjects from the MicroCOPD study [27]. Subject characteristics are 102	
provided in Table 1.   103	
 104	
Table 1. Subject characteristics.  105	
 Controls COPD Asthma 
Subjects 9 10 4 
Age, mean ± SD years 63.0±6.7 68.2±5.2 63.6±3.1 
Men 6 (66.7%) 8 (80.0%) 2 (50.0%) 
Current-smokers 2 (22.2%) 1 (10.0%) 0 
Former-smokers 5 (55.6%) 9 (90.0%) 3 (75.0%) 
Never-smokers 2 (22.2%) 0 1 (25.0%) 
Smoker pack years, mean ± SD years  11.8±6.1 25.2±8.1 12.1±6.2 
FEV1 (% predicted), mean ± SD  97.0±13.7 72.6±23.2 101.6±9.3 
Inhaled corticosteroids 0 2 (20.0%) 3 (75.0%) 
LABA 0 3 (30.0%) 1 (25.0%) 
LAMA 0 4 (40.0%) 0 
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; LABA: long-acting 106	
beta-agonist; LAMA: long-acting muscarinic antagonist. 1 smoker pack year = 20 cigarettes (one pack) smoked 107	
daily for 1 year. Age, smoker pack years and FEV1 (% predicted) are presented as the mean ± standard 108	
deviation.SD: standard deviation. 109	
  110	
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Number of Sequences and Amplicon Sequence Variants (ASVs) 111	
We began our analyses with a comparison of the number of sequences and amplicon 112	
sequence variants (ASVs) retained at each step when processing through the bioinformatic 113	
pipeline (Figure 1). For sequencing setup 1, the procedural samples were dispersed across four 114	
sequencing runs (I-IV). For sequencing setups 2 and 3, two separate sequencing runs (one per 115	
setup) were conducted including all samples.  116	
 117	
As the sequences were passed through the different bioinformatic filtering steps, the total 118	
number of sequences and ASVs across the three setups became more similar. Denoising in 119	
DADA2 (Figure 1, step 1) resulted in the greatest decrease in sequence number. The  greatest 120	
decrease in ASV number occurred after the removal of small ASVs, for which the number of 121	
sequences was calculated to be less than 0.005% of the total number of sequences on the 122	
same run (Figure 1, step 3). The drop in ASV number was greatest for sequencing setups 1 and 123	
2, both of which are based on the longer 2-step PCR protocol.   124	
 125	
After the final filtering step (Figure 1, step 6), the number of ASVs was significantly higher for 126	
setup 1 compared to that observed for setups 2 and 3. When we restricted analyses to samples 127	
from the largest sequencing run in setup 1 (14 participants, 56 samples) (Figure 2), the number 128	
of ASVs for setup 1 was now more comparable to that observed for setups 2 and 3 (Figure 2, 129	
step 6). The higher number of ASVs still observed for setup 1, was expected due to the greater 130	





Protocol effects on mock community sample 135	
The mock community sample HM-783D, consisting of genomic DNA from 20 different 136	
bacterial species (17 genera) was included on each sequencing run. For a detailed 137	
presentation of the mock community, see Additional file 5: Supplementary Methods. 138	
Because the protocols targeting different hypervariable regions result in different ASVs, we 139	
describe ASVs obtained for setup 1 (V3 V4 target) and setups 2 and 3 (V4 target), separately. 140	
 141	
When following setup 1 across four sequencing runs, we obtained the following number of 142	
sequences and ASVs: run I: 128,413 (27 ASVs); run II: 109,709 (23 ASVs); run III: 110,492 (24 143	
ASVs) and run IV: 84,909 (27 ASVs). As the number of sequences obtained for each run was 144	
similar, ASV numbers were also comparable across the four runs. While most genera were 145	
defined by a single ASV, genera Escherichia, Staphylococcus, Streptococcus, Clostridium and 146	
Rhodobacter were defined by multiple ASVs. The major ASVs attributed to each genus (i.e. 147	
those with the highest number of sequences) were the same across all four sequencing runs. 148	
For a detailed presentation of the ASVs observed in the mock community following setup 1, 149	
see Additional File 1: Table S.1. 150	
 151	
When following setups 2 and 3, we obtained 103,409 sequences (31 ASVs) and 120,073 152	
sequences (23 ASVs), respectively. The genera Escherichia, Staphylococcus, Streptococcus, 153	
Clostridium and Neisseria were defined by multiple ASVs. The major ASVs attributed to each 154	
genus were the same in both setups 2 and 3. For a detailed presentation of the ASVs 155	
observed in the mock community following each setup, see Additional File 2: Table S.2. and 156	
Additional File 3:Table S.3..  157	
 158	
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A summary of the expected and observed taxonomic distribution in the mock community 159	
sample, obtained for each setup is presented in Figure 3 and Table 2. We found that the 160	
three sequencing setups were for the most part equally efficient at recovering high 161	
abundant mock community members. Sequencing setup 3, was least efficient at recovering 162	
the low abundant members. Across all setups, we observed an increase in the relative 163	
abundances of genera Escherichia and Staphylococcus and a significant decrease in 164	
Rhodobacter compared to that expected. All setups generated low abundant ASVs that did 165	
not match to any of the expected taxa in the mock community (i.e contaminants). Because 166	
the mock community sample was included on each of the four sequencing runs I-IV 167	



















Genera Expected  Setup 1 
(I) 
Setup 1  
(II) 
Setup 1  
(III) 
Setup 1  
(IV) 
Setup 2 Setup 3 
Escherichia 21.91 27.68 23.99 25.20 26.65 22.54 32.90 
Rhodobacter 21.91 5.98 9.52 9.23 8.94 11.00 8.77 
Staphylococcus 24.10 29.02 29.27 29.66 30.56 29.88 24.98 
Streptococcus 24.12 28.51 27.39 27.03 25.38 26.20 25.81 
Bacillus 2.19 3.38 2.86 2.95 2.85 3.15 2.49 
Clostridium 2.19 2.18 3.28 2.19 1.88 2.64 1.69 
Pseudomonas 2.19 1.44 1.68 1.75 1.93 2.12 2.02 
Acinetobacter 0.22 0.32 0.29 0.33 0.30 0.29 0.12 
Helicobacter 0.22 0.36 0.49 0.44 0.38 0.61 0.26 
Lactobacillus 0.22 0.22 0.20 0.23 0.24 0.35 0.18 
Listeria 0.22 0.33 0.33 0.30 0.32 0.37 0.26 
Neisseria 0.22 0.24 0.31 0.30 0.27 0.43 0.39 
Propionibacterium 0.22 0.13 0.22 0.18 0.15 0.29 0.00 
Actinomyces 0.02 0.01 0.01 0.00 0.00 0.01 0.00 
Bacteroides 0.02 0.02 0.00 0.03 0.02 0.04 0.02 
Deinococcus 0.02 0.02 0.04 0.03 0.02 0.03 0.02 
Enterococcus 0.02 0.03 0.02 0.03 0.02 0.02 0.00 
Other 0.00 0.13 0.11 0.10 0.09 0.03 0.08 
 186	
 187	
Table 2. Expected and observed relative abundance (%) of genera in mock community 188	
sample HM-783D. Setup 1 (2-step PCR; V3 V4 region); Setup 2 (2-step PCR; V4 region); Setup 189	









Protocol effects on contamination profiles  197	
Our working hypothesis linked protocol bias to differences in susceptibility to laboratory 198	
contamination. We therefore proceeded with an examination of the average top 20 ASVs 199	
found in NCS. Because the same DNA extracts were processed through each of the three 200	
setups, any observed differences in taxonomic distribution would be attributed to library 201	
preparation steps (post DNA extraction). We also examined PCR water samples included on 202	
each sequencing run. In contrast to NCS, this later sample reflects contamination introduced 203	
during library preparation steps without interference from contaminating DNA introduced 204	
from the DNA extraction kit. ASVs obtained for setups 2 and 3, targeting the V4 region and 205	
the single setup targeting the V3 V4 region are described separately.  206	
 207	
The average top 20 ASVs observed in NCS in setups 2 and 3, are presented in Figure 4. The 208	
samples were dominated by many of the same taxa, and most of these taxa were defined by 209	
the same ASVs. The Decontam package (method=either, threshold= 0.5) applied 210	
downstream of the presented data identified the majority of the top 20 ASVs presented in 211	
NCS as contaminants. Exceptions included both ASVs mapping to the genus Streptococcus (in 212	
line with our previous findings [3]) (using NCBI blastn these ASVs were determined to be 213	
Streptococcus oralis (06f825b512d903b9230e1a55d87359ee) and Streptococcus 214	
thermophilus (fd496fd32dc8c08ade2e8b6c9d8ee13d) and the single ASV mapping to the 215	
family Pasteurellaceae.  216	
 217	
The distribution of ASVs in NCS (Figure 4) differed the most between setups 2 and 3 for an 218	
ASV belonging to the family Enterobacteriaceae (mapped to Escherichia using NCBI blastn), 219	
with a significant increase observed in samples sequenced by setup 3 (0.02% observed for 220	
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setup 2 and 29.34% observed for setup 3). These findings were in accordance with the 221	
results from the mock community analysis (Figure 3), for which the same Escherichia ASV 222	
was also found at higher levels in the mock community sample sequenced by setup 3 223	
(22.54% observed for setup 2 and 32.90% observed for setup 3). Its relatively high 224	
abundance in the mock community processed through setup 2 compared to NCS was 225	
expected as the Escherichia genus defined by this ASV constituted 21.91% of the expected 226	
mock community profile; i.e. for this sample the ASV represented both a contaminant and a 227	
non-contaminant.  228	
 229	
We proceeded with a comparison of the taxonomic distribution in PCR water samples 230	
sequenced following setups 2 and 3 (Table 3).  A relatively low number of sequences and 231	
ASVs were obtained (setup 2: 178 sequences (10 ASVs); setup 3: 130 sequences (6 ASVs)). 232	
Importantly, the dominating ASV (35.38%) found in the PCR water samples sequenced 233	
following setup 3, was the same ASV mapping to Escherichia discussed above. The same ASV 234	
was not found in the PCR water sample sequenced by setup 2. Together these findings 235	
indicate that the Escherichia ASV is a contaminant introduced during steps of library 236	
preparation using a reagent that is exclusive to setup 3.  237	
 238	
We next looked at the average top 20 ASVs observed in NCS when sequencing following 239	
setup 1 (Figure 5). The taxonomic profiles obtained after sequencing the longer V3 V4 region 240	
resulted in greater taxonomic resolution compared to that observed when sequencing the 241	
V4 region in setups 2 and 3. Whereas the three ASVs belonging to the family 242	
Enterobacteriaceae classified down to genus level Gluconacetobacter in setup 1, the 243	
Enterobacteriaceae ASVs classified no lower than to family level in setups 2 and 3 (Figure 5). 244	
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The cumulative average relative abundance of the three ASVs mapping to Gluconacetobacter 245	
when following setup 1 (22 %) was however the same as that found for the single ASV 246	
mapping to the family Enterobacteriaceae when following setup 2 (23%). Thus, for these two 247	
setups, the contamination profiles were similar although greater resolution was obtained 248	






















ASV Lowest Classification Setup 2 Setup 3 
06f825b512d903b9230e1a55d87359ee∆ f__Streptococcaceae; g__Streptococcus 35.39 20.77 
ddfd49f939f92958b1ec816741055348 f__Oxalobacteraceae; g__Ralstonia; s__ 12.36 0.00 
394eda29c886632f514dd94b58381186 f__Pasteurellaceae 8.99 0.00 
d32e579b3ae7b2aae8d5bf9f027c29af f__Comamonadaceae 8.99 0.00 
5648dccee530d68ceb3e4d7d22cf8756 f__Pseudomonadaceae; g__Pseudomonas 7.87 0.00 
4f5efd25dacb5d639316e7291ff6ff8b f__Neisseriaceae; g__Neisseria 7.87 7.69 
85c44c83eddc5d3028261a1000b7d0e1 f__Gemellaceae 5.62 0.00 
923f521b9cf313f1f95c9367e09bbc1c f__Veillonellaceae; g__Veillonella; s__dispar 5.62 12.31 
dcba105f35d8ebc9e22269c7491ad3a7 f__Xanthomonadaceae; g__Stenotrophomonas; s__geniculata 5.06 0.00 
df8456a1abbfb4c8a2c450b44378d4cb f__Actinomycetaceae; g__Actinomyces; s__ 2.25 0.00 
d46e2205f0c6ecf67b51f83d111c509c* f__Enterobacteriaceae 0.00 35.38 
edc9e5c16e40aff1eadce6597940f08f f__Streptococcaceae; g__Streptococcus; s__ 0.00 13.85 
65d43491988bfe557da4d86a5ba25dae f__Staphylococcaceae; g__Staphylococcus 0.00 10.00 
 270	
 271	
Table 3. Relative abundance (%) of ASVs observed in PCR water samples in setups 2 and 3. 272	
The same Escherichia ASV (*) that differentiated mock community samples and NCS in 273	
setups 2 and 3, also caused the greatest difference observed in PCR water samples. 274	
Bioinformatic processing steps were performed up until the removal of contaminants 275	
identified using Decontam. Taxonomic rank is described using prefixes (f__: family, g__: 276	









Protocol effects on procedural samples 285	
We next compared the sequencing output obtained for the procedural samples sequenced 286	
following each of the three setups. Because we suspected that any differences observed 287	
between sequencing setups could be explained by differences in susceptibility to laboratory 288	
contamination, comparisons were made both before and after the removal of contaminants 289	
identified in Decontam (Figure 1, Step 5).  290	
 291	
Before the removal of Decontam contaminants (Figure 6), we found that across all three 292	
sequencing setups, procedural samples (OW, PSB, PBAL) were dominated by many of the 293	
same taxa. The most prominent taxa averaged across all samples in order of decreasing 294	
relative abundance were genera Streptococcus, Prevotella, Veillonella and Rothia. We 295	
interpreted these as representative of the authentic airway microbiota based on the growing 296	
body of literature for which these same taxa have been consistently observed in airways.  297	
 298	
Several less abundant taxa for which we interpreted as contaminants, based on their 299	
dominance in NCS were also observed in the data. We previously learned that ASVs 300	
attributed to the family Enterobacteriaceae dominated the NCS and that an ASV mapping to 301	
Escherichia had a discriminating impact on NCS and mock communities processed through 302	
setup 3. We were therefore particularly interested in understanding whether 303	
Enterobacteriaceae would also have a discriminating impact on procedural samples 304	
processed through the different sequencing setups. Across all three sequencing setups we 305	
found that the levels of Enterobacteriaceae was highest in samples from the lower airways 306	
(PSB>PBAL) and nearly undetected in OW samples (Figure 6). The higher levels of 307	
Enterobacteriaceae in PSB samples compared to PBAL, was expected as less sample volume 308	
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was used as input to the DNA extraction protocol (450 µl PSB vs 1800 µl PBAL) thereby 309	
securing a lower bacterial load in PSB compared to PBAL. Across all sample types, the 310	
relative abundance of Enterobacteriaceae was highest when sequencing following setup 3; 311	
this was also in accordance with our results when sequencing the mock community and 312	
likely due to the additional Escherichia contamination introduced during library preparation 313	
following setup 3 (Figure 4). By analysis of beta diversity using the unweighted UniFrac 314	
metric, we were able to confirm that there was greater overlap or similarity between the 315	
bacterial communities found in NCS and procedural samples from the lungs when 316	
sequencing following setup 3 (Additional file 4: Figure S.1). 317	
 318	
After the removal of Decontam contaminants, the less abundant taxa that we predicted as 319	
representative of contaminants had been filtered out (Figure 7). Although the dominating 320	
taxa across all samples were now mainly expected core airway microbiota members, the 321	
relative abundances of these taxa still varied across the three setups.  322	
 323	
A direct comparison of the bacterial communities recovered when sequencing by a 1 or 2 324	
steps PCR protocol was achieved by analysis of beta-diversity on samples processed through 325	
each of setups 2 and 3. Before the removal of Decontam contaminants, OW and NCS 326	
clustered together regardless of whether they had been processed through setups 2 or 3 327	
(Figure 8). The samples from the lungs however clustered separately according to the 328	
protocol for which they were processed. When Decontam contaminants were removed, the 329	
samples from the lungs processed by setups 2 and 3 became more similar in bacterial 330	
community composition, as indicated by a greater degree of overlap in PCoA space (Figure 331	
9). The separation of the lower airway samples based on the setup for which they were 332	
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processed was however still apparent. This indicated that mechanisms related to the low 333	
bacterial load, other than differences in contamination were driving the observed protocol 334	
























We have shown that choice of library preparation protocol for high-throughput amplicon-358	
based sequencing of the 16S rRNA gene (1-step PCR vs 2-step PCR) will have an impact on 359	
final bacterial community descriptions for airway samples - and more so for samples of low 360	
bacterial load. Differences observed when sequencing the different target regions (V3 V4 361	
and V4) appeared to be relatively small in comparison, and mainly attributed to differences 362	
in taxonomic resolution. Using bioinformatic filtering parameters, we were able to reduce 363	
but not completely remove the differences in sequencing output observed for the three 364	
sequencing setups: Setup 1 (2-step PCR; V3 V4), Setup 2 (2-step PCR; V4) and Setup 3 (1-step 365	
PCR; V4). We propose that protocol bias in studies of the lung microbiome are related not 366	
only to differences in susceptibility to contamination but also to less understood (and largely 367	
ignored) mechanisms of PCR bias.  368	
 369	
Beginning with a comparison of the number of sequences and ASVs retained at each 370	
bioinformatic processing step, we gained insight into the differences in the sequencing 371	
output generated for each of the three setups. We found that the removal of small ASVs 372	
resulted in the greatest decrease in total ASV number across all three setups - with greatest 373	
impact on data generated from the two sequencing setups based on the 2-step PCR protocol 374	
(setup 1 and 2). Our interpretation was that the small ASVs likely represent low abundant 375	
contamination and that the observed higher frequencies in data generated when processing 376	
through longer laboratory workflows was as predicted. Interestingly, this filtering step was 377	
originally recommended for filtering out spurious operational taxonomic units (OTUs) 378	
derived from PCR and sequencing error [28], and therefore not regarded as necessary after 379	
denoisning to ASVs [29]. The total number of ASVs after the removal of small ASVs, was still 380	
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markedly higher when sequencing was performed following setup 1, for which samples were 381	
spread across four different sequencing runs. We can expect contamination profiles to vary 382	
across sequencing runs, thereby adding to the number of ASVs in the data set, and we 383	
therefore interpreted the higher number of ASVs as contamination that had not been 384	
filtered out. When analyses were conducted on the subset of samples sequenced on the 385	
same run, we still observed a slight increase in ASV count in setup 1; this likely attributed to 386	
the greater taxonomic resolution obtained when sequencing a larger gene region. Based on 387	
the raw sequencing data, the take home message is therefore that researchers need to pay 388	
particular attention to small ASVs when making comparisons across datasets sequenced 389	
following different protocols. The observed inflation of ASVs when sequencing across 390	
multiple sequencing runs also needs to be accounted for.   391	
 392	
By sequencing of a mock community sample, we were able to show that the three 393	
sequencing setups were for the most part equally efficient at recovering the high abundant 394	
mock community members. For reasons that are unclear to us, we found that sequencing 395	
setup 3, was least efficient at recovering the low abundant members. Together with the 396	
observation that the total number of ASVs recovered following setup 3 was lower than for 397	
Setups 1 and 2, we concluded that the 1 step-PCR protocol may be less apt for detecting rare 398	
but potentially significant taxa [30, 31]. Berry et al. [32] also compared sequencing data 399	
generated when processing samples through PCR protocols that differed in the number of 400	
PCR steps (1-step PCR vs 2-step PCR). In accordance with our findings, they observed 401	
reduced richness when processing samples through the 1-step PCR protocol. Thus, it could 402	
be that although the 1-step PCR protocol may generate data less influenced by small 403	
contaminating ASVs, measures of alpha diversity may be underestimated. 404	
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  405	
To further explore the potential impact of contamination, we compared the contamination 406	
profiles (based on NCS) obtained for the three sequencing setups. We were surprised to find 407	
that the NCS samples processed through setup 3 were dominated by an ASV mapping to 408	
Escherichia coli (family Enterobacteriaceae). It was unexpected because we have previously 409	
traced the main source of contamination in the MicroCOPD study to the DNA extraction kit 410	
[3]. Because the same DNA extracts were used as input into the sequencing setup 3, we 411	
expected that the lower number of laboratory processing steps compared to setups 1 and 2, 412	
would secure a contaminant profile representative of that introduced during DNA 413	
extraction. We however learned that a contaminant introduced during library preparation 414	
was enough to overwhelm the contamination profile of the entire sequencing run. We 415	
immediately suspected that the DNA polymerase, manufactured in Escherichia coli and used 416	
exclusively in the PCR amplification step when sequencing following setup 3, was the main 417	
contamination source. Our findings emphasize the fact that researchers must be meticulous 418	
in their choice of PCR reagents and also aware of these effects when comparing data 419	
generated using different protocols.  420	
 421	
We have previously estimated that contaminants will represent 10-50% of the sequencing 422	
output for lower airway samples when sequencing by setup 1 [3]. We found that the 423	
Enterobacteriaceae family represented less than 10% of the taxonomy profiles for the 424	
procedural samples in all three setups and recognized that a significant fraction of the 425	
contaminants, were likely also represented by small ASVs and other taxa. For a more 426	
accurate assessment of the impact of contamination, we therefore also relied on the 427	
Decontam R package [33] for the identification of contaminants. We predicted that if 428	
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contamination was the main distinguishing factor causing the separation in sequencing 429	
output across sequencing setups, the removal of Decontam contaminants would close this 430	
gap. By analysis of unweighted Unifrac distances in PCoA space, both before and after the 431	
removal of Decontam contaminants, we observed that while the high biomass OW samples 432	
clustered together, the low biomass samples from the lungs (PBAL,PSB) separated according 433	
to the setup 2 or 3, for which they had been processed. We concluded that factors related to 434	
bacterial load, other than contamination must also be contributing to the observed protocol 435	
bias.  436	
 437	
The polymerase chain reaction (PCR) lies at the core of all amplicon-based sequencing 438	
protocols. The impact of PCR related bias (i.e. all mechanisms that may lead to the 439	
preferential amplification of particular sequences or taxa) on studies involving samples 440	
holding a low bacterial load is however not well understood. This despite that recent papers 441	
as well as research dating back even two decades has documented that PCR related bias 442	
appears to increase with decreasing template DNA concentration [1, 34–36].  Kennedy et al. 443	
[36] observed that bacterial community profiles of replicate soil samples decreased in 444	
similarity after sample dilution. The authors attributed these observations to an increased 445	
impact of stochastic fluctuations in PCR amplifications at lower bacterial loads. Biesbroek et 446	
al. [1] observed an increase in Firmicutes and decrease in Bacteriodetes across a serially 447	
diluted saliva sample, but were unable to explain the direct mechanism behind their 448	
observations. Our study contributes to the literature addressing these issues by 449	
demonstrating that samples of high bacterial load (OW) appear to be able to buffer against 450	
protocol bias (i.e. differences in number of PCR steps), while samples of low bacterial load 451	
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(PSB, PBAL) are directly impacted. More research is needed in order to understand the 452	
extent to which these mechanisms are responsible for our observations.  453	
 454	
The results presented in the current study have several important implications. Because the 455	
upper respiratory tract represents both i) a major potential source of contamination under 456	
sampling and ii) the main source community for the lung microbiota, most studies include 457	
representative samples from this site (e.g. OW samples) [4, 17, 19, 37, 38]. Our findings 458	
demonstrate that the observed overlap between the bacterial communities of the upper and 459	
lower respiratory tract may be protocol dependent. Of concern is also that similar 460	
community descriptions obtained for upper respiratory tract samples across protocols may 461	
mistakenly be interpreted as evidence that datasets are comparable also for lower 462	
respiratory tract samples. Our findings also lead us to question the conclusions made in 463	
studies where similar PCR reagents have been used. Dickson et al. [12] have for example 464	
suggested that Escherichia coli may be a significant lung pathogen that has previously gone 465	
undetected using culture-based techniques. Our results open for interpreting the bacterium 466	
as a contaminant introduced with the recombinant DNA polymerase used in the PCR.  467	
 468	
Conclusion 469	
Our findings show that choice of protocol for library preparation and sequencing (1- or 2- 470	
steps of PCR) will have an impact on the analyses of the airway microbiome. Upper airway 471	
samples (high biomass) were less impacted than lower airway samples (low biomass), 472	
indicating that protocol bias is related to sample biomass. This did not appear to be 473	
associated with differences in contamination levels when following a longer or shorter 474	
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protocol, but rather to mechanisms related to the PCR, for which more research is required. 475	
These methodological limitations likely explain the variable conclusions across studies of the 476	
airway microbiome (e.g. for comparisons of upper and lower airway samples). Differences in 477	
targeted amplicon region (16S rRNA gene V3 V4 versus V4) did not appear have a great 478	
impact on final bacterial community descriptions, although greater taxonomic resolution 479	




The 23 study subjects were chosen from the Bergen COPD Microbiome Study (short name 484	
“MicroCOPD”) for representation of both healthy (n=9) and diseased (asthma (n=4), COPD 485	
(n=10)) states. Out of the 350 study subjects included in the MicroCOPD study (with samples 486	
dispersed across over 30 sequencing runs), the subset of subjects included in the current 487	
investigation were chosen in order to minimize the spread of samples across multiple runs. 488	
Details on the MicroCOPD study design and bronchoschopy procedures have been 489	
previously published [27]. The MicroCOPD study was approved by the regional ethical 490	
committee (REK-Vest, case # 2011-1307), and all subjects signed written informed consent.  491	
 492	
In brief, voluntary bronchoscopies were performed on adult subjects (with and without 493	
obstructive lung disease) recruited from Western Norway between 2013 and 2015, at the 494	
Department of Thoracic Medicine, Haukeland University Hospital. Subjects were examined in 495	
the stable state and were not to have received antibiotics at minimum 2 weeks prior to the 496	
procedure. Samples collected under each procedure included the first and second fraction of 497	
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2 x 50 mL protected (through a sterile inner catheter passed through the scope channel) 498	
bronchoalveolar lavage (PBAL1 and PBAL2) from the right middle lobe, three protected 499	
specimen brushes sampled from the right lower lobe (PSB), an oral wash (OW) sample, and a 500	
negative control sample (NCS) taken from the sterile bottle of phosphate buffered saline 501	
directly; the same fluid used for BAL sampling, OW, and dissolution of the PSBs.  502	
We also included a mock community sample, obtained through BEI Resources NIAID, NIH as 503	
part of the Human Microbiome Project: Genomic DNA from Microbial Mock Community B 504	
(Staggered, Low Concentration), v5.2L, for 16S rRNA Gene Sequencing, HM783D.  505	
 506	
Bacterial DNA Extraction 507	
Bacterial DNA extraction was performed first by treatment with lytic enzymes mutanolysin, 508	
lysozyme and lysostaphin (all from Sigma-Aldrich, St. Louis, MO, USA) and subsequently by 509	
processing through the Fast DNA Spin Kit (MP Biomedcals, LLC, Solon, OH, USA) following 510	
the manufacturer´s instructions. The sample volume used as input into the DNA extraction 511	
protocol varied with sample type; 450 µl for PSB and NCS and 1800 µl for OW and PBAL.  512	
 513	
Library Preparation for MiSeq Sequencing 514	
We processed the same DNA extracts through three different library preparation setups for 515	
MiSeq sequencing of the bacterial 16S rRNA marker gene: Setup 1 (2-step PCR; 16S rRNA 516	
gene region V3 V4); Setup 2 (2-step PCR; 16S rRNA gene region V4); Setup 3 (1-step PCR; 16S 517	
rRNA gene region V4). Setups 1 and 2, were based on the 2-step PCR protocol described in 518	
the Illumina 16S Metagenomic Sequencing Library Preparation guide (Part no. 15044223 519	
Rev. B). In the first PCR, the 16S rRNA gene regions V3 V4 (setup 1) and V4 (setup 2) were 520	
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targeted using primers (gene specific sequences are underlined): 521	
Setup 1: 522	






PCR cycling was performed with an initial cycle at 95 °C for 3 min followed by 45 cycles of 95 529	
°C for 30s, 55 °C for 30 s (setup1)/ 50 °C (setup 2), 72 °C for 30 s and a final extension cycle at 530	
72 °C for 5 min. In the second PCR (8 cycles), index sequences were added to the ends of the 531	
amplicons generated in the first PCR, using primers from the Nextera XT Index Kit (Illumina 532	
Inc., San Diego. CA, USA). Amplifications were performed using the Kappa HiFi HotStart 533	
ReadyMix (KAPA Biosystems, USA). Setup 3 was based on the 1-step PCR protocol described 534	
in Kozich et al. [25], with modifications (see Additional file 5: Supplementary Methods). The 535	
primers used targeted the 16S rRNA gene region V4 and consisted of both gene specific 536	




PCR cycling was performed with an initial cycle at 95 °C for 2 min followed by 45 cycles of 95 541	
°C for 20 s, 55 °C for 15 s, 72 °C for 5 min and a final extension cycle at 72 °C for 5 min. 542	
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Amplifications were performed using the recombinant DNA polymerse Accuprime Pfx Super 543	
Mix (Thermo Fisher Scientific, USA). 544	
Bioinformatics 545	
General Steps. Sequences were processed using plugin tools available within the 546	
Quantitative Insights Into Microbial Ecology (QIIME2) bioinformatic package (release 547	
2019.1). Two fastq-files per sample (demulitiplexed, paired-end reads) were imported into 548	
the QIIME2 environment. Using the dada2 denoise-paired plugin i) primer sequences and 549	
low quality bases at read-ends were trimmed off, ii) paired-end reads were joined, iii) 550	
chimeras discarded and iv) amplicon sequence variants (ASVs) inferred [26, 29]. Additional 551	
chimera filtering was performed using the vsearch uchime-denovo plugin [39].  ASVs with 552	
fewer sequences than 0.005% of the total number of sequences and ASVs not found in at 553	
least two samples were then discarded [28]. Taxonomy was assigned using the feature-554	
classifier classify-sklearn plugin together with a Naïve Bayes classifier that had been pre-555	
trained on the full-length Greengenes 13_8 99% OTU reference database (available on 556	
qiime2.org). ASVs classified as mitochondria, chloroplasts or archaea were discarded 557	
together with classifications that ended above the phylum level. Contaminant ASVs 558	
identified using the Decontam package in R were then discarded [40]. The Decontam 559	
method “either” (threshold=0.5) was chosen based on our previous work [3]. As the study 560	
samples were found across multiple sequencing runs, bioinformatics processing of samples 561	
was performed in batches according to run number. Samples not included in the study, but 562	
present on the same run were also included in the pipeline to optimize performance of run 563	
specific algorithms (e.g. DADA2 and Decontam). Analyses. Analysis on taxonomic 564	
composition was performed in Excel on ASV tables generated at various stages of the 565	
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bioinformatic pipeline. Analyses on procedural samples (PSB, PBAL, OW) were performed on 566	
the ASV table processed through all general steps described above. Analyses on the top 20 567	
ASVs found in NCS and in PCR water controls, were based on the ASV table processed 568	
through all steps in the pipeline except removal of contaminants identified in Decontam. For 569	
analyses on mock community samples, processing steps were limited to DADA2, VSEARCH 570	
and removal of ASVs not classified at minimum to phylum level. Analyses of beta-diversity 571	
were conducted using PCoA on unweighted UniFrac distances. The unweighted UniFrac 572	
metric scores samples with bacterial communities found at similar positions within the 573	
phylogenetic tree, as more similar than samples with bacterial communities found at 574	
different positions within the tree. The (dis)similarity between samples is visualized in 575	
principal coordinates of analysis (PCoA) space, with samples similar in bacterial composition 576	
plotted closer together. The unweighted UniFrac metric was chosen to ensure that the less 577	




Additional file 1: Table S.1: The table presents an overview of the sequence count per ASV 582	
obtained after V3 V4 sequencing of mock community sample HM-783D following setup 1.  583	
Additional file 2: Table S.2: The table presents an overview of the sequence count per ASV 584	
obtained after V4 sequencing of mock community sample HM-783D following setup 2.  585	
Additional file 3: Table S.3: The table presents an overview of the sequence count per ASV 586	
obtained after V4 sequencing of mock community sample HM-783D following setup 3. 587	
Additional file 4: Figure S.1: Principal coordinates analysis on unweighted UniFrac distances 588	
for procedural samples sequenced following each setup before the removal of Decontam 589	
contaminants. 590	
Additional file 5: Supplementary Methods. The file provides a detailed description of the 591	
mock community HMD 783-D, protocols for sequencing. (DOCX) 592	
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Figure 1. Comparison of the number of sequences and amplicon sequence variants (ASVs), 763	
retained at each bioinformatic filtering step for procedural samples (PSB, PBAL, OW, NCS) 764	
collected from 23 participants (n=92 samples). Setup 1 (2-step PCR; V3 V4 region), Setup 2 (2-765	
step PCR; V4 region), Setup 3 (1-step PCR; V4 region). 766	
 767	
Figure 2. Comparison of the number of sequences and amplicon sequence variants (ASVs), 768	
retained at each bioinformatic filtering step for procedural samples (PSB, PBAL, OW, NCS)  769	
	 33	
collected from 14 participants (n=56). Setup 1 (2-step PCR; V3 V4 region), Setup 2 (2-step PCR; 770	
V4 region), Setup 3 (1-step PCR; V4 region). 771	
 772	
Figure 3. Analysis of mock community HM-783D. The expected relative abundances of 773	
genera in the mock community sample is presented next to that observed in the sequencing 774	
output across the three setups. The Escherichia genus consisted of ASVs classified to family 775	
level (Enterobacteriaceae); ASV ffc36e27c82042664a16bcd4d380b286 dominated Setup 1 776	
targeting the 16S rRNA gene V3 V4 region and ASV d46e2205f0c6ecf67b51f83d111c509c 777	
dominated Setups 2 and 3 targeting the V4 region. Using the NCBI blastn tool we were able 778	
to confirm that these ASVs belonged to the Escherichia coli genus. Bioinformatics processing 779	
steps were limited to DADA2, VSEARCH, taxonomy assignment and removal of features not 780	
classified at minimum to phylum level. Setup 1 (2-step PCR; V3 V4 region), Setup 2 (2-step 781	
PCR; V4 region), Setup 3 (1-step PCR; V4 region). 782	
 783	
Figure 4. Comparison of the 20 most abundant amplicon sequence variants (ASVs) observed 784	
in negative control samples (NCS) after sequencing following setups 2 and 3.  Taxa presented 785	
according to decreasing abundance for ASVs observed following setup 2. Bioinformatic 786	
processing steps were performed up the removal of contaminants identified using 787	
Decontam. Taxonomic rank is described using prefixes (c__: class, o__: order, f__: family, 788	
g__: genus). Setup 2 (2-step PCR; V4 region); Setup 3 (1-step PCR; V4 region). Data is 789	
presented as the average relative abundance. Data unrarefied.   790	
 791	
Figure 5. The 20 most abundant amplicon sequence variants (ASVs) observed in negative 792	
control samples (NCS) after sequencing following setup 1. Multiple ASVs mapped to genera 793	
	 34	
Gluconacetobacter, belonging to familiy Enterobacteriaceae (cummulative 22%). 794	
Bioinformatic processing steps were performed up until the removal of contaminants 795	
identified using Decontam. Taxonomic rank is described using prefixes (c__: class, o__: 796	
order, f__: family, g__: genus). Data is presented as the average relative abundance. Data 797	
unrarefied.   798	
 799	
Figure 6. Taxonomic distribution obtained for procedural samples before the removal of 800	
Decontam contaminants. ASVs attributed to the family Enterobacteriaceae, had dominated 801	
the NCS across all setups. In the procedural samples, Enterobacteriaceae was observed with 802	
the following relative abundances in setups 2 and 3: setup 2 (OW: 0%; PBAL: 0.83%; PSB: 803	
5.23%); setup 3 (OW: 0.01%; PBAL: 1.87%; PSB: 7.51%). ASVs attributed to the genus 804	
Gluconacetobacter within the family Enterobacteriaceae was observed in procedural 805	
samples with the following relative abundances in setup 1 (OW: 0%; PBAL: 1.42%; PSB: 6.32 806	
%). Samples with fewer than 1000 sequences had been omitted from the analyses leaving 807	
the following number of samples in each setup: Setup 1 (OW: n=22; PBAL: n=23; PSB: n=23); 808	
Setup 2 (OW: n=23; PBAL: n=23; PSB: n=23); Setup 3 (OW: n=23; PBAL: n=21; PSB: n= 22). 809	
Setup 1 (2-step PCR; V3 V4 region); Setup 2 (2-step PCR; V4 region); Setup 3 (1-step PCR; V4 810	
region). Taxonomic rank is described using prefixes (p__: phyla; c__: class; o__: order; f__: 811	
family; g__: genus). 812	
 813	
Figure 7. Taxonomic distribution obtained for procedural samples after the removal of 814	
Decontam contaminants. Samples with fewer than 1000 sequences were omitted. Number 815	
of samples in each setup: V3V4 protocol A (OW: n=22; PBAL: n=22; PSB: n=21), V4 protocol A 816	
(OW: n=23; PBAL: n=22; PSB: n=20); V4 protocol B (OW: n=23; PBAL: n=21; PSB: n= 21). 817	
	 35	
Setup 1 (2-step PCR; V3 V4 region); Setup 2 (2-step PCR; V4 region); Setup 3 (1-step PCR; V4 818	
region). Taxonomic rank is described using prefixes (p__: phyla; c__: class; o__: order; f__: 819	
family; g__: genus). 820	
 821	
Figure 8. Principal coordinates analysis on unweighted UniFrac distances for procedural 822	
samples sequenced following setup 2 (sphere) and 3 (diamond) before the removal of 823	
Decontam contaminants. Rarefaction depth: 1066 sequences. Setup 2 samples include OW: 824	
n=23; PBAL: n=23; PSB: n= 23; NCS: n=21 and setup 3 samples include OW: n=23; PBAL: 825	
n=21; PSB: n=22; NCS: n=18. Oral Wash (OW): blue; Protected bronchoalveolar lavage 826	
(PBAL): green; Protected specimen brushes (PSB): purple; Negative control samples (NCS): 827	
red. Setup 2 (2-step PCR; V4 region), Setup 3 (1-step PCR; V4 region). 828	
 829	
Figure 9. Principal coordinates analysis on unweighted UniFrac distances for procedural 830	
samples sequenced following setup 2 (sphere) and 3 (diamond) after the removal of 831	
Decontam contaminants. Rarefaction depth: 1139 sequences. Setup 2 samples include OW: 832	
n=23; PBAL: n=21; PSB: n= 20 and setup 3 samples include OW: n=23; PBAL: n=21; PSB: 833	
n=21. Oral Wash (OW): blue; Protected bronchoalveolar lavage (PBAL): green; Protected 834	








































































































































































































































































































































































































































































































































































































































































































































































































































































































































f__Oxalobacteraceae; g__Ralstonia; s__ d026ba8391312cd4726993268770b541 21 0,016353484
128413 100 100,00
Mock Community HM-783D, Sample ID MKOLS1946, Setup 1 (II)







Escherichia f__Enterobacteriaceae ffc36e27c82042664a16bcd4d380b286 26321 23,99165064 23,99
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 5497318e515a8c328a68f95975d9c7d4 24930 22,72375101 29,27
f__Staphylococcaceae; g__Staphylococcus 908e9b387f6b9ce7d3f794e658fba37e 4529 4,128193676
f__Staphylococcaceae; g__Staphylococcus 04be702b895fe5ed0568344daf564276 2651 2,416392456
Streptococcus f__Streptococcaceae; g__Streptococcus; s__ ef5af48ec2b6c023c5de28c59cb08a40 26478 24,13475649 27,39
f__Streptococcaceae; g__Streptococcus; s__agalactiae c3a3a503752209bc052b3995236b079f 3549 3,234921474
f__Streptococcaceae; g__Streptococcus a3725fbb7f4a76528d54dd283e88cad8 23 0,020964552
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides 332b70897316f7f62b81dfc53f41ca52 10448 9,523375475 9,52
Bacillus f__Bacillaceae; g__Bacillus 8cb24777cb48dde0aac60dfeca125d10 3142 2,86394006 2,86
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 318669d5d926e9b81ca6911da00a14ea 3333 3,038036989 3,28
f__Clostridiaceae; g__Clostridium; s__butyricum 88a3a8e95e3605bd051054f937cde102 261 0,237902086
Pseudomonas f__Pseudomonadaceae 052ba7abaeaa968c4f79e3f97d1f0a2f 1842 1,678987139 1,68
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e8de9432f2ada1078a2fda56ba92675a 534 0,4867422 0,49
Neisseria f__Neisseriaceae; g__Neisseria; s__cinerea f71e5aacd4c976a1833958c2870b1d8b 339 0,308999262 0,31
Listeria f__Listeriaceae; g__Listeria b77b151f7481fd080bedbf415e736539 357 0,325406302 0,33
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 9b23053de8f4269fe6b5ce286dfbef3c 218 0,19870749 0,20
Acinetobacter f__Moraxellaceae; g__Acinetobacter; s__guillouiae c49cc7c2c45bd7a87913453e515ea14f 319 0,290769217 0,29
Propionibacterium f__Propionibacteriaceae; g__Propionibacterium; s__acnes b02a8d33d018119dedb2db15db887bfd 240 0,218760539 0,22
Bacteroides NA NA 0 0 0,00
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ e4c0868fdefcdf2037ab5f7a071e4cc7 39 0,035548588 0,04
Enterococcus  f__Enterococcaceae; g__Enterococcus; s__ 892a20bbdc3ce599dc0c5d9f0866c352 23 0,020964552 0,02
Mock Community HM-783D, Sample ID MKOLS1848, Setup 1 (I)







Escherichia f__Enterobacteriaceae ffc36e27c82042664a16bcd4d380b286 35542 27,67788308 27,68
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 5497318e515a8c328a68f95975d9c7d4 29124 22,67994673 29,02
f__Staphylococcaceae; g__Staphylococcus 908e9b387f6b9ce7d3f794e658fba37e 5133 3,997258845
f__Staphylococcaceae; g__Staphylococcus 04be702b895fe5ed0568344daf564276 3004 2,339327015
Streptococcus f__Streptococcaceae; g__Streptococcus; s__ ef5af48ec2b6c023c5de28c59cb08a40 32219 25,09013885 28,51
f__Streptococcaceae; g__Streptococcus; s__agalactiae c3a3a503752209bc052b3995236b079f 4377 3,408533404
f__Streptococcaceae; g__Streptococcus a3725fbb7f4a76528d54dd283e88cad8 13 0,010123586
f__Streptococcaceae; g__Streptococcus 2a025812c0b5b9ce4c6dab4c692bed7d 4 0,003114949
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides 332b70897316f7f62b81dfc53f41ca52 7676 5,977587939 5,98
Bacillus f__Bacillaceae; g__Bacillus 8cb24777cb48dde0aac60dfeca125d10 4343 3,382056334 3,38
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 318669d5d926e9b81ca6911da00a14ea 2577 2,006806164 2,18
f__Clostridiaceae; g__Clostridium; s__butyricum 88a3a8e95e3605bd051054f937cde102 228 0,177552117
Pseudomonas f__Pseudomonadaceae 052ba7abaeaa968c4f79e3f97d1f0a2f 1850 1,440664107 1,44
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e8de9432f2ada1078a2fda56ba92675a 464 0,361334133 0,36
Neisseria f__Neisseriaceae; g__Neisseria; s__cinerea f71e5aacd4c976a1833958c2870b1d8b 306 0,238293631 0,24
Listeria f__Listeriaceae; g__Listeria b77b151f7481fd080bedbf415e736539 430 0,334857063 0,33
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 9b23053de8f4269fe6b5ce286dfbef3c 279 0,217267722 0,22
Acinetobacter f__Moraxellaceae; g__Acinetobacter; s__guillouiae c49cc7c2c45bd7a87913453e515ea14f 416 0,32395474 0,32
Propionibacterium f__Propionibacteriaceae; g__Propionibacterium; s__acnes b02a8d33d018119dedb2db15db887bfd 166 0,129270401 0,13
Bacteroides f__Bacteroidaceae; g__Bacteroides; s__ b6635d67cb594473ddba9f8cfba5d13d 26 0,020247171 0,02
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ e4c0868fdefcdf2037ab5f7a071e4cc7 21 0,016353484 0,02
Enterococcus  f__Enterococcaceae; g__Enterococcus; s__ 892a20bbdc3ce599dc0c5d9f0866c352 34 0,02647707 0,03
Actinomyces f__Actinomycetaceae; g__Actinomyces; s__ c42488aff4cc842bf285a401dba39cc4 8 0,006229899 0,01
Other p__OD1; c__; o__; f__; g__; s__ 3be770f858d48a8c64d91c71fd000951 111 0,086439846 0,13
p__OD1; c__; o__; f__; g__; s__ 787efccde8e499d021ddb015a190b3b0 16 0,012459798
f__Comamonadaceae; g__Curvibacter; s__ 9e44fc82a0d6ac6109dac3dc4f1a3409 25 0,019468434
Actinomyces f__Actinomycetaceae; g__Actinomyces; s__ c42488aff4cc842bf285a401dba39cc4 7 0,006380516 0,01
Other p__OD1; c__; o__; f__; g__; s__ 3be770f858d48a8c64d91c71fd000951 108 0,098442243 0,11
p__OD1; c__; o__; f__; g__; s__ 787efccde8e499d021ddb015a190b3b0 18 0,01640704
109709 100 100,00
Mock Community HM-783D, Sample ID MKOLS2042, Setup 1 (III)







Escherichia f__Enterobacteriaceae ffc36e27c82042664a16bcd4d380b286 27844 25,20001448 25,20
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 5497318e515a8c328a68f95975d9c7d4 25520 23,09669478 29,66
f__Staphylococcaceae; g__Staphylococcus 908e9b387f6b9ce7d3f794e658fba37e 4622 4,183108279
f__Staphylococcaceae; g__Staphylococcus 04be702b895fe5ed0568344daf564276 2634 2,383882996
Streptococcus f__Streptococcaceae; g__Streptococcus; s__ ef5af48ec2b6c023c5de28c59cb08a40 26375 23,87050646 27,03
f__Streptococcaceae; g__Streptococcus; s__agalactiae c3a3a503752209bc052b3995236b079f 3454 3,126018173
f__Streptococcaceae; g__Streptococcus a3725fbb7f4a76528d54dd283e88cad8 36 0,032581544
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides 332b70897316f7f62b81dfc53f41ca52 10200 9,23143757 9,23
Bacillus f__Bacillaceae; g__Bacillus 8cb24777cb48dde0aac60dfeca125d10 3257 2,947724722 2,95
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 318669d5d926e9b81ca6911da00a14ea 2250 2,036346523 2,19
f__Clostridiaceae; g__Clostridium; s__butyricum 88a3a8e95e3605bd051054f937cde102 172 0,155667379
Pseudomonas f__Pseudomonadaceae 052ba7abaeaa968c4f79e3f97d1f0a2f 1939 1,754878181 1,75
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e8de9432f2ada1078a2fda56ba92675a 489 0,442565978 0,44
Neisseria f__Neisseriaceae; g__Neisseria; s__cinerea f71e5aacd4c976a1833958c2870b1d8b 327 0,295949028 0,30
Listeria f__Listeriaceae; g__Listeria b77b151f7481fd080bedbf415e736539 337 0,304999457 0,30
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 9b23053de8f4269fe6b5ce286dfbef3c 258 0,233501068 0,23







Pseudomonas f__Pseudomonadaceae 052ba7abaeaa968c4f79e3f97d1f0a2f 1641 1,932657315 1,93
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e8de9432f2ada1078a2fda56ba92675a 324 0,381584991 0,38
Neisseria f__Neisseriaceae; g__Neisseria; s__cinerea f71e5aacd4c976a1833958c2870b1d8b 230 0,270878234 0,27
Listeria f__Listeriaceae; g__Listeria b77b151f7481fd080bedbf415e736539 274 0,322698418 0,32
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 9b23053de8f4269fe6b5ce286dfbef3c 201 0,236724022 0,24
Acinetobacter f__Moraxellaceae; g__Acinetobacter; s__guillouiae c49cc7c2c45bd7a87913453e515ea14f 257 0,302676984 0,30
Propionibacterium f__Propionibacteriaceae; g__Propionibacterium; s__acnes b02a8d33d018119dedb2db15db887bfd 124 0,1460387 0,15
Bacteroides f__Bacteroidaceae; g__Bacteroides; s__ b6635d67cb594473ddba9f8cfba5d13d 18 0,021199166 0,02
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ e4c0868fdefcdf2037ab5f7a071e4cc7 19 0,022376898 0,02
Enterococcus  f__Enterococcaceae; g__Enterococcus; s__ 892a20bbdc3ce599dc0c5d9f0866c352 13 0,015310509 0,02
Actinomyces NA NA 0 0 0,00
Other p__OD1; c__; o__; f__; g__; s__ 3be770f858d48a8c64d91c71fd000951 58 0,068308424 0,09
f__Enterobacteriaceae; g__Gluconacetobacter; s__ e8165c825d679874a9c71c16408fbbfd 11 0,012955046
c__ML635J-21; o__; f__; g__; s__ 6de3d71f0b5574f91e4569ad3168d64c 11 0,012955046
84909 100 100,00
Propionibacterium f__Propionibacteriaceae; g__Propionibacterium; s__acnes b02a8d33d018119dedb2db15db887bfd 203 0,183723709 0,18
Bacteroides f__Bacteroidaceae; g__Bacteroides; s__ b6635d67cb594473ddba9f8cfba5d13d 38 0,03439163 0,03
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ e4c0868fdefcdf2037ab5f7a071e4cc7 31 0,02805633 0,03
Enterococcus  f__Enterococcaceae; g__Enterococcus; s__ 892a20bbdc3ce599dc0c5d9f0866c352 28 0,025341201 0,03
Actinomyces NA NA 0 0 0,00
Other p__OD1; c__; o__; f__; g__; s__ 3be770f858d48a8c64d91c71fd000951 94 0,085074033 0,10
p__OD1; c__; o__; f__; g__; s__ 787efccde8e499d021ddb015a190b3b0 11 0,009955472
p__OD1; c__; o__; f__; g__; s__ 35801c031a5311c7d870432585668de7 4 0,003620172
110492 100 100,00
Mock Community HM-783D, Sample ID MKOLS2138, Setup 1 (IV)







Escherichia f__Enterobacteriaceae ffc36e27c82042664a16bcd4d380b286 22060 25,98075587 26,65
f__Enterobacteriaceae b0728b5f5f391ce7f6f2c7f944a6afcd 570 0,671306929
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 5497318e515a8c328a68f95975d9c7d4 19807 23,3273269 30,56
f__Staphylococcaceae; g__Staphylococcus 908e9b387f6b9ce7d3f794e658fba37e 3471 4,087905876
f__Staphylococcaceae; g__Staphylococcus 04be702b895fe5ed0568344daf564276 2163 2,547433134
f__Staphylococcaceae; g__Staphylococcus cafb603c773ad5283866c506359242c7 505 0,594754384
Streptococcus f__Streptococcaceae; g__Streptococcus; s__ ef5af48ec2b6c023c5de28c59cb08a40 18608 21,91522689 25,38
f__Streptococcaceae; g__Streptococcus; s__agalactiae c3a3a503752209bc052b3995236b079f 2477 2,917240811
f__Streptococcaceae; g__Streptococcus; s__ 6fbbc62750f01a6bd96182337b85b090 464 0,546467395
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides 332b70897316f7f62b81dfc53f41ca52 7404 8,719923683 8,94
f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides c5f93cc01baff5679295e847f9c6b259 183 0,215524856
Bacillus f__Bacillaceae; g__Bacillus 8cb24777cb48dde0aac60dfeca125d10 2417 2,846576924 2,85
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 318669d5d926e9b81ca6911da00a14ea 1491 1,755997597 1,88




Mock Community HM-783D, Sample ID MKOLS2491, Setup 2
Mock Community 







Escherichia f__Enterobacteriaceae d46e2205f0c6ecf67b51f83d111c509c 23274 22,50674506 22,54
f__Enterobacteriaceae 6e39a9f573846663e97117b62fad86f2 34 0,03287915
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 65d43491988bfe557da4d86a5ba25dae 30851 29,83396029 29,88
f__Staphylococcaceae; g__Staphylococcus 4008f0a6a397740091ad145f78d08e5c 36 0,034813217
f__Staphylococcaceae; g__Staphylococcus 1776e0004f84ad79443ce2b037c69741 10 0,009670338
Streptococcus f__Streptococcaceae; g__Streptococcus e7cfd084265c4df4856ca07b1c9b24ee 24279 23,47861405 26,20
f__Streptococcaceae; g__Streptococcus; s__agalactiae e3055f1b3a2ef5ffe239567f02e0e758 2744 2,653540794
f__Streptococcaceae; g__Streptococcus e3e8d451223353321b8f96c9b2ecc2d8 35 0,033846184
f__Streptococcaceae; g__Streptococcus 02df8598ac39f1ef54609afb19c8c450 23 0,022241778
f__Streptococcaceae; g__Streptococcus; s__ 5195aa3753b9257988f5339baca424e3 8 0,007736271
f__Streptococcaceae; g__Streptococcus 2082fcd6d3ed62054d6730e77350f1f8 2 0,001934068
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides dffc86cefa76e3e3d93e7eea450e6807 11372 10,99710857 11,00
Bacillus f__Bacillaceae; g__Bacillus bdf8a26094624622d68509a87fa75ba7 3261 3,153497278 3,15
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 4e8d7a4662640b90817f015280cf5713 2549 2,4649692 2,64
f__Clostridiaceae; g__Clostridium; s__butyricum cb97fb83d4c8cc6eccded352a4ca3f8f 181 0,175033121
Pseudomonas f__Pseudomonadaceae; g__Pseudomonas ff9d93d7b7e46787568f2d241caeaf3b 2194 2,121672195 2,12
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e832be098a5318684958d14305267752 634 0,61309944 0,61
Neisseria f__Neisseriaceae; g__Neisseria 8224351b2abd16dd4d58c3015ff5e795 449 0,434198184 0,43
Listeria f__Listeriaceae; g__Listeria 8ae518dbb29595b3f79214be0b589066 380 0,367472851 0,37
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 0df6c802966e8670279671824da4f10a 357 0,345231073 0,35
Acinetobacter f__Moraxellaceae; g__Acinetobacter; s__guillouiae ea403646ed22d679fa4586263d8fc32f 300 0,290110145 0,29
Propionibacterium f__Propionibacteriaceae; g__Propionibacterium; s__acnes 5a7b179b1b45f0fe2282f260bf073f60 302 0,292044213 0,29
Bacteroides f__Bacteroidaceae; g__Bacteroides; s__ 99deb3c5ecb022ec05609ebd1112a557 45 0,043516522 0,04
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ 2385fe1c2dd5a3f83237272a6644088b 28 0,027076947 0,03
Enterococcus  f__Enterococcaceae; g__Enterococcus 9908fffab7ed4f3bec44cda2f5084d49 22 0,021274744 0,02
Actinomyces f__Actinomycetaceae; g__Actinomyces; s__ df8456a1abbfb4c8a2c450b44378d4cb 7 0,006769237 0,01
Other p__OD1; c__; o__; f__; g__; s__ 4479c551f476e1599cf18a69523c5395 18 0,017406609 0,03
p__OD1 cb68de6534f0baf0aac84a0e027862c9 3 0,002901101
p__OD1; c__; o__; f__; g__; s__ 9cb241738be5cc7ede67aaa803cddf70 2 0,001934068
f__mitochondria; g__; s 7859d5f3e16e553f08178cb43bf95802 5 0,004835169
o__Actinomycetales 29f83e66700f19358051530ce2f68e96 4 0,003868135
103409 100 100,00
Mock Community HM-783D, Sample ID MKOLS2830, Setup 3 
Mock Community 







Escherichia f__Enterobacteriaceae d46e2205f0c6ecf67b51f83d111c509c 39507 32,90248432 32,90
Staphylococcus f__Staphylococcaceae; g__Staphylococcus 65d43491988bfe557da4d86a5ba25dae 29989 24,97563982 24,98
Streptococcus f__Streptococcaceae; g__Streptococcus e7cfd084265c4df4856ca07b1c9b24ee 27912 23,24585877 25,81
f__Streptococcaceae; g__Streptococcus; s__agalactiae e3055f1b3a2ef5ffe239567f02e0e758 2945 2,452674623
f__Streptococcaceae; g__Streptococcus 06f825b512d903b9230e1a55d87359ee 65 0,054133735
f__Streptococcaceae; g__Streptococcus; s__ edc9e5c16e40aff1eadce6597940f08f 46 0,038310028
f__Streptococcaceae; g__Streptococcus; s__ fd496fd32dc8c08ade2e8b6c9d8ee13d 26 0,021653494
Rhodobacter f__Rhodobacteraceae; g__Rhodobacter; s__sphaeroides dffc86cefa76e3e3d93e7eea450e6807 10534 8,772996427 8,77
Bacillus f__Bacillaceae; g__Bacillus bdf8a26094624622d68509a87fa75ba7 2992 2,491817478 2,49
Pseudomonas f__Pseudomonadaceae; g__Pseudomonas ff9d93d7b7e46787568f2d241caeaf3b 2430 2,023768874 2,02
Clostridium f__Clostridiaceae; g__Clostridium; s__butyricum 4e8d7a4662640b90817f015280cf5713 1923 1,601525739 1,69
f__Clostridiaceae; g__Clostridium; s__butyricum cb97fb83d4c8cc6eccded352a4ca3f8f 110 0,091610937
Neisseria f__Neisseriaceae; g__Neisseria 8224351b2abd16dd4d58c3015ff5e795 442 0,3681094 0,39
f__Neisseriaceae; g__Neisseria 4f5efd25dacb5d639316e7291ff6ff8b 21 0,017489361
Helicobacter f__Helicobacteraceae; g__Helicobacter; s__pylori e832be098a5318684958d14305267752 317 0,264006063 0,26
Listeria f__Listeriaceae; g__Listeria 8ae518dbb29595b3f79214be0b589066 309 0,257343449 0,26
Lactobacillus f__Lactobacillaceae; g__Lactobacillus; s__ 0df6c802966e8670279671824da4f10a 220 0,183221873 0,18
Acinetobacter f__Moraxellaceae; g__Acinetobacter; s__guillouiae ea403646ed22d679fa4586263d8fc32f 144 0,119927044 0,12
Propionibacterium NA NA 0 0 0,00
Bacteroides f__Bacteroidaceae; g__Bacteroides; s__ 99deb3c5ecb022ec05609ebd1112a557 30 0,024984801 0,02
Deinococcus f__Deinococcaceae; g__Deinococcus; s__ 2385fe1c2dd5a3f83237272a6644088b 19 0,015823707 0,02
Enterococcus  NA NA 0 0 0,00
Actinomyces NA NA 0 0 0,00
Other f__Pasteurellaceae 394eda29c886632f514dd94b58381186 36 0,029981761 0,08
f__Prevotellaceae; g__Prevotella; s__melaninogenica 32f8fd11d2bee278d609a1d4ab767554 36 0,029981761
































Supplementary Figure 1. Principal coordinates analysis on unweighted UniFrac distances for 956	
procedural samples sequenced following each setup before the removal of Decontam 957	
contaminants. A. Setup 1 (OW: n=22; PBAL: n=23; PSB: n=23; NCS: n=20).  B. Setup 2 (OW: 958	
n=23; PBAL: n=23; PSB: n= 23; NCS: n=21). C. Setup 3 (OW: n=23; PBAL: n=21; PSB: n=22; 959	
NCS: n=18). Setup 1 (2-step PCR; V3 V4 region); Setup 2 (2-step PCR; V4 region); Setup 3 (1-960	
step PCR; V4 region). Rarefaction depth: 1066 sequences.  Oral Wash (OW): blue; Protected 961	
bronchoalveolar lavage (PBAL): green; Protected specimen brushes (PSB): purple; Negative 962	
































































Mock Community Sample HM-783D 1025	
The mock community sample was obtained through BEI Resources, NIAID, NIH, as part of the 1026	
Human Microbiome Project: Genomic DNA from Microbial Mock Community B (Staggered, 1027	
Low Concentration), v5.2L, for 16S rRNA Gene Sequencing, HM-783D. The input number of 1028	
16S rRNA gene operons was given on the certificate of analysis provided by the BEI 1029	
Resources, and used to calculate the relative abundance of the different bacteria in the 1030	
sample (Table S.1). 1031	
 1032	
Table S.1. Mock community HM-783D  1033	
Species Number of operons Relative abundance (%) 
Acinetobacter baumannii 10000 0.22 % 
Actinomyces odontolyticus 1000 0.02 % 
Bacillus cereus 100000 2.19 % 
Bacteroides vulgatus 1000 0.02 % 
Clostridium beijerinckii 100000 2.19 % 
Deinococcus radiodurans 1000 0.02 % 
Enterococcus faecalis 1000 0.02 % 
Escherichia coli 1000000 21.91 % 
Helicobacter pylori 10000 0.22 % 
Lactobacillus gasseri 10000 0.22 % 
Listeria monocytogenes 10000 0.22 % 
Neisseria meningitidis 10000 0.22 % 
Propionibacterium acnes 10000 0.22 % 
Pseudomonas aeruginosa 100000 2.19 % 
Rhodobacter sphaeroides 1000000 21.91 % 
Staphylococcus aureus 100000 2.19 % 
Staphylococcus epidermidis 1000000 21.91 % 
Streptococcus agalactiae 100000 2.19 % 
Streptococcus mutans 1000000 21.91 % 
	 49	
Streptococcus pneumoniae 1000 0.02 % 
 1034	
Library Preparation for MiSeq Sequencing  (Setups 1, 2 and 3) 1035	
We compare three different library preparation setups for MiSeq sequencing of the bacterial 1036	
16S rRNA gene. The three setups vary with regards to the number of PCR steps (one or two) 1037	
and the target marker gene region sequenced (16S rRNA gene region V3 V4 or V4): Setup 1 1038	
(2-step PCR; region V3 V4); Setup 2 (2-step PCR; region V4); Setup 3 (1-step PCR; region V4).  1039	
Setups 1 and 2 1040	
Setups 1 and 2 were performed according to the the Illumina 16S Metagenomic Sequencing 1041	
Library Preparation guide (Part no. 15044223 Rev. B). The protocol consists of two PCR 1042	
steps; the first for amplification of the target marker gene region to be sequenced and the 1043	
second for the addition of index sequences required for sample multiplexing.  1044	
 1045	
Setup 1. In the first PCR step, the 16S rRNA gene V3 V4 region was targeted using primers: 1046	
5ʹ-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3ʹ (forward) and  1047	
5ʹ-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3ʹ (reverse).  1048	
Illumina overhang adapter sequences are italicized. Gene specific sequences (underlined) 1049	
are taken from Klindworth et al. [1]. Each reaction consisted of 5 µl sample, 12.5 µl KAPA 1050	
HiFi HotStart ReadyMix (2X) (KAPA Biosystems, USA), 0.5 µl of each primer (10 µM) and 6.5 1051	
µl RT-PCR grade water (Thermo Fisher Scientific, USA) for a total volume of 25 µl. PCR cycling 1052	
was performed using the following program: an initial cycle at 95 °C for 3 minutes, followed 1053	
by 45 cycles of 95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C for 30 seconds, and a final 1054	
extension cycle at 72 °C for 5 minutes.  1055	
 1056	
Setup 2. In the first PCR step, the 16S rRNA gene V4 region was targeted using primers: 1057	
5´-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGCCAGCMGCCGCGGTAA-3´ (forward) and 1058	
5´-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTACHVGGGTWTCTAAT-3´ (reverse).  1059	
Illumina overhang adapter sequences are italicized. Gene specific sequences (underlined) 1060	
are taken from Caporaso et al. [2]. Each reaction consisted of 5 µl sample, 12.5 µl KAPA HiFi 1061	
HotStart ReadyMix (2X), 1.25 µl of each primer (10 µM), and 5 µl RT-PCR grade water 1062	
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(Thermo Fisher Scientific, USA) for a total volume of 25 µl. PCR cycling was performed using 1063	
the following program: an initial cycle at 95 °C for 3 minutes, followed by 45 cycles of 95 °C 1064	
for 30 seconds, 50 °C for 30 seconds, 72 °C for 30 seconds, and a final extension cycle at 72 1065	
°C for 5 minutes. 1066	
 1067	
For both setups 1 and 2, the second PCR step was performed using primers from the Nextera 1068	
XT Index kit (Illumina Inc., USA). Each reaction consisted of 5 µl amplicons from PCR step 1069	
one, 25 µl KAPA HiFi HotStart ReadyMix (2X), 5 µl of each forward and reverse index primer 1070	
(Nextera XT Kit), and 10 µl RT-PCR grade water (Thermo Fisher Scientific, USA) for a total 1071	
volume of 50 µl. PCR cycling was performed using the following program: an initial cycle of 1072	
95 °C for 3 minutes, followed by 8 cycles of 95 °C for 30 seconds, 55 °C for 30 seconds, 72 °C 1073	
for 30 seconds, and a final extension cycle at 72 °C for 5 minutes. 1074	
 1075	
Amplicon libraries were quantified using the Qubit dsDNA HS Assay Kit (Life Technologies, 1076	
USA), normalized to 4 nM and pooled together. The pooled library was denatured with 1077	
NaOH and diluted to 10 pM. The library was then spiked (15%) with PhiX from the PhiX 1078	
Control Kit (Illumina). Paired-end sequencing was performed using 2x300 cycles (setup 1079	
1)/2x275 cycles (setup 2) on the Illumina MiSeq using reagents from the MiSeq reagent kit 1080	
v3 (Illumina).  1081	
 1082	
Setup 3  1083	
Setup 3 was based on the 1-step PCR protocol described by Kozich et al. [3]. The protocol 1084	
consists of just one PCR step using primers that contain gene targeting sequences, index 1085	
sequences and illumina sequencing adapter sequences.  1086	
 1087	
The 16S rRNA gene V4 region was targeted using primers 5´-1088	
AATGATACGGCGACCACCGAGATCTA CACNNNNNNNNTATGGTAATTGTGTGCCAGCMGCCGCGGTAA-3´ 1089	
and 5-´CAAGCAGAAGACGGCATACGA GATNNNNNNNNAGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-1090	
3´. As detailed in Kozich et al. [3], the primers consist of different regions including: the Illumina 1091	
sequencing adapter sequence, index sequence (NNNNNNNN), pad and linker sequence 1092	
(reading 5´-3´).	The gene specific sequences (underlined) are the same as for the primers 1093	
	 51	
used in the sequencing setup 2. Each reaction consisted of 5 µl sample, 18 µl AccuPrime Pfx 1094	
SuperMix (Thermo Fisher Scientific, USA) and 1 µl of each primer (10 µM) for a total volume 1095	
of 25 µl. PCR cycling was performed using the following program: an initial cycle at 95 °C for 1096	
2 minutes, followed by 45 cycles of 95 °C for 20 seconds, 55 °C for 15 seconds, 72 °C for 5 1097	
minutes, and a final extension cycle at 72 °C for 5 minutes. PCR clean-up was performed 1098	
using Agencourt AMPure XP beads (Beckman Coulter, USA). 1099	
 1100	
Amplicon libraries were quantified using the Qubit dsDNA HS Assay Kit, normalized to 4 nM 1101	
and pooled together. The pooled library was denatured with NaOH and diluted to 10 pM. 1102	
The library was spiked (15%) with PhiX from the PhiX Control Kit (Illumina). Paired-end 1103	
sequencing was performed using 2x250 cycles on the Illumina MiSeq using reagents from 1104	
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